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An abdominal aortic aneurysm (AAA) is a progressive dilatation of the abdominal aorta that 
is most often located in the infrarenal aorta, i.e. between the level of the renal and the iliac 
arteries. In Western countries, the prevalence of AAA reaches approximately 10% among 
those over the age of 65.1 Clinical risk factors that predispose individuals to have an aortic 
aneurysm include: smoking, advanced age, male gender, chronic obstructive pulmonary 
disease, hypertension, and a family history of aneurysmal disease.2,3,4
Atherosclerotic lesions are a common finding in pathological examinations of aneurysm 
walls. As such, the formation of aortic aneurysms has been attributed to a complication of 
atherosclerosis.5 However, there is growing evidence suggesting that aneurysm formation 
is a multifactorial process that leads to defects in the structural components of the wall.6 
Progression of atherosclerosis may result in an occlusive disease, whereas aneurysm 
formation and progression represents a dilatation of the aortic wall. Atherosclerosis and 
aneurysmal disease have different risk factor profiles. Although elevated cholesterol level 
and hypertension are prominent risk factors for atherosclerosis, their role in AAA appears 
minimal.7 Moreover, diabetes, an established risk factor for atherosclerosis, is not associated 
with AAA, and AAA diameter progression appears to be slower in patients with diabetes.7 
Further, smoking appears to be a stronger risk factor for AAA than for atherosclerosis.8 
Together, these observations suggest that AAA and atherosclerosis are different diseases 
and imply a more complex pathophysiology of aortic aneurysms than previously thought.
 
Typically, an aortic aneurysm enlarges slowly but without symptoms. At some point 
aneurysms may rupture, causing life-threatening bleeding. The risk of rupture is strongly 
determined by the diameter of the aneurysm. The risk of rupture of small aneurysms (i.e. a 
diameter of 5.5 cm or less) is very low (1–2% a year). The rupture risk, however, increases 
exponentially with an aneurysm diameter over 5.5 cm, and the estimated annual rupture 
rates of aneurysms over 7 cm exceed 15–20%.9 Despite major improvements in medical 
care, the overall mortality rate for ruptured aneurysms remains as high as 60–80%.1 Hence, 
current strategies for AAA are watchful waiting in small AAA, and elective repair of AAA over 
5.5 cm.
Elective repair can either be done through an open abdominal operation or by an endovascular 
approach. The open abdominal approach, shown in Figure 1, is a major surgical procedure 
and has a significant complication risk. The mortality rate is approximately 3–5% and 
morbidity is significant.10,11 Complications are commonly associated with patients with 
preexisting cardiovascular, pulmonary and renal conditions, the use of general anesthesia, 
and the duration of cross-clamp time of the aorta.11
The endovascular procedure is shown in Figure 2, and is generally considered a more 
elegant and less invasive approach. However, a large group of AAA patients with unfavorable 
anatomical AAA characteristics, such as severe aortic angulation and aneurysm neck 
morphology, cannot be repaired by endovascular techniques. Large clinical trials show 
that endovascular repair is associated with a significant lower operative mortality than 
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In a conventional open aortic aneurysm repair, an abdominal incision is made to enter the 
peritoneal cavity. A prosthetic graft is used to replace the diseased segment of the aorta.
AAA illustrating endovascular stent graft placement. The procedure is done percutaneously. 
It usually involves two small incisions to expose the femoral arteries. A synthetic graft and 
stents are introduced through these arteries with guidewires and catheters until the graft 
is positioned correctly at the neck and normal iliac arteries. Removal of the sheath allows 
expansion of the stentgraft with barbs or other fixing devices to attach to the artery wall and 




open repair. However, the long-term results in terms of total mortality or aneurysm-related 
mortality appear similar in both approaches.12,13,14 Further, endovascular repair requires life-
long follow-up because of the increased risk of graft-related complications, necessitating 
reinterventions.15 Several studies indicate that endovascular repair is not cost-effective.16,17
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Randomized controlled trials comparing open repair versus conservative treatment dictate 
current operative management, for both open and endovascular treatment.18,19 Current 
treatments are reserved for patients with aneurysms that have grown to more than 5.5 cm 
in diameter. Aneurysms smaller than 5.5 cm are not recommended for intervention since 
the risk does not outweigh the risk of future rupture of a small aneurysm.18,19,20,21 The more 
widespread use of ultrasound screening and abdominal imaging has led to an increase in 
the number of AAAs referred for management.22 Most abdominal aneurysms detected in 
screening programmes are smaller than 5.5 cm in diameter and operative treatment is 
not required. These patients are treated with a wait-and-see policy and they are usually 
followed by ultrasound. Remarkably, a large group of patients with a small aneurysm do 
never develop a large aneurysm that requires operative treatment due to the high incidence 
of cardiovascular disease and early mortality.23
Current elective therapies have significant limitations: open repair is associated with a 
significant mortality and morbidity; whereas application of endovascular repair is limited by 
anatomical restrictions and concern over the long-term stability of the endograft. Moreover, 
the costs of treatment are high and are a major burden on the individual and society. 
Hence there is a need for a medical therapy that reduces the progression of small AAAs 
into large AAAs, which might decrease the risk of rupture and, consequently, the need for 
elective invasive treatment in patients with aneurysms. Moreover, medical therapy might be 
beneficial to reduce the need for repair and minimize the risk of rupture in patients with large 
AAAs unfit for aneurysm repair.24 To develop such a medical therapy, a better understanding 
of the pathology of AAA is needed to develop pharmaceutical therapeutic strategies for 
aneurysm patients.
The pathophysiology of an AAA
The aorta is a so-called ‘elastic’ or conducting artery. The human aorta consists of three 
different layers; the tunica intima, the tunica media, and the tunica adventitia, as shown 
in Figure 3. The tunica intima is the innermost layer which consists of a monolayer of 
endothelial cells located on a basal lamina and a very thin layer of connective tissue.25 
The tunica intima acts as a semi-permeable barrier to the passage of molecules from the 
bloodstream into the arterial wall.25 The tunica media is composed mainly of smooth muscle 
cells intermixed with elastin sheets, embedded in an extracellular matrix. It accounts for 
most of the elasticity of the arterial wall.25 During systole, the elastic wall is stretched to 
accommodate the pressure volume of blood ejected from the heart, and subsequently the 
accumulated passive energy is released by a recoil action of the vessel, acting as a second 
subsidiary pump (known as the ‘Windkessel phenomenon’).25,26,27 The outermost layer, the 
tunica adventitia, contains blood vessels required for nutrition of the outer layers of the 
vessel wall (vasa vasorum) which are embedded in collagen-rich connective tissue (mainly 
type I and III). The adventitia contributes significantly to the stability and strength of the 
arterial wall because of the dense network of collagen fibers which are neatly organized in a 
matrix or skeleton.28 In diastole, or unstressed tissue, the collagen fibers are embedded in 
a wavy form, which causes the adventitia to be less stiff than the media in the stress-free 
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configuration; however, at significant levels of strain during systole, the collagen fibers reach 
their straightened maximum lengths and the adventitia becomes stiff. This mechanism 
prevents acute over-distension of the vessel wall, and in particular, of the smooth muscle 
cells in the media.25
The process of aneurysm formation and progression is associated with loss of the 
extracellular matrix components, elastin and collagen.28 Although loss of elastin is the most 
prominent feature of AAA, it has been suggested that loss of collagen (fibrillar collagen type 
I and III) leads to the actual weakening of the arterial wall.29 This has been supported by 
in vitro experiments showing that infusion of elastase in human aortic and iliac arteries only 
causes a slight vessel wall dilatation, whereas collagenase infusion leads to rapid dilatation 
and rupture.30 Furthermore, the critical role of collagen in maintaining the integrity of the 
vessel wall is supported, as shown in Figure 4, by the observation that elastolysis is already 
complete in small aneurysms that are not prone to rupture. Hence progression and rupture 
of larger AAA represents degradation of the collagen matrix.29








Observations suggest that aneurysmal growth occurs through a gradually increasing 
imbalance between connective tissue degradation and repair. Thompson et al. proposed a 
model for aneurysm formation and growth, as shown in Figure 5.31 Elastolysis is considered 
as the first step of aneurysm formation (AAAs <3.5 cm; stage I). Further progression of 
an aneurysm is caused by collagen degradation, which is replaced and repaired (stage 
II). Ultimately, the collagen degradation exceeds the collagen repair. This results in the 
fatal weakening of the vessel wall and subsequent rupture, which causes life-threatening 
hemorrhage (stage III). Preservation of this collagen network in the wall of the aorta may 
provide another way for reducing expansion of an aneurysm.32
Degradation of structural collagen involves two types of extracellular proteases: initial cleavage 
of the intact triple helix by collagenases, and subsequent degradation of the denatured or 
partially hydrolyzed forms of collagen into more soluble peptides by gelatinases.33,34 Both 
activities have mainly been attributed to members of the matrix metalloproteinase (MMP) 
family and the cathepsins.35,36
The collagenases responsible for collagen degradation in the aneurysmal wall have not 
been fully identified. Reportedly, expression of MMP-gelatinase (MMP 2 and 9) as well 
as collagenase (MMP 1, 8 and 13) are increased in the wall of human aneurysms.37,38 
However, quantitative data on MMP expression and activity, and on their relationship to 
their inhibitors, are still absent. Furthermore, the involvement of other critical collagenases, 
A comparison of the elastin concentration within normal human 
infrarenal aorta and small, moderate, and large aneurysms. There was 
no difference among the elastin concentrations of the aneurysm groups 
despite the significant differences in aneurysm diameter. Adapted from 
White JV, Mazzacco SL: Formation and growth of aortic aneurysms 
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such as the cysteine proteases cathepsin K, L, and S, has not been studied in the wall of 
human aneurysms.39
A role for MMPs in the progression and rupture of AAA has been shown in animal models. 
Inhibition of MMP activity (either by overexpression of tissue inhibitor of metalloproteinase 
(TIMP) or by doxycycline) provides protection against aneurysm formation.40,41,42,43 
This suggests that MMP inhibition may be an effective clinical strategy for the medical 
stabilization of AAA. Unfortunately, the use of specific MMP inhibitors such as batimastat 
and PG-116800 is limited by severe side effects on the musculoskeletal syndrome.44
Doxycycline
Doxycycline, a member of the tetracycline family of antibiotics, is well recognized for its 
ability to reduce MMP activity.45 Coupled with its clinical availability, low cost and well-
recognized safety profile, doxycycline seems to be an excellent candidate for evaluation 
of MMP inhibition in patients with an aneurysm. Doxycycline has been shown to suppress 
aneurysm formation in various animal models of AAA.40,41,42,43 Moreover, doxycycline has 
been shown to attenuate or even stop aneurysm growth in two phase I/II studies: Mosorin 
et al. studied the effect of doxycycline in a small double-blind placebo-controlled study 
(n=32) and found that doxycycline significantly suppressed the expansion rate.46 The authors 
reported that significant expansion (>5 mm in 18 months) occurred in five patients in the 
placebo group compared to only one patient in the doxycycline-treated group.46 Baxter et al. 
Stages of aneurysmal degeneration. Adapted from Thompson RW, Geraghty PJ, Lee JK. 




performed an open study in 36 patients with small abdominal aneurysm, and found evidence 
that doxycycline forestalled aneurysm growth during a six month follow-up.47 
Doxycycline is a promising candidate for inhibiting aneurysm growth. Current studies attribute 
the beneficial effect of doxycycline to the inhibition of elastolytic MMPs (MMP 2 and 9). Yet, 
these proteases are unable to cleave intact structural collagens, which are critical for the 
stability of the vessel wall.29 Arterial collagen degradation requires the action of specific 
collagenases that are able to cleave fibrillar collagen. So far, the effect of doxycycline on the 
possible inhibition of these collagenases has been not tested in human AAA.
Outline of the thesis
The aim of this thesis is to evaluate the effect of doxycycline on the proteolytic and 
inflammatory processes in abdominal aneurysms. This data is essential for the development 
of pharmaceutical strategies for the stabilization of an AAA. Such an approach could reduce 
the need for elective surgery and endovascular repair.
It has repeatedly been shown that AAA progression and rupture is related to the failure of 
collagen in the aortic wall. Yet the exact mechanism underlying this failure remains unknown. 
Furthermore, the precise mechanism of activation of collagenases and their inflammatory 
mediators that are responsible for the collagen turnover of AAA are unknown.
In this thesis we attempt to determine how collagen metabolism is balanced in aneurysmal 
diseases and contribute to the knowledge which collagenases and inflammatory mediators 
are involved in the destruction of the collagen network in AAA disease. Moreover, we evaluate 
some of the effects of doxycycline on the proteases and inflammatory mediators in AAA. 
Analyses showed that doxycycline inhibits specific MMPs and inflammatory pathways that 
are involved in the collagen balance and aneurysm growth. Together, these observations 
provide a rationale for a randomized clinical trial studying the effect of doxycycline on 
aneurysm growth. 
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Abstract
Growth and rupture of abdominal aortic aneurysms (AAAs) result from increased collagen 
turnover. Collagen turnover critically depends on specific collagenases that cleave the 
triple helical region of fibrillar collagen. As yet, the collagenases responsible for collagen 
degradation in AAAs have not been identified. Increased type I collagen degradation products 
confirmed collagen turnover in AAAs (median values: <1, 43, and 108 ng/mg protein in 
control, growing, and ruptured AAAs, respectively). mRNA and protein analysis identified 
neutrophil collagenase [matrix metalloproteinase (MMP)-8] and cysteine collagenases 
cathepsin K, L, and S as the principle collagenases in growing and ruptured AAAs. Except 
for modestly increased MMP-14 mRNA levels, collagenase expression was similar in growing 
and ruptured AAAs (anteriorlateral wall). Evaluation of posttranslational regulation of 
protease activity showed a threefold increase in MMP-8, a fivefold increase in cathepsins 
K and L, and a 30-fold increase in cathepsin S activation in growing and ruptured AAAs. 
The presence of the osteoclastic proton pump indicated optimal conditions for extracellular 
cysteine protease activity. Protease inhibitor mRNA expression was similar in AAAs and 
controls, but AAA protein levels of cystatin C, the principle cysteine protease inhibitor, were 
profoundly reduced (>80%). We found indications that this secondary deficiency relates to 
cystatin C degradation by (neutrophil-derived) proteases.
 
Introduction
Abdominal aortic aneurysm (AAA) is a common pathology and a major cause of death 
because of rupture.1,2 The hallmark pathology of AAA is a persistent proteolytic imbalance 
that results in excess matrix destruction and progressive weakening of the arterial wall. A 
number of matrix metalloproteinases (MMPs) (in particular the gelatinases MMP-2 and -9)1,3 
have been implicated as primary proteolytic culprits in the disease, but it is dubious whether 
these proteases are directly responsible for the weakening and ultimate failure of the aortic 
wall. Biomechanical studies invariably show that the mechanical stability of the arterial wall 
essentially relies on fibrillar collagens in media and adventitia.4–6 These structural collagens 
are highly resistant toward proteolytic degradation, and the only mammalian proteases that 
have been shown to cleave the native triple helical region of fibrillar collagen are the classic 
collagenases of the MMP family7 [i.e., MMP-1, -8, and -13 and the membrane type-1 MMP 
(MT-1 MMP or MMP-148)], as well as selected members of the cysteine protease family (ie, 
cathepsin K,9,10 L,11 and possibly S12).
Several reports indicate expression of these collagenases in AAA on an individual basis, but 
comparative data regarding expression of the collagenases, and their possible relationship 
to rupture of the aneurysm,13,14 are not available. Moreover, available studies15 do not 
address the critical and complex posttranslational regulation of protease activity that 
involves controlled secretion of an inactive proenzyme, activation of the proenzyme, and 
rapid inhibition of protease activity by specific and nonspecific inhibitors.
To characterize collagenases involved in AAA growth and to test whether rupture is 
associated with increased collagenase expression, we used an integrated approach. We 
C HAP TER 2
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first confirmed excess fibrillar collagen turnover in AAA and ruptured AAA wall samples 
through quantification of collagen degradation products and next established mRNA 
expression profiles of the MMP and cysteine collagenases by semi quantitative real-time 
polymerase chain reaction (RT-PCR). Because this approach does not provide information 
on the post-transcriptional regulation of protease activity, we quantified tissue expression 
of specific inhibitors of proteases activity and applied specific protease activity assays and 
Western blot analyses to address the post-translational regulation of protease activity.16,17 
Data from this study characterize members of the cysteine protease family, cathepsin K, L, 





Tissue from the anterior-lateral aneurysm wall was obtained during elective surgery for 
asymptomatic AAA (-5.5 cm or larger, growing AAA) or during emergency surgery (ruptured 
AAA). Aortic patches removed along with the renal artery during kidney explantation from 
brain-dead, heart-beating, adult organ donors were used as controls. Samples were 
immediately halved. One half was snap-frozen in CO2-cooled isopentane or liquid N2 and 
stored at -80°C for later analysis. The other half was fixed in formaldehyde (24 hours), 
decalcified (Kristensen’s solution, 120 hours), and paraffin-embedded for histological 
analysis. Sample collection and handling was performed in accordance with the guidelines 
of the medical ethical committee of the Leiden University Medical Center, Leiden, The 
Netherlands.
RNA Isolation and Real-Time Competitive LightCycler PCR
RNA isolation and semi quantitative mRNA analysis using real-time competitive LightCycler 
PCR (Applied Biosystems, Nieuwerkerk aan den IJssel, The Netherlands) were performed 
following protocols detailed by Lindeman and colleagues.17 All mRNA data were normalized 
on basis of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression.
Tissue Homogenization
Aortic wall tissues were pulverized in liquid nitrogen and homogenized in lysis buffer [10 
mmol/L Tris, pH 7.0, 0.1 mmol/L CaCl2, 0.1 mol/L NaCl, and 0.25% (v/v) Triton X-100]. 
This protocol releases both soluble as well as membrane-bound proteases. Samples were 
subsequently centrifuged at 13,000 rpm for 10 minutes at 4°C, snap-frozen, and stored at 
-80°C until use. Homogenates were normalized on the basis of their protein content (Pierce, 
Rockford, IL).
Collagen Degradation Assay
Collagen turn-over was assessed by the CTX assay for type I collagen degradation (Serum 
Cross laps; Nordic Biosciences, Milsbeek, The Netherlands). This assay is based on the 
detection of a neo-epitope that is released on cleavage of the GVG/L peptide bond in the 
C-terminal telopeptide of 2(I)-chain of mature type I collagen.
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Specific Immunocapture MMP and Cathepsin Activity Assays
MMP-1, -8, -9, -13, and -14 (MT1-MMP) activity assays (Amersham Biosciences, 
Buckinghamshire, UK) were performed according to the suppliers’ recommendations. In 
short, target proteases were captured by an immobilized specific antibody on microtiter 
plates, and the proteolytic activation of a modified proenzyme by the captured protease 
was used to quantify the protease activity.17 MMP activity was quantified using recombinant 
MMP as standard. These assays have been shown to allow sensitive and specific 
assessment of active MMP as well as pro-MMP (on activation of latent MMP by a mercuric 
salt (p-aminophenylmercuric acetate) in in vitro systems. Conversely, assessment of active 
MMP in more complex samples such as tissue homogenates is generally hampered by 
rapid inactivation of active proteases because of the high levels of endogenous protease 
inhibitors that are present during initial sample preparation. Indeed, preliminary studies 
failed to indicate active MMPs in both aneurysmal and normal aortic wall homogenates; 
hence, only latent MMP activity (ie, on p-aminophenylmercuric acetate activation of the 
captured proenzyme) was assessed.
Cathepsin K activity was measured by a novel activity assay, based on the same principle 
as the MMP assays.17 We developed a similar assay for assessment of cathepsin S activity; 
however, because of dissociation of the cathepsin S-cystatin C complex in the incubation 
steps required in the test, this assay measures both active cathepsin S as well as cathepsin S 
that was previously bound to cystatin C (cystatin C-complexed cathepsin S). Costar Stripwell 
plates were coated (2 hours, 37°C) with 1 µg/ml cathepsin S-specific monoclonal antibody 
(TNO-1503). This antibody does not cross-react with cathepsin K (<0.5%), L (0%), or V 
(<0.1%) and does not interfere with the enzyme activity. Purified cathepsin S (Calbiochem, 
Merck Biosciences, Darmstadt, Germany) or sample in binding buffer (20 mmol/L HEPES, 
1 mmol/L ethylenediaminetetraacetic acid, and 0.1% Triton X-100, pH 6.5) were incubated 
for 16 hours at 4°C. Plates were subsequently washed four times with capture buffer (20 
mmol/L HEPES, pH 6.5), and captured active cathepsin S was quantified through activation 
of a modified prourokinase variant (UKcatS) in detection buffer (20 mmol/L HEPES, 1 mmol/L 
ethylenediaminetetraacetic acid, and 0.1% Triton X-100, pH 8.5). Cathepsin S activation of 
the proenzyme was quantified using a chromogenic peptide substrate (S-2444). Cathepsin 
S activity was calculated from a standard curve using recombinant enzyme, and expressed 




Western blot analysis was used to quantify proteaseinhibitor complexes. Preliminary 
analysis showed that the primary antibodies used in the analysis allowed analysis of 
both pro- and active forms of the respective proteases and that the standard denaturing 
conditions required for Western blot analysis resulted in full dissociation of MMP-8-TIMP-1 
and cathepsin-cystatin C complexes, thus indicating that the analysis allows assessment of 
MMP-8-TIMP and cathepsin K-, L-, and S-cystatin C complexes.
C HAP TER 2
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Western blot analyses for these proteases as well as for cystatin C and TIMP-1 were 
performed as described in Kleemann and colleagues,18 using the following antibodies: 
anti-human cathepsin K (IM55L; Calbiochem, Breda, The Netherlands), anti-cathepsin 
L (AF952; R&D Systems, Abingdon, UK), anti-cathepsin S (sc-6505; Santa Cruz Biotechnology, 
Heerhugowaard, The Netherlands), anti MMP-8 (MAB3316; Chemicon, Chemicon Europe, 
Ltd., Chandlers Ford, UK), anti-cystatin C (sc-16989; Santa Cruz Biotechnology), and anti-
TIMP-1 (Ab8229; Chemicon). All samples were normalized on the basis of total actin [anti-
actin (sc-1615; Santa Cruz Biotechnology)] levels. All secondary antibodies were obtained 
from Santa Cruz Biotechnology. Immunoblots were visualized and quantified using Super 
Signal West dura extended duration substrate (Perbio Science, Etten-Leur, The Netherlands), 
LabWorks 4.6 software and the luminescent image workstation (UVP, Cambridge, UK).
Immunohistochemistry
Immunohistochemistry was performed using 4-µm deparaffinized, ethanol-dehydrated tissue 
sections. Sections were incubated overnight with a polyclonal antibody against MMP-8 
(Medix Biochemica, Milsbeek, The Netherlands) or by a polyclonal antibody against the 
100-kd transmembrane subunit of human osteoclast v-H+ATPase (a generous gift from 
Dr. M.A. Harrison, School of Biochemistry and Molecular Biology, University of Leeds, 
Leeds, UK).16 Conjugated biotinylated antigoat or rabbit anti-IgG were used as secondary 
antibodies. Sections were stained with Nova Red (Vector Laboratories, Burlingame, CA) and 
counterstained with Mayer hematoxylin. Controls were performed by omitting the primary 
antibody.
In Vitro Cystatin C Degradation
Putative cystatin C degradation by MMP and serine proteases was evaluated in vitro. To that 
end, human cystatin C (5 ng/ml; Biovendor, Brno, Czech Republic) was incubated (24 hours, 
37°C) with preactivated MMP-9 (0.3 ng/ml; Invitek, Leusden, The Netherlands), preactivated 
MMP-8 (0.3 ng/ml; Chemicon) or the serine protease neutrophil elastase (0.1 ng/ml; 
Calbiochem) in a 50 mmol/L Tris, pH 7.5, buffer containing 1.5 mmol/L NaCl, 1 µmol/L Zn+, 
0.5 mmol/L Ca2+, 0.01% Brij, and 2 E/ml heparin, and remaining cystatin C was quantified 
by Western blotting (see above).
Statistical Analysis
mRNA expression (Ct values) was compared by Student’s t-test or Wilcoxon-Mann-Whitney 
U-test. Results of activity assays and Western blots were analyzed by the Wilcoxon-Mann-
Whitney U-test to compare the different groups. Putative correlations between cystatin 
C protein concentrations and cysteine protease mRNA and protein expression were analyzed 
by Pearsons’ test. P values <0.05 were considered significant.
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Results
Patients
Baseline clinical characteristics of the patients are provided in Table 1. Two of the AAA 
patients and two of the ruptured AAA patients had aneurysms elsewhere and one of the 
AAA patients had a family history of AAA. Because of national regulations, clinical data, 
other than sex and age, was not available for the controls; however, all donor organs were 
considered eligible for transplantation. The median age of the donors was 48 years (range, 
27 to 76 years) and 45% were male.
TABLE 1
Patient Characteristics





72.4 ± 6.2 72.5 ± 9.9 P=ns
Male/female 14/3 13/3 P=ns
AAA diameter
(cm, mean±SD)
6.9 ± 1.3 7.7 ± 1.4 P=ns
Location AAA








Increased Collagen Turnover in AAA and Ruptured AAA
Sharply increased type I collagen carboxyterminal telopeptide fragments [CTX enzyme-linked 
immunosorbent assay (ELISA)] in AAA (AAA versus controls, P < 0.001; Figure 1) and a 
further increase in ruptured AAA (ruptured AAA versus AAA, P < 0.02) confirmed increased 
fibrillar collagen degradation in aneurysmal disease.
C HAP TER 2
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mRNA Expression Profiles of MMP and Cathepsin Collagenases and Their Inhibitors
Normalized mRNA expression of MMP collagenases (MMP-1, -8, -13, -14), the gelatinase 
MMP-9 (an MMP gelatinase that is frequently associated with AAA), cysteine collagenases, 
and the endogenous inhibitors of protease activity is shown in Figure 2, A and B, and the 
normalized (GAPDH = 0) number of amplification cycles (Ct values) is provided in Table 2. 
Our findings confirm prominent expression of MMP-9 in AAA as well as in ruptured AAA (P < 
0.01; Figure 2A, Table 2); however, with the sole exception of a modest increase in MMP-14 
expression in ruptured AAA (P < 0.05), mRNA expression of MMP collagenases was similar 
and low in all three study groups (Figure 2A, Table 2). Expression of the cysteine collagenases 
cathepsin K, L, and S, on the other hand, was equally increased in both AAA and ruptured 
AAA (P < 0.04; Figure 2B, Table 2). Cathepsin V mRNA expression was similar and low in all 
groups. mRNA expression for the tissue inhibitors of MMP (TIMPs) as well as cystatin C, the 
cognate inhibitor of cysteine protease activity, is shown in Table 2. Expression of TIMP-1 and 
-3, the most prominently expressed TIMPs in the aortic wall, was similar and high in all study 
groups, whereas a moderate increase in TIMP-2 expression was observed in ruptured AAA 
(P < 0.05). Cystatin C expression was similar and high in all three study groups.
F IGURE 1
Collagen degradation (CTX assay for collagen type I degradation) in aortic wall samples of 
control aorta, growing AAAs, and ruptured aneurysms (ruptured AAAs). *P < 0.02; #P < 0.001.
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A: Relative mRNA expression (GAPDH=1) of MMP collagenases and the gelatinase MMP-9 
in the infrarenal aorta of controls, growing AAAs, and ruptured aneurysms. *P< 0.05 versus 
controls. 
B: Relative mRNA expression (GAPDH=1) of the cysteine collagenases in the infrarenal aorta 
of controls, growing AAAs, and ruptured AAAs. *P<0.05 versus controls.
F IGURE 2
C HAP TER 2
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Protease Activity Assays and Western Blot Analysis
Posttranslational regulation of protease activity was evaluated by specific protein activity 
assays and Western blot analysis. Preliminary studies did not indicate direct MMP activity 
in the tissue homogenates (ie, activities below the detection limit of the respective assays 
(1.4, 5.0, 2.7, 8.1, and 0.2 ng/ml for MMP-1, -8, -9, -13, and -14, respectively); hence 
only latent (pro) forms (ie, on activation of captured latent MMPs) of the respective MMP 
collagenases were assessed. MMP-9 activities were included as positive control. Activation 
of captured latent MMP proteases revealed prominent MMP-8 [350 (161 to 622) ng eq/mg 
protein versus 275 (56 to 1361) ng eq/mg protein, median, (range); P = ns] and MMP-9 [84 
(15 to 334) ng eq/mg protein versus 118 (68 to 1484) ng eq/mg protein in AAA and ruptured 
AAA, respectively, P = ns] activities, as well as marginal MMP-13 [37 (21 to 49) ng eq/mg 
and 34 (21 to 44) ng eq/mg protein, P = ns] proenzyme expression in AAA and ruptured 
AAA, respectively. Activities for MMP-1 remained below the detection threshold of the assay.
Immunohistochemical analysis of MMP-8 expression (Figure 3) showed that MMP-8 
expression was primarily confined to infiltrating neutrophils, thus accounting for the apparent 
TABLE 2
Normalized (GAPDH= 0) ΔCt Values of proteases and their inhibitors 
in Control Aorta, AAA, and Ruptured AAA.
Mean (SD) is in parentheses and median (range) is in brackets. Ct values represent the 
number of amplification cycles required before reaching a predefined threshold in the  
real-time PCR. All values were normalized on basis of duplex measurement of GAPDH 
expression. Normalized Ct values (ΔCt values) inversely relate to the mRNA expression  
(ie, a negative ΔCt value indicates expression exceeding GAPDH expression, whereas high 
Ct values indicate low mRNA expression). A ΔCt value of 20 reflects the detection limit of 
the assay (40 cycles). *P < 0.05 versus control.
Control AAA Ruptured AAA
(n =11) (n=17)  (n=15)
MMP-1 14.2 [7.8 to 20.0] 9.7 [5.3 to 13.6] 9.4 [6.6 to 20]
MMP-8 11.9 [4.3 to 20] 15.9 [13.4 to 20.0]* 16.5 [12.6 to 20.0]*
MMP-9 7.7 (3.4) 4.0 (1.4)* 4.9 (1.8)*
MMP-13 11.5 (4.4) 10.1 (2.3) 9.9 (2.2)
MMP-14 10.1 (2.8) 10.7 (2.7) 9.4 (1.0)*
Cathepsin K 7.9 (2.3) 5.8 (2.3)* 6.4 (1.3)*
Cathepsin L 0.4 (1.9) -1.6 (2.2)* -2.3 (0.9)*
Cathepsin S 4.0 [-1.5 to 7.6] 2.2 [0.3 to 4.0]* 1.4 [-1.3 to 3.9]*
Cathepsin V 9.3 (3.5) 8.0 (2.4) 8.4 (2.1)
TIMP-1 -1.6 (1.6) -2.7 (2.0) -2.2 (0.9)
TIMP-2 5.7 (1.0) 4.2 (1.3) 4.9 (0.6)*
TIMP-3 1.5 (1.1) 1.6 (2.4) 2.0 (1.1)
Cystatin C -3.1 (1.2) -3.1 (1.1) -3.1 (1.3)
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discrepancy between minimal MMP-8 mRNA expression and abundant pro-MMP-8 activities. 
Unlike MMPs, cysteine protease are not readily activated by small molecular compounds; 
hence the cathepsin K activity assay only allows analysis of active cathepsin K. Analogous to 
assays for active MMP, the cathepsin K activity assay did not reveal net cathepsin K activity 
in AAA and ruptured AAA (detection threshold 0.001 ng/ml). We used a novel assay for the 
quantification of cathepsin S activity; however, do to the dissociation of cathepsin S-cystatin 
C complex in the assay, this assay measures both active cathepsin S as well as cystatin 
C-complexed cathepsin S. We found significant activities for cathepsin S in both AAA and 
ruptured AAA [37.3 (16.3 to 78.4) ng eq/mg protein and 49 (11.6 to 93.4) ng eq/mg protein 
(median ranges) in AAA and ruptured AAA, respectively; P = ns].
F IGURE 3
Immunohistochemical staining of MMP-8 (top) and the osteoclastic proton pump v-H+-ATPase 
(bottom) in normal control aorta, AAA, and ruptured AAA. MMP-8 is expressed in infiltrating 
neutrophils, whereas v-H+-ATPase is primarily expressed in monocytes/macrophages and to a 
lesser extent in smooth muscle cells.
Control AAA Ruptured AAA
Although detectable cathepsin S activities and absent MMP and cathepsin K activity may 
identify cathepsin S as the primary collagenase in AAA and ruptured AAA, these results 
mostly likely reflect the rapid inactivation of active proteases by excess endogenous protease 
inhibitors during the preparation of the tissue homogenates. It was reasoned that formation 
of protease-inhibitor complexes critically depends on preceding protease activation and that 
quantification of these complexes thus provides an indirect means of establishing preceding 
protease activation. We performed Western blot analysis for pro and active forms of MMP-8, 
cathepsin K, L, and S that indeed showed strongly increased activation of these proteases 
C HAP TER 2
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in growing AAAs and ruptured AAAs (Figure 4). No differences were found between growing 
AAAs and ruptured AAAs.
Extracellular cathepsin K and L activity and stability critically depends on formation of an 
acidic pericellular microenvironment. In osteoclasts such an environment is created by the 
osteoclastic trans-membranous proton pump (v-H+-ATPase). Expression of this proton pump 
in cysteine protease-expressing mononuclear cells and smooth muscle cells in AAA and 
ruptured AAA (Figure 3) shows that conditions required for extracellular cathepsin K and L 
activities are present in aneurysmal disease.
F IGURE 4
Increased expression of the activated forms of the collagenases MMP-8, cathepsin K, L (24- 
and 28-kd bands1), and S in growing AAAs (light gray boxes) and ruptured aneurysms (dark 
gray boxes) compared with control aorta (white boxes). *P<0.05 versus controls.
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TIMP-1 and Cystatin C Protein Expression
Protein expression of TIMP-1, the principal TIMP in the arterial wall, as well as expression of 
cystatin C was evaluated by Western blot analysis. Data in Figure 5 suggest a trend toward 
lower TIMP-1 protein expression in AAA and ruptured AAA; however, this difference did not 
reach significance (P < 0.1). Cystatin C protein levels were significantly reduced in growing 
AAA (P < 0.05) and further ruptured AAA (P < 0.05 versus growing AAA). Decreased cystatin 
C protein levels along with abundant cystatin C mRNA expression in AAA suggests that the 
decreased cystatin C levels in AAA are secondary and may relate to increased cystatin C 
consumption as result of increased cysteine protease activity or alternatively may reflect 
increased cystatin C catabolism. We found no indication for an association between reduced 
cystatin C protein levels and cysteine collagenase mRNA or protein expression (data not 
shown). However, the observed inverse relationship between active MMP-8 and cystatin 
C protein levels (r = -0.78, P < 0.05) in growing AAA suggests that cystatin C deficiency is 
secondary and may result from proteolytic degradation by MMP-8 or other neutrophil-derived 
proteases. Indeed, in vitro experiments showed that cystatin C is degraded by various 
neutrophil-derived proteases such as MMP-8 and the serine protease neutrophil elastase, 
and to a lesser extend by MMP-9 (Figure 6).
F IGURE 5
Relative protein expression of the principal inhibitor of MMP activity (TIMP-1) and of cystatin 
C, the principal inhibitor of cysteine protease activity in control infrarenal aorta (white boxes), 
growing AAAs (light gray boxes), and ruptured AAAs (dark gray boxes). *P<0.05 versus 
controls;+P<0.05 AAA versus ruptured AAAs.
C HAP TER 2
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F IGURE 5
Discussion
Biomechanical4–6 and clinical studies19 demonstrate that the mechanical strength of the 
vascular wall relies on the structural collagen network in the media and adventitia. Increased 
collagen turnover that is not adequately matched by collagen deposition is held responsible 
for the growth and ultimate rupture of AAA.1 However, the proteases responsible for the 
increased collagen turnover have not been identified. Load-bearing collagens within the 
arterial wall are predominantly type I/III fibrillar collagens that are highly resistant toward 
proteolysis. Degradation of these collagens critically depends on the action of specific 
collagenases that are able to destabilize the triple helix of native fibrillar collagen.20 
Destabilized collagen helices can than be further degraded by less specific proteases 
such as the gelatinases MMP-2 and -9, and the stromelysins MMP-3 and -10. Hence, 
degradation of collagen matrix in arterial wall primarily dependent on the initial action of 
specific collagenases (ie, the classic MMP collagenases as well as selected members of 
the cysteine protease family).
Several reports indicate expression of MMP as well as cysteine collagenases in AAA on an 
individual basis,21–26 but these studies15 are not quantitative and do not address the important 
posttranslational regulation of protease activity, which involves controlled activation of the 
inactive proenzyme and subsequent inactivation by specific and nonspecific endogenous 
inhibitors.16,27 Moreover, the possible involvement of increased collagenase activity13,14 as 
the underlying cause of rupture has not been addressed in detail.
To confirm increased collagen turnover in AAA and to identify candidate collagenases involved 
in AAA growth and possible rupture, we used an integrated approach that involved evaluation 
of collagen degradation, expression of all MMP and cysteine collagen-degrading enzymes, 
and the posttranslational regulation of protease activity. Putative increases in aortic wall 
collagen turnover1 were evaluated by the Serum Crosslaps ELISA. This ELISA specifically 
detects C-telopeptide fragments that are released on proteolytic cleavage of native type I 
fibrillar collagen. Sharp increases in C-telopeptide fragments in AAA wall samples, and an 
even further increase in wall samples of ruptured AAA, confirms increased fibrillar collagen 
degradation in AAA and corroborates earlier observations of increased collagen degradation 
in ruptured AAA.13,14
Cystatin C degradation by neutrophil proteases MMP-8, MMP-9, and neutrophil elastase in vitro. 












PROTE A SES IN A A A
To identify collagenases responsible for the excess collagen degradation, we first explored 
mRNA expression of the classic collagenases (namely the MMP collagenases, MMP-1, 
-8, -13, and -14) by semi quantitative real-time PCR. We included expression of MMP-9, a 
gelatinase that is prominently expressed in AAA, as the positive control. Findings from the 
mRNA analysis confirmed prominent expression of MMP-9 in AAA3 and ruptured AAA. With 
the exception of a modest increase in MMP-14 expression in the ruptured AAA, analysis did 
not indicate increased MMP collagenase mRNA expression in growing AAA or ruptured AAA. 
We used specific immunocapture-protease activity assays to validate the MMP mRNA data. 
These activity assays have been shown to allow quantification of active proteases16 and, 
after in vitro activation of the latent MMPs, assessment of the pool of pro-MMP.16 Direct 
assessment of MMP collagenases (ie, active enzymes) did not reveal detectable protease 
activity in the tissue homogenates (all activities were below the detection threshold of the 
assay). Although this finding may indicate that all collagenases present are in their inactive, 
latent form, it most likely reflects a technical limitation when assessing protease activity in 
complex biological samples such as tissue homogenates. Under such conditions, high levels 
of endogenous inhibitor will rapidly inactivate any active protease present, thus resulting in 
the absence of detectable protease activity.
Findings for the latent (pro) MMPs (ie, on in vitro activation of the latent proteases) primarily 
paralleled findings from mRNA analysis and indicated significant expression of proMMP-9 
but only minimal expression of the collagenases pro-MMP-1 and -13. Indicating that the 
absolute expression of MMP-1 and -13 in AAA23–25 is low, suggesting that their contribution 
to collagen degradation in growing and ruptured AAA is limited. Prominent pro-MMP-8 
activities sharply contrast with minimal MMP-8 mRNA expression, and our activity data 
actually put MMP-8 on par with MMP-9 as the most prominently expressed MMP in AAA. 
Neutrophil MMP-8 is a stored secondary granule protein that is transiently expressed during 
the late myeloid maturation pathway of neutrophils28,29 Immunohistochemical analysis 
confirmed MMP-8 abundance in growing and ruptured AAA and showed that MMP-8 
is predominantly expressed in infiltrating neutrophils, thus accounting for the apparent 
discrepancy between MMP-8 mRNA and protein expression.
The activity assays did not indicate net MMP-8 activity. Failure to detect any appreciable 
MMP-8 activity most likely relates to inactivation of active proteases by excess endogenous 
protease inhibitor during preparation of tissue homogenates. This notion is supported by 
our observation of increased MMP-8 inhibitor complexes (Western blot analysis) in growing 
and ruptured AAA. Formation of these complexes critically depends on protease activation, 
and assessment of protease-inhibitor complexes thus provides a means of establishing 
preceding protease activation. We validated Western blot analysis as a means of quantifying 
protease inhibitor complexes and found abundant expression of the active 28-kd MMP-8 
form in growing and ruptured AAA, thus showing that MMP-8 activation had occurred in AAA 
and ruptured AAA.
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Although the MMP-collagenases are referred to as the classic collagenases, it is now apparent 
that selected members of the cysteine family of proteases are involved in remodeling of the 
collagen matrix as well.30 Extracellular activities of cathepsin K and L have been recognized 
as critical factors in bone turnover31 and endothelial stem cell trafficking,32 and evidence 
from animal studies identifies cathepsin K and S as critical factors in remodeling of the 
atherosclerotic plaque.33 Sharply increased C-telopeptide fragments (CrossLaps ELISA) 
in aortic wall samples of AAA and an even further increase in ruptured AAA show that 
the cysteine proteases are also involved in collagen degradation in growing and ruptured 
AAA.34 We analyzed mRNA expression of the cysteine proteases cathepsin K, L, S, and 
V35 as well as expression of cystatin C, the cognate endogenous inhibitor of extracellular 
cysteine protease activity. In contrast to the data for the MMP-collagenases, this analysis 
indicated clear increases in mRNA expression of cathepsin K, L, and S in both AAA as well 
as ruptured AAA. Again, no apparent differences were found between growing and ruptured 
AAA. Activation36,37 and stability of cysteine proteases cathepsin K and L critically relies on 
an acidic pericellular environment.38–40 In osteoclasts such a microenvironment is created 
by a transmembraneous proton pump v-H+-ATPase.41 We performed immunohistochemical 
staining for this osteoclastic v-H+-ATPase17 and found abundant expression of this proton 
pump in infiltrating mononuclear cells and to a lesser extend in the vascular smooth muscle 
cells in growing and ruptured AAA, indicating that the optimal conditions required for 
pericellular cysteine protease activity may indeed exist in aneurysmal disease.
We used novel specific activity assays based on the same principle as the MMP activity 
assays to evaluate cathepsin K17 and S activities in AAA and ruptured AAA. Akin to the MMP 
activity assays, the cathepsin K activity assay did not indicate net cathepsin K activity, but 
we did observe significant cathepsin S activity in growing AAAs and ruptured AAAs in the 
cathepsin S activity assay. Abundance of activated cathepsin K by Western blot analysis 
shows that cathepsin K activation occurs in AAA and indicates that failure to detect active 
cathepsin K in the activity assay presumably reflects inactivation of active cathepsin K 
by the endogenous inhibitors during preparation of the tissue homogenates. Abundant 
cathepsin S activities in the novel cathepsin S assay may identify cathepsin S as the 
principal collagenase in AAA and ruptured AAA; however, we found indications that observed 
cathepsin S activities relate to dissociation of the cathepsin S-cystatin C complex during the 
washing steps required in the cathepsin S activity assay, an effect that is not seen in MMP 
and cathepsin K activity assays.
Reported deficiencies in cystatin C, the principle inhibitor of extracellular cysteine protease 
activity42,43 in AAA may amplify the role of the cysteine proteases. It was postulated that 
these deficiencies occur at the transcriptional level and relate to transforming growth factor-
deficiency.42 However, our data point to a different mechanism. Reduced protein levels, 
albeit similar cystatin C mRNA expression, along with the inverse relationship between 
tissue MMP-8 and cystatin C levels and our in vitro data showing that cystatin C is degraded 
by various neutrophil-derived proteases such as neutrophil elastase and MMP-8, suggest 
that cystatin C deficiency in AAA is secondary and may relate to cystatin C degradation by 
35
PROTE A SES IN A A A
neutrophil-derived proteases. Such a mechanism is not known for cystatin C, but a similar 
gain of function mechanism44 has previously been described for the serpin 1-proteinase 
inhibitor.45 Eliason and colleagues46 recently showed that neutrophil depletion inhibits 
aneurysm formation in the elastase model of aneurysm formation but also observed that, 
although neutrophils are critical for the process of aneurysm formation in this model, their 
contribution is independent of MMP-8 (as well as of MMP-2 and -9). Neutrophil-mediated 
cystatin C degradation may well explain the putative prominent role of neutrophils in the 
process of aneurysm formation.
In conclusion, our results confirm excess collagen degradation in AAA and ruptured AAA 
and identify MMP-8 and the cysteine proteases cathepsin K, L, and S that are expressed 
along with the osteoclastic proton pump v-H+-ATPase as the principle collagenolytic culprits 
in AAA. Our findings confirm and extend findings from Wilson and colleagues47 but do not 
indicate increased MMP or cysteine collagenase expression in the anterior aneurysmal 
wall as the cause of rupture,47,48 yet we cannot exclude that local increases in cysteine 
collagenase activities at the site of rupture contribute to rupture of the aneurysm. Reduced 
cystatin C protein expression along with increased collagen degradation products in the 
anterior aneurysmal wall of ruptured aneurysms points to an alternative mechanism and 
suggests that protease inhibitor deficiency rather than increased protease expression may 
contribute to AAA rupture. Pharmaceutical inhibition of cysteine protease activity49 and/or 
manipulation of neutrophil activation50 may provide a pharmaceutical means of stabilizing 
AAA.51
C HAP TER 2
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Abstract
Background: Matrix metalloproteinase-9 (MMP-9) is thought to play a central role in 
abdominal aortic aneurysm (AAA) initiation. Doxycycline, a tetracycline analogue, has 
direct MMP-9-inhibiting properties in vitro, and it effectively suppresses AAA development 
in rodents. Observed inhibition of AAA progression, and contradictory findings in human 
studies evaluating the effect of doxycycline therapy on aortic wall MMP-9, suggest that 
the effects of doxycycline extend beyond MMP-9 inhibition and that the effect may be 
dose-dependent.
Methods: This clinical trial evaluated the effect of 2 weeks of low- (50 mg/d), medium- 
(100 mg/d), or high-dose (300 mg/d) doxycycline vs no medication in four groups of 15 
patients undergoing elective AAA repair. The effect of doxycycline treatment on MMP 
and cysteine proteases, and their respective inhibitors, was evaluated by quantitative 
polymerase chain reaction, Western blot analysis, immunocapture protease activity assays, 
and immunohistochemistry.
Results: Doxycycline was well tolerated and no participants dropped out. Doxycycline 
treatment reduced aortic wall MMP-3 and MMP-25 messenger RNA expression (P < 0.045 
and P < 0.014, respectively), selectively suppressed neutrophil collagenase and gelatinase 
(MMP-8 and MMP-9) protein levels (P < 0.013 and <0.004, respectively), and increased 
protein levels of the protease inhibitors tissue inhibitor of metalloproteinase 1 and cystatin 
C (P < 0.029). As for the apparent selective effect on neutrophil-associated proteases, we 
sought for a reducing effect on aortic wall neutrophil content that was indeed confirmed by 
immunohistochemical analysis that revealed a 75% reduction in aneurysm wall neutrophil 
content (P < .001).
Conclusions: Independent of its dose, short-term preoperative doxycycline therapy improves 
the proteolytic balance in AAA, presumably through an effect on aortic wall neutrophil 
content. This study provides a rationale for doxycycline treatment in patients with an AAA as 
well as in other (vascular) conditions involving neutrophil influx such as Kawasaki disease 
and Behçet disease.
Clinical Relevance: The concept of pharmaceutical stabilization of abdominal aneurysms 
is promising. Doxycycline, a tetracycline analogue, is considered a lead candidate, but its 
mode of action is still unclear. This clinical trial showed that doxycycline treatment, through 
a profound effect on the number aortic wall neutrophils, has a pronounced but selective 
effect on the proteolytic balance in the abdominal aneurysm, as indicated by reduced 
matrix metalloproteinase (MMP)-8 and -9 levels and concentrations of tissue inhibitor of 
metalloproteinase-1 and cystatin C. The observation that doxycycline has a selective effect 
on neutrophil-derived proteases is remarkable and novel, and suggests that doxycycline 
may also be effective in other vascular conditions involving neutrophils, such as Kawasaki 
disease and Behçet disease, and nonvascular conditions such as chronic obstructive 
pulmonary disease.
C HAP TER 3
42
EFFEC T OF d Ox yCyC L INE ON PROTE A SES IN A A A
Introduction
An aneurysm of the abdominal aorta (AAA) is a common pathology and a major cause of death 
due to rupture.1 Risk of rupture is negligible in small AAAs, but increases exponentially in 
AAAs with a diameter of ≥55 mm.1 Hence, current approaches toward AAAs are surveillance 
of small AAAs and preventive surgical repair of larger AAAs (i.e., ≥55 mm).2 Unfortunately, 
conventional transabdominal (open) repair is associated with considerable morbidity and 
mortality.3 Although short-term results of endovascular repair appear more favorable, rates 
of mid- and long term mortality are similar to those of conventional repair.4,5 Endovascular 
repair, moreover, requires life-long follow up, and the number of reinterventions after 
endovascular repair is high (approximately 9%), although most are minor.6 As a consequence, 
the effectiveness of endovascular AAA repair is now being challenged.7,8
Pharmaceutical therapy inhibiting aneurysmal growth, and thus reducing the need for 
invasive treatment, could have major advantages for patients as well as socioeconomic 
benefits.9 Excess matrix degradation that is not balanced by matrix deposition is considered 
pivotal to aneurismal growth.1 This led to the proposal that pharmaceutical intervention 
that would reduce protease activity, in particular, matrix metalloproteinase-9 (MMP-9), could 
restore the balance between matrix degradation and deposition and thus reduce aneurysmal 
growth.10,11
Members of the tetracycline family of antibiotics have been recognized as inhibitors of MMP 
expression and activity. It was thus proposed that doxycycline, a tetracycline analogue, may 
reduce excess MMP-9 activity in AAA and constitute a pharmaceutical means of reducing 
aneurismal growth.10,11 Indeed, doxycycline has been shown to inhibit aneurysm formation in 
various animal models of AAA.10-13 Moreover, results from two preliminary phase I/II studies 
in patients under surveillance for AAA suggest that long-term doxycycline treatment may 
also attenuate or even forestall aneurysm growth.14,15
Despite these promising findings, a number of questions, in particular the mode of action of 
the drug,16 remain to be answered. The rationale behind doxycycline therapy was to prevent 
aneurysmal growth through inhibition of elastolysis mediated by MMP-9.10,17 Yet, it is now 
recognized that loss of elastin is a very early event in AAA formation and that aneurysmal 
growth and ultimate rupture essentially depend on loss of structural collagens.1,18 However, 
MMP-9 is a gelatinase that can only degrade collagen after initial cleavage by specific 
collagenases.18 Observed inhibition of aneurysmal growth in animal models and human 
studies therefore suggests that apart from its effects on MMP-9, doxycycline therapy also 
influences the collagenases.
A recent study19 evaluated the effect of preoperative doxycycline treatment on messenger 
RNA (mRNA) expression of the collagenases MMP-1, MMP-13, and MMP-14, but failed to 
observe an effect on these proteases. The effects on the primary collagenases in AAA 
(MMP-8 and the cysteine proteases cathepsins K, L, or S)18 were not evaluated.
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Another issue that has not been addressed is the contradictory results of human studies 
evaluating the effects of doxycycline on MMP-9 expression and activity. Although the initial 
human study showed that preoperative doxycycline reduced MMP-9 mRNA expression and 
activity,17 a later more elaborate study failed to observe such an effect.19 The basis for these 
divergent findings is unclear, but they may reflect increased MMP-9 expression as result 
of an immunostimulatory effect on monocytes as seen at higher doses of tetracyclines20; 
indicating that the contrasting findings in human studies may reflect a dose–response 
relationship.
To evaluate the effects of doxycycline therapy on the MMP and cysteine proteases,18 their 
respective inhibitors,18,21 and to test whether the apparent contradictory findings of human 
studies on MMP-9 relate to dose dependency, we evaluated the effect of low (50 mg/d) 
regular (100 mg/d) and high (300 mg/d) doses of doxycycline on the members of the MMP 
family of proteases and the cysteine collagenases cathepsin K, L, and S. Results from 
this study show that, irrespective of dose, 2 weeks of preoperative doxycycline treatment 
improves the proteolytic balance through reduction of the neutrophilassociated proteases 
MMP-8, MMP-9 and MMP-25, and an increase of the protease inhibitors tissue inhibitor of 
metalloproteinase 1 (TIMP1) and cystatin C. Further evaluation of this phenomenon showed 





The study was performed on intention-to treat basis. The study included 60 patients scheduled 
for elective, open aneurysm repair and excluded patients with chronic inflammatory disease 
or inflammatory aortic aneurysms. Decisions for open repair were based on anatomic (e.g., 
neck, elongation) and patient characteristics (age), and on patient preferences. Patients 
were randomly assigned to receive 50, 100 or 300 mg doxycycline per day, or no medication 
(control group), with 15 patients in each group. In two patients in the low-dose doxycycline 
group, the operation had to be postponed because of full occupancy of the intensive care 
unit; therefore, 13 patients were evaluated in this group. Medication was started 14 days 
before the planned operation, and the last dose was taken in the evening before surgery. 
Postoperative outcome was similar in all groups.
The aneurysm sac was opened and adhering thrombus was manually removed. A tissue 
sample was obtained from the anterior-lateral aneurysm wall at the maximum diameter of the 
aneurysm. Wall samples were immediately halved. One half was snap-frozen in carbon dioxide-
cooled isopentane or liquid nitrogen and stored at -80°C for later analysis. The other half was 
fixed in formaldehyde (24 hours), decalcified (Kristensens solution, 120 hours), and paraffin-
embedded for histologic analysis. All analyses were performed in a researcher-blind fashion. 
For comparison of AAA wall with nonaneurysmal wall, we used nonaneurysmal aortic wall 
samples from braindead kidney donors. Only patches displaying advanced atherosclerotic 
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lesions (equalling the characteristics of grade IV-VI lesions by the Stary classification)22 
were selected. The nonaneurysmal control group comprised 11 patients (7 men, 4 women) 
aged 55.6±10.2 years, with an aortic diameter of <2.0-cm. All nonaneurysmal control 
samples were obtained from the level of the renal artery and during a laparotomy (ie, from a 
comparable region and during a similar procedure as the AAA samples).
The study was approved by the Medical Ethical Committee of the Leiden University Medical 
Centre (LUMC), Leiden, The Netherlands.
RNA isolation and real-time quantitative polymerase chain reaction
RNA isolation and quantitative mRNA analysis by LightCycler Real-time polymerase chain 
reaction (PCR, Applied Biosystems, Nieuwerkerk aan den Ijssel, The Netherlands) were 
performed by following previously published protocols.21 All mRNA data were standardized 
on basis of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression.
Tissue homogenization
Aortic wall tissues were pulverized in liquid nitrogen and homogenized in lysis buffer (10mM 
Tris, pH 7.0; 0.1mM calcium chloride, 0.1M sodium chloride, 0.25% (v/v) Triton X-100). 
This protocol releases both soluble as well as membrane-bound proteases. Samples were 
subsequently centrifuged at 13,000 rpm for 10 minutes at 4°C, snap-frozen, and stored at 
-80°C until use. Homogenates were standardized according to their protein content (Pierce, 
Rockford, III).
Specific immunocapture MMP activity assays
MMP-1, MMP-2, MMP-8, MMP-9, MMP-13, and MMP-14 activity assays (Amersham Biosciences, 
Buckinghamshire, United Kingdom [UK]) were performed according to the supplier’s 
recommendations. In these assays, target proteases are captured by a specific antibody 
immobilized on microtiter plates, and the proteolytic activation of a modified proenzyme 
by the captured protease is used to quantify the activity of the captured protease. These 
assays allow sensitive and specific assessment of active MMPs, as well as pro-MMP upon 
activation of latentMMP by a mercuric salt (p-aminophenylmercuric acetate) in in vitro systems. 
Western blot analysis
Western blot analysis was used to quantify the amount of proenzyme as well as the preceding 
protease activation through quantification of the amount of activated protease that was 
present in the tissue homogenates as protease-inhibitor complex.18 Preliminary analyses 
showed that the antibodies used allow evaluation of both pro and active forms of the 
respective proteases and that the standard denaturing conditions required for Western blot 
analysis result in full dissociation of MMP–TIMP and cathepsin–cystatin C complexes, thus 
showing that these analyses allow assessment of inhibitor-bound MMPs and cathepsins.18
Western blot analyses for the proteases, as well as for cystatin C and TIMP1, were performed 
as previously described23 using the antibodies antihuman MMP-2 (PC- 158, the Bindingsite, 
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Birmingham, UK), anti-MMP-3 (PC-112, the Bindingsite), anti-MMP-7 (RP1MMP7, Triple 
Point Biologics, Cambridge, UK), anti-MMP8 (MAB3316, Chemicon, Chemicon Europe 
Ltd, Chandlers Ford, UK), anti-MMP-9 (TNO-BEA-21, TNO, Leiden, The Netherlands), 
anti-cathepsin K (IM55L, Calbiochem, Breda, The Netherlands), anti-cathepsin L (AF952, 
R&D Systems, Abingdon, UK), anti-cathepsin S (sc-6505, Santa Cruz, Heerhugowaard, The 
Netherlands), anti-cystatin C (sc- 16989, Santa Cruz), and anti-TIMP1 (AB8229, Chemicon). 
The amount of protein in all samples was standardized using actin levels (anti-actin sc-1615, 
Santa Cruz).
All secondary antibodies were obtained from Santa Cruz Biotechnology (Heerhugowaard, 
The Netherlands). Immunoblots were visualized using Super Signal West Dura Extended 
Duration Substrate (Perbio Science, Etten-Leur, The Netherlands), and a luminescent image 
workstation (UVP, Cambridge, UK). LabWorks 4.6 software (UVP, Upland, Calif) was used to 
quantify the immunoblots.
Immunohistochemistry
Immunohistochemistry was performed using 4-µm deparaffinized, ethanol-dehydrated 
tissue sections. Sections were incubated overnight with a myeloperoxidase (A 0398 DAKO, 
Heverlee, Belgium), a MMP-8 (Medix Biochemica, Milsbeek, The Netherlands), or a CD68 
(M 0718 DAKO) antibody. Sections were stained with Nova Red (Vector Laboratories, 
Burlingame, Calif) and counterstained with Mayer hematoxylin. Controls were performed 
by omitting the primary antibody. Specificity of myeloperoxidase staining for neutrophils 
was validated by morphometric analysis of myeloperoxidasepositive cells by an experienced 
vascular pathologist (Dr J. H. von der Thüsen). Slides were examined by two independent 
observers who were unaware of the patient’s status.
Statistical analysis
Expression of mRNA was compared by t test or Wilcoxon Mann-Whitney U test, where 
appropriate. Results of the Western blots and immunohistochemistry were analyzed by 
Wilcoxon- Mann-Whitney U test to compare different groups. Statistical significance was 
accepted at a value of P < 0.05. Many findings in this study reflect correlated data, and as 
such a Bonferroni correction was not applied for the data in this study. Yet, a Bonferroni 
correction should be considered when interpreting the results of uncorrelated data. Possible 
dose–response relationships were evaluated by quadratic regression analysis. All analyses 
were performed using SPSS 12.0.1 software (SPSS Inc, Chicago, III).
Results
Patients
Clinical characteristics of the patients are compiled in the Table. All four groups were 
comparable with regard to age, sex, pharmaceutical treatment, and AAA diameter. Owing 
to the reticence toward statin use in The Netherlands, <10% of the patients in the study 
were receiving statin therapy. Doxycycline treatment was well tolerated, and no patients 
dropped out.
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Effects of doxycycline treatment on MMP expression and activation
Compared with nonaneurysmal control aorta wall, AAA tissue was characterized by 
increased mRNA expression of soluble MMP-3 (P < 0.029) and MMP-9 (P < 0.001), as well 
as by abundant expression of the membrane type MMPs, MMP-16 (P < 0.016) and MMP-25 
(P < 0.001). Expression of all other proteases and their inhibitors was similar in control 
tissue and AAA (Supplementary Table I, online only).
Figure 1 shows that independent of its dose, 14 days of preoperative doxycycline therapy 
attenuated MMP-3 (P <0.045) and MMP-25 (P < 0.014) mRNA expression. All three doses 
of doxycycline increased MMP-8 mRNA expression to values comparable to those found in 
control aorta (Supplementary Table II, online only). Expression of all other MMPs, including 
MMP-9, was not influenced by doxycycline treatment (Supplementary Table II, online only).
Possible effects of doxycycline treatment on the posttranscriptional regulation of MMP 
protein levels and activity were evaluated by specific protease activity assays and Western 
blot analyses. Direct measurement of active MMPs in aortic tissue is not feasible because of 
the rapid inactivation of the active enzymes by the endogenous inhibitors18; therefore, MMP 
activities in the protease activity assays were only measured after in vitro activation of latent 
proenzymes. Results from these assays showed a maximum level of suppression of MMP-2, 
MMP-8, and MMP-9 proenzyme levels in the low-dose doxycycline group (MMP-2, P < 0.015; 
TABLE
Patient characteristics
a Values of P for all variables were not significant
Variablesa Control AAA Doxy Doxy Doxy
AAA 50mg 100mg 300mg
Number of patients 15 13 15 15
Age (y), mean(range) 74.8 (69-84) 72.7 (62-85) 74.1 (50-88) 72.1 (58-87)
AAA diameter, 
mean cm





6 7 5 4
Female sex 1 2 2 3
Current smoker, No. 6 6 7 5
Medication use
Statins 1 1 1 2
Antihypertensives 8 7 8 7
Antiplatelet therapy 10 8 8 8
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MMP-8, P < 0.013; and MMP-9, P < 0.004; Figure 2). Results for the higher doses were more 
variable and showed reduced aortic wall MMP-8 proenzyme levels in the standard-dose (100 
mg), and reduced MMP-9 proenzyme levels in the high-dose (300 mg) doxycycline group (P < 
0.020; Figure 2). MMP-1 and MMP-13 proenzyme levels both remained below the detection 
limit of the protease activity assays.
F IGURE 1
Left, Matrix metalloproteinase (MMP)-3 and (right) MMP-25 transcript levels relative to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Independent of its dose, doxycycline 
reduces aortic wall MMP-3 and MMP-25 messenger RNA expression. Maximum level of 
suppression was already found in the low-dose doxycycline group. Results for the higher doses 
are more variable. Results are presented in box plots depicting median value (horizontal line), 
interquartile range (box borders), and range (bars). 
*P < 0.045 and P < 0.014 respectively (t test).
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F IGURE 2
The effect of doxycycline on matrix metalloproteinase (MMP)-2, MMP-8, and MMP-9 
proenzyme levels in untreated abdominal aortic aneurysm controls and doxycycline-treated 
patients as measured in the protease activity assays. Maximum level of suppression was 
already found in the low-dose doxycycline group. Results for the higher doses are more 
variable. *P < .015 for MMP-2, P < 0.013 for MMP-8, and P < 0.004 for MMP-9 by  
Wilcoxon-Mann-Whitney U test. Results are presented in box plots depicting median value 
(horizontal line), interquartile range (box borders), and range (bars).
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We performed Western blot analysis to evaluate a possible effect of doxycycline treatment 
on protease activation. Figure 3 shows that doxycycline treatment was associated with 
a dose-independent reduction of MMP-8 and MMP-9 activation (P < 0.004). Findings for 
MMP-8 proenzyme paralleled results of the protease activity assays and showed reduced 
MMP-8 proenzyme levels for all doses of doxycycline (P < 0.010). However, results for 
MMP-9 proenzyme were not statistically significant in the low-dose and normal-dose 
doxycycline groups (P < 0.073; Figure 3). MMP-2, MMP-3, and MMP-7 proenzyme and 
active enzyme levels were not influenced by doxycycline treatment (Supplementary Table III, 
online only). This indicates that doxycycline treatment neither influenced protein levels nor 
activation of these proteases.
F IGURE 3
Doxycycline treatment: cysteine protease expression and activation
Doxycycline treatment for 14 days did not influence mRNA expression of the cysteine 
proteases cathepsin K, L, and S (Supplementary Table II, online only). Western blot analysis 
for pro and activated forms of cathepsin K, L, and S showed that doxycycline therapy did not 
influence cysteine proenzyme levels or their activation (Supplementary Table III, online only).
Doxycycline treatment: protease inhibitor expression
With the exception of a moderate reduction of TIMP2 mRNA expression (P < 0.004), none 
of the doxycycline doses influenced expression of the protease inhibitors (Supplementary 
Table II, online only). Yet, as shown in Figure 4, doxycycline therapy increased cystatin C and 
TIMP1 protein levels (TIMP1 normal-dose and high-dose doxycycline only, P < 0.029).
The effect of doxycycline on pro (gray bars) and activated (white bars) (left) matrix 
metalloprotein (MMP)-8 and (right) MMP-9 levels (relative protein levels, mean control, 100%) 
in untreated abdominal aortic aneurysm controls (n=5) and doxycycline-treated patients (n=4 
per dose) measured by Western blot analysis. Results are presented with the standard error 
(range bars). *P < 0.020 by Wilcoxon-Mann-Whitney U test.
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F IGURE 4
Doxycycline treatment reduces neutrophil influx in the aneurysmal wall.
The rather selective reduction of MMP-8 and MMP-9 (neutrophil collagenase and gelatinase, 
respectively) protein levels—but not of their mRNA expression—along with reduced mRNA 
expression of MT6-MMP, the neutrophil-specific MMP-25,24 suggested that the observed 
effects of preoperative doxycycline treatment on MMP expression are indirect and may 
relate to a reduced aortic wall neutrophil content. We quantified the aortic wall neutrophil 
content by immunohistochemistry (myeloperoxidase staining, Figure 5) that indeed showed 
that 2 weeks of preoperative doxycycline treatment resulted in a profound reduction of the 
neutrophil content (Figure 5, P < .001). Specificity of myeloperoxidase (Figure 5, B and C) 
staining for neutrophils was validated by morphometric analysis of myeloperoxidase-positive 
cells and absence of an effect of doxycycline on myeloperoxidase mRNA expression and 
on aortic wall macrophage content (Supplementary Fig, online only). The findings for 
myeloperoxidase staining were validated by MMP-8 staining, which showed similar results 
as the myeloperoxidase staining (data not shown).
Doxycycline treatment increases protein levels of (left) cystatin C, the principle extracellular 
inhibitor of cysteine proteases, as well as (right) tissue inhibitor of metalloproteinase 1 
(TIMP1) protein levels (100 and 300 mg only). Results are presented in box plots depicting 
median value (horizontal line), interquartile range (box borders), and range (bars). *P < 0.029 
by Wilcoxon-Mann-Whitney U test.
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F IGURE 5
Discussion
Doxycycline has been shown convincingly to prevent AAA formation in a variety of animal 
models,10-13 and the results from two small clinical studies suggest that doxycycline may also 
reduce AAA expansion in people.14,15 Remarkably, although the rationale behind doxycycline 
therapy is based on its putative effects on MMP-9 expression and activity,9 the effects 
of doxycycline on MMPs in the human aneurysm are unclear, with published studies17,19 
suggesting that doxycycline acts through a different mechanism.16
In this prospective clinical trial, we examined the effect of three pharmacologically 
relevant doses of doxycycline—low (50 mg/d), regular (100 mg/d) or high (300 mg/d)—on 
inflammatory processes in the aneurysmal wall of patients scheduled for elective, open 
AAA repair in an integrative approach. We first established mRNA expression profiles of 
the MMP and cysteine collagenases by quantitative real-time PCR. Because this approach 
does not provide information on the post-transcriptional regulation of protease activity, we 
applied specific protease activity assays and Western blot analyses to address the post-
translational regulation of protease activity, and quantified tissue expression of specific 
inhibitors of proteases.
Preoperative doxycycline treatment resulted in a selective reduction of MMP-8 and MMP-9 
protein levels, as well as suppression of MMP-25 mRNA expression. The effect on MMP-8 
and MMP-9 protein levels, but not on mRNA expression, along with the rather selective 
effect on MMP-25 mRNA expression,24 suggests that the effect of doxycycline on protease 
A, Doxycycline reduces neutrophil content in the aneurysmal wall. Results are presented 
in box plots depicting median value (horizontal line), interquartile range (box borders), and 
range (bars). *P < 0.001 by Wilcoxon-Mann- Whitney U test. B, Aneurysm wall neutrophil 
infiltration (myeloperoxidase staining) in the medial-adventitial border zone in untreated and 
(C) doxycycline-treated individuals. Bar represents 100 µm
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expression was indirect and may relate to suppression of neutrophil influx. Neutrophil MMP-8 
and MMP-9 are both stored (secondary granule) proteins that are temporarily expressed 
during the late myeloid maturation pathway of neutrophils and are minimally expressed in 
mature neutrophils.25,26 This could well account for the apparent discrepancy between the 
effects of doxycycline therapy on MMP-8 and MMP-9 protein and mRNA expression.
We evaluated a possible effect on neutrophil influx in the aneurysm wall by 
immunohistochemical staining for myeloperoxidase, the preferred neutrophil marker (Prof 
D. Roos, Sanquin Research, Amsterdam, The Netherlands, personal, communication) and 
indeed found that doxycycline treatment profoundly reduced the number of myeloperoxidase-
positive cells. The specificity of the myeloperoxidase staining for neutrophils was confirmed 
by morphometric analysis that showed that all myeloperoxidasepositive cells exhibit a lobed 
nucleus, typical for neutrophils, and by MMP-8 staining that showed analogous results to 
the myeloperoxidase staining.
Our immunohistochemical analysis did not indicate myeloperoxidase expression in monocytes 
and or macrophages.27 To exclude possible interference by an effect of doxycycline on 
monocyte/macrophage content or their myeloperoxidase expression, we quantified the 
number of CD68-positive cells and assessed myeloperoxidase mRNA expression, both of 
which remained unaffected by doxycycline therapy (Supplementary data, online only).
Our observations are remarkable and suggest that doxycycline may act through an effect 
on neutrophil infiltration. Neutrophil abundance (presumably resulting from interleukin-8 
hyperexpression) is a striking characteristic of AAA disease,28 and neutrophils may be 
critically involved in aneurysm formation and growth. Eliason et al29 and Pagano et al30 
recently showed that abrogated neutrophil influx forestalls aneurysm formation in the 
elastase model of aneurysm formation, indicating that neutrophil influx is critically involved in 
aneurysm formation in this established model of aneurysm formation. The pathophysiologic 
role of the neutrophils in AAA formation and aneurismal growth is still unclear. Eliason et al29 
showed that the effect occurred independently from MMP-8. Our findings of increased TIMP1 
and cystatin C protein levels upon doxycycline therapy provide an alternative explanation: we 
previously showed that cystatin C deficiency in AAA is secondary and relates to proteolytic 
degradation by neutrophilderived proteases.18 An analogous mechanism has been described 
for TIMP1,31 suggesting that neutrophils may unfavorably influence the proteolytic balance 
through an effect on the inhibitors of protease activity.
Doxycycline has been shown to inhibit neutrophil migration in in vitro studies and studies 
in healthy volunteers32; but to our knowledge, this is the first clinical study showing that 
doxycycline treatment results in a significantly reduced neutrophil influx in a chronic 
inflammatory condition such as AAA. The mechanism underlying the reduced neutrophil 
influx is yet unclear. Tetracyclines, including doxycycline, are known for their pleiotropic 
immunomodulatory activities that include suppression of inducible nitric oxide synthase 
and cyclooxygenase-2 expression.33 Both pathways are implicated in the perpetuation of 
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the inflammatory processes of AAA,34,35 suggesting that doxycycline treatment may act 
by attenuation of vascular inflammation. Sugita et al,36 on the other hand, showed that 
doxycycline treatment by chelation of intracellular Ca++-ions resulted in a dose-dependent 
inhibition of neutrophil chemotaxis. Reductions in aortic wall neutrophil content in 
patients in this study occurred independently of the dose and were already maximal at the 
sub-antimicrobial dose of doxycycline, suggesting that the effect relates to an 
anti-inflammatory mechanism.
Independent of its effects on neutrophil influx, doxycycline may further act through direct 
inhibition of MMP activity (zinc scavenging).37 Presumably, this effect is dosedependent and 
thus more prominent at higher doses. Unfortunately, such binding is lost during the washing 
steps required in MMP activity assays and not recognizable in Western blot analysis, and we 
are therefore unable to address the relevance of such an effect.
Conclusion
Preoperative doxycycline therapy for 14 days resulted in reduced aortic wall neutrophil 
content that is accompanied by a selective suppression of neutrophil-derived proteases 
and increased protein levels of the protease inhibitors TIMP1 and cystatin C. Results from 
this study provide a rationale for the evaluation of doxycycline as a therapeutic means of 
inhibition of aneurysmal growth. Moreover, our observations argue for a broader application 
for doxycycline therapy in other pathologies involving neutrophil infiltration and aneurysm 
formation, such as Kawasaki disease and Behçet disease,38,39 as well as nonvascular 
conditions with prominent neutrophil involvement such as Sweet syndrome40 and chronic 
obstructive pulmonary disease.41
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Abstract
Inflammation plays a key role in the pathogenesis of an AAA (abdominal aortic aneurysm); 
however, the nature of the inflammatory factors and cellular response(s) involved in AAA 
growth is controversial. In the present study, we set out to determine the aortic levels of 
inflammatory cytokines in relation to downstream inflammatory transcription factors and 
cellular responses. A comparison of AAA wall samples with atherosclerotic wall samples taken 
from the same aortic region allowed AAA-specific inflammatory parameters to be identified 
that distinguish AAAs from ASD (aortic atherosclerotic disease). RT-PCR (real-time PCR), 
ELISA, Western blotting and immunohistochemistry were combined to assess cytokines and 
transcription factors at the mRNA and protein level, and their activation status. Compared 
with ASD, inflammatory parameters associated with Th1-type [T-bet, IL (interleukin)-2, 
IFN-  (interferon-  ), TNF-  (tumor necrosis factor- ), IL-1  and cytotoxic T-cells] and Th2-
type [GATA3, IL-4, IL-10, IL-13 and B-cells] responses were all increased in AAA samples. 
Evaluation of major downstream inflammatory transcription factors revealed higher baseline 
levels of C/EBP (CCAAT/enhancer-binding protein) ,  and  in the AAA samples. Baseline 
p65 NF- B (nuclear factor B) and c-Jun [AP-1 (activator protein-1)] levels were comparable, 
but their activated forms were strongly increased in the AAA samples. Downstream target 
genes of p65 NF- B, c-Jun, IL-6 and IL-8 were hyperexpressed.
Molecular and cellular processes associated with IL-6 and IL-8 hyperactivation were 
enhanced in the AAA samples, i.e. the expression of phospho-STAT-3 (signal transducer and 
activator of transcription-3) and perforin were elevated, and the content of plasma cells, 
neutrophils and vasa vasorum was increased. In conclusion, our findings demonstrate that 
an AAA is a general inflammatory condition which is characterized by enhanced expression 
and activation of pro-inflammatory transcription factors, accompanied by IL-6 and IL-8 
hyperexpression and exaggerated downstream cellular responses, which together clearly 
distinguish an AAA from ASD.
 
Introduction
An AAA (abdominal aortic aneurysm) is a focal balloon-like dilation of the terminal aortic 
segment. The atherosclerotic aneurysm, the common fusiform form of an AAA, is a frequent 
pathology and a major cause of death due to rupture1. The hallmark pathology of an 
atherosclerotic AAA is a chronic inflammatory condition of the arterial wall that is accompanied 
by a proteolytic imbalance2. Increased proteolytic activity results in excessive matrix 
degradation and progressive weakening of the vessel wall3. Despite considerable knowledge 
of the pathomorphology of AAAs, understanding the cellular and molecular inflammatory 
processes which underlie the increased protease expression and that drive aneurysmal 
growth is limited3. Available human studies analyzing the cellular composition of AAAs 
indicate an extensive heterogeneous inflammatory response that involves macrophages, 
neutrophils and cytotoxic T-cells as well as Th1 and Th2 (T-helper 1 and 2) cell subsets4–6.
It is well established that the Th1-/Th2-type balance is controlled tightly, and that 
exaggerated Th1 or Th2 responses are causatively associated with the development of 
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inflammatory pathologies7,8. Th1- and Th2- type cellular responses involve distinct (and partly 
even opposite) immune and inflammatory processes, which are mediated by specific sets 
of cytokines and transcription factors. Although Th1-type responses are typically associated 
with enhanced expression of the cytokines IL (interleukin)-2 and IFN-  (interferon- ) and the 
transcription factor T-bet, Th2-type responses are characterized by a dominance of IL-4, IL-5 
and/or IL-10 and elevated levels of the transcriptional regulator GATA39.
In the context of a developing AAA, the Th1/Th2 balance is thought to play an important 
regulatory role in the control of matrix remodeling and inflammatory processes relevant 
for AAA growth and rupture3. However, the nature of the predominant cellular response 
(Th1 or Th2) and the inflammatory factors predominantly involved in human AAA growth is 
controversial. For example, Galle and co-workers10 reported a predominance of Th1-type 
cellular and cytokine responses, whereas other studies have demonstrated the predominance 
of a Th2-type immune response11, which is reflected by the enhanced expression of Th2 
associated cytokines and minimal expression of the Th1-associated cytokine IFN- 3,11. A 
recent protein array study assessing the cytokine and chemokine profile of aortic wall tissue 
from advanced (>5.5 cm) AAAs has reported the up-regulation of both Th1-associated [IL-1 
and TNF-  (tumor necrosis factor- )] and Th2- associated (IL-10) inflammatory mediators12. 
The downstream consequences of these and similar13, 14 observations remain uncertain as, 
at the transcription factor level, cytokines can exert opposite effects. For example, IL-1 can 
activate NF- B (nuclear factor B), whereas IL-10 can suppress its activation.
With a comprehensive analysis of transcription factors lacking in the human studies 
performed so far, it remains unclear whether, and if so how, the observed changes in 
cytokine expression in the human AAA wall affect the basal expression of major inflammatory 
transcription factors and their degree of activation.
In the present study, we set out to address this issue and characterized AAA samples 
>5.5 cm with respect to their cytokine expression profile (at the mRNA and protein levels) 
and their cellular composition (using immunohistochemistry). We subsequently analyzed the 
basal expression levels of major inflammatory transcription factors [p65 NF- B, c-Jun, C/EBP 
(CCAAT/ enhancer-binding protein)  and STAT-3 (signal transducer and activator of 
transcription-3)] and their activation status (active p65 NF- B, phospho-c-Jun and phospho-
STAT-3) in relation to relevant inflammatory processes controlled by these transcription 
factors, i.e. the expression of putative target genes (IL-6 and IL-8) and their associated 
cellular effects (B cell, plasma cell and neutrophil content, and perforin expression)
Because a putatively exaggerated Th2 response in an AAA would clearly distinguish this 
pathology from ASD (aortic atherosclerotic disease), which is governed by Th1-type cellular 
and cytokine responses3, a comparison of AAAs with ASD was considered relevant. The more 
so as AAAs and ASD share common pathological features and risk factors, but differences 
in their pathogenesis are only poorly defined to date3.
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The results of the present study demonstrate elevated levels of the three C/EBP isoforms 
( ,  and ), and comparable basal but enhanced activated levels of the inflammatory 
transcription factors NF- B and c-Jun in the AAA wall. These findings at the transcription 
factor level are in accordance with hyperexpression of downstream genes, in particular 
the cytokines IL-6 and IL-8, and subsequent functional effects at the molecular (increased 
phospho-STAT-3) and cellular (increased plasma cell and cytotoxic T-cell content) level. 
Taken together, these differences characterize AAAs as an inflammatory condition and 




All human arterial wall samples were provided by the Vascular Tissue Bank (Department of 
Vascular Surgery, Leiden, The Netherlands). Sample collection and handling was performed 
in accordance with the guidelines of Medical Ethical Committee of the Leiden University 
Medical Center, Leiden, The Netherlands. All samples were obtained following consent of 
the patients. None of the patients in the present study had a history of diabetic or chronic 
inflammatory disease. The primary cause of the fatal brain injury in the ASD group was a 
major head trauma or subarachnoidal bleeding.
Anterior lateral aneurysm wall samples were obtained from patients with an AAA >5.5 cm 
undergoing elective open repair (AAA group: n=17; age, 72.4+− 6.2 years (value is the 
mean+− S.D.); 14 males/three females; and AAA diameter, 6.7+− 1.1 cm). Due to reticent 
statin use only one patient with an AAA used a statin. For comparison of the AAA wall with 
the atherosclerotic aortic wall, we used non-aneurysmal aortic wall samples from brain-dead 
kidney donors. Only patches displaying advanced atherosclerosis with advanced 
atherosclerotic lesions (equaling the characteristics of grade IV– VI lesions according to 
the Stary classification 15) were selected (ASD group; n=11; age, 55.6+− 10.2 years; seven 
males/four females; aortic diameter, <2.0 cm). Of note, all ASD samples were obtained 
at the level of the renal artery and during a laparotomy, i.e. from a comparable region and 
during a similar procedure as the AAA samples.
Any adhering thrombus was carefully removed and the aortic walls (either AAA or ASD) were 
divided in two. One half was immediately snap-frozen in liquid nitrogen and stored at −80 ◦C 
for mRNA [RT-PCR (real-time PCR)] and protein (Western blot, Multiplex and ELISA) analysis. 
The other half was fixed in formaldehyde for 24 h, decalcified using Kristensen’s solution for 
120 h and embedded in paraffin for histological analysis.
RNA extraction and mRNA analysis
Total RNA extraction was performed using RNAzol (Campro Scientific) and glass beads 
according to the manufacturer’s instructions. Subsequently, cDNA was prepared using 
a Promega kit for RT-PCR. The mastermix (Eurogentec), an ABI-7700 system (Applied 
Biosystems) and established primer/probe sets (Applied Biosystems; Table 1) were 
used according to the manufacturer’s instructions and as reported previously16. GAPDH 
(glyceraldehyde-3-phosphate dehydrogenase) was used as a reference and for normalization.
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Tissue homogenization for protein analysis
Aortic wall tissues were pulverized in liquid nitrogen and homogenized in 2 voles of lysis buffer 
[10 mmol/l Tris/HCl (pH 7.0), 0.1 mmol/l CaCl2, 0.1 mol/l NaCl and 0.25%TritonX-100]. 
This protocol releases both soluble as well as membrane-bound proteins. Samples were 
subsequently centrifuged at 10 000 g for 15 min at 4◦C, snapfrozen in liquid nitrogen and 
stored at −80◦C until use. Protein content in the homogenates was determined with a BCA 
(bicinchoninic acid) protein assay kit (Pierce).
Multiplex assay and ELISAs
IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17A, G-CSF (granulocyte colony-
stimulating factor), GM-CSF (granulocyte/macrophage colony-stimulating factor), IFN-γ ,MCP-
1 (monocyte chemoattractant protein-1), MIP-1β (macrophage inflammatory protein-1β) and 
TNF-α protein levels in tissue homogenates were determined using a Bio-Plex 17 panel for 
multiple cytokines (Bio-Rad Laboratories). Detection thresholds for the cytokine panel was 
<0.5 pg/ml for IL-1, IL-2, IL-5, IL-6, IL-7, IL-8, IL-10 and TNF-α, <1 pg/ml for IL-12 and IL-17A, 
and <5 pg/ml for IL-4, IL-13, G-CSF, GM-CSF, IFN-γ and MCP-1. IL-6, IL-8 and MCP-1 levels 






















TaqMan®gene expression assays (Applied Biosystems) or probe/primer combinations (IL-6 
and MIF) used in RT-PCR 
FAM, 6-carboxyfluorescein; TGF-β, transforming growth factor-β
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accurately using separate specific ELISAs [PeliKane compact kit (Sanquin Reagents) for IL-6 
and IL-8 and a Quantikine kit (R&D Systems) for MCP-1]. sIL-6R [soluble IL-6R (IL-6 receptor)] 
levels were determined using an ELISA specific for human sIL-6Rs (R&D Systems).
 
Western blot analysis
Western blot analysis was performed essentially as described previously 17 using antibodies 
specific for human p65 NF-κB (both non-active and active; Santa Cruz Laboratories and 
Chemicon respectively), c-Jun (Santa Cruz Laboratories), phospho-c-Jun (Ser73) (Santa Cruz 
Laboratories), perforin (SantaCruzLaboratories), STAT- 3 (Santa Cruz Laboratories), phospho-
STAT-3 (Epitomics), C/EBPα (Santa Cruz Laboratories), C/EBPβ (Santa Cruz Laboratories), 
C/EBPδ (Santa Cruz Laboratories) and β-actin (Santa Cruz Laboratories) as described 
previously 18.
The corresponding secondary antibodies were obtained from Santa Cruz Biotechnology 
[donkey anti- (goat IgG)] and Pierce [goat anti-(rabbit IgG) and goat anti-(mouse IgG)]. 
Immunoblots were visualized and quantified using the Super Signal West Dura Extended 
Duration Substrate (Perbio Science), LabWorks 4.6 software and a luminescent image 
workstation (UVP). Protein expression levels in aortic wall samples were normalized for 
β-actin, and separate anti-(β-actin) immunoblots were performed for each sample.
Immunohistochemistry
Immunohistochemistry was performed using deparaffinized ethanol-dehydrated tissue 
sections (4 μm thick) essentially as described previously 16, 19. Sections were incubated 
overnight with polyclonal antibodies specifically staining human MPO (myeloperoxidase; 
1:4000 dilution; DAKO), CD20 (1:1000 dilution; DAKO), CD138 (1:1000 dilution; Serotec), 
IL-6 (1:2000 dilution; Biogenesis) or IL-8 (1:200 dilution; Biogenesis). Conjugated 
biotinylated anti-(goat IgG) or anti-(rabbit IgG) were used as secondary antibodies. Sections 
were developed with Nova Red® (Vector Laboratories) and counterstained with Mayer’s 
haematoxylin to allow morphological analysis. The specificity of the antibody staining was 
confirmed by omitting the primary antibody. The presence of eosinophils was evaluated 
morphologically by haematoxylin/eosin staining.
Statistical analysis
All values are expressed as means+− S.D. for normally distributed data or medians (range) 
for non normally distributed data. Normally distributed continuous variables were analyzed 
using a Student t test, whereas non-normally distributed continuous data were analyzed with 
a Wilcoxon–Mann–Whitney test using (SPSS 11.5 for Windows). CIA (Confidence Interval 
Analysis; version 2.0.0. 41; https://www.som.soton.ac.uk/cia/) was used to calculate the 
non-parametric 95% CI (confidence interval) for differences in mRNA expression. Possible 
relationships between aneurysm diameter and inflammatory markers were evaluated by 
Pearson’s correlation test. The level of statistical significance was set at P<0.05. The 
present study incorporates multiple statistical comparisons. For the sake of clarity, non-
corrected data are provided; however, a Bonferroni correction should be considered when 
interpreting non-correlated data. 
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Results
Characterization of aneurysmal and atherosclerotic aortic walls based on cytokine 
expression profiles
Aortic aneuysmal (AAA) and atherosclerotic (ASD) wall samples used in the present 
study were characterized for the expression of markers of inflammation. RTPCR and the 
Bio-Plex assay were used to determine the expression level of specific Th1-associated, 
Th2- associated and general inflammatory factors on the mRNA and/or protein level.
Compared with ASD, the AAA group had significantly higher aortic mRNA expression levels 
of the Th1- associated transcription factor T-bet (24-fold increase) and the Th2-associated 
transcription factor GATA3 (12-fold increase; Table 2). The T-bet/GATA3 ratio was similar in 
both experimental groups (P=0.52).
A subsequent analysis of cytokines in aortic mRNA extracts revealed substantially increased 
mRNA levels of the Th1-associated cytokines IL-2, IFN-γ, TNF-α, IL- 1α and IL-1β in AAA 
samples. In line with this observation, the protein levels of IL-2, IFN-γ, TNF-α and IL-1α were 
significantly higher in AAA homogenates (Table 3).
With respect to Th2-associated cytokines, higher mRNA levels of IL-4, IL-10 and IL-13 
(P<0.01) were found in the AAA samples (Table 2). An increase in IL-4 and IL-13 protein 
levels was also observed, whereas IL-5 and IL-10 levels were below the detection limit of the 
Bio-Plex assay (Table 3).
In addition to these typical Th1- and Th2-associated factors, cytokines/chemokines reflecting 
a general pro-inflammatory status, such as MCP-1, MIP-1β, MIF (migration inhibitory factor), 
G-CSF and GM-CSF, were also significantly expressed in the AAA samples compared with the 
ASD samples (at the mRNA and/or protein level; Tables 2 and 3).
Taken together, the above molecular characterization of aortic wall samples by cytokine 
profiling does not indicate a clear Th1/Th2 polarization in AAAs, but points to a generic 
enhancement of inflammation compared with ASD.
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TABLE 2
fold increase in AAA P value ΔCt AAA ΔCt ASD
Th1-associated
T-bet 24.3 ≤0.05 8.7 [4.3-20] 13.3 [5.2-20]
IL-2 8.6 <0.001 9.7 [6.0-13.3] 16.2 [10.7-20]
Interferon-γ 630 <0.001 9.0 [5.8-13.5] 18.3 [8.6-20]
TNF-α 2.3 0.09 8.1[3.9-11.1] 9.3 [6.0-20]
IL-1α 315.2 <0.01 8.3 [4.0-20.0] 16.6 [5.7-20.0]
IL-1β 11.3 <0.001 2.7 (1.5) 6.2 (2.8)
Th2-associated
GATA-3 12.1 <0.01 6.8 [3.1-11.4] 10.4 [5.4-20]
IL-4 1.7 0.12 1.9 [7.1-15.2] 12.7 [9.9-20]
IL-10 1.4 0.55 5.8 [3.2-9.4] 6.3 [3.3-20]
IL-13 512 <0.01 11.0 [4.8-20] 20.0 [11.8-20]
General inflammatory
MCP-1 3.2 <0.05 -1.7 (1.8) 0.0 (1.7)
MIP-1β 3.7 <0.05 1.2 (1.3) 3.1 (3.0)
MIF 2.1 <0.01 -2.0 (1.2) -0.9 (0.9)
TGF-β 1.3 0.19 -0.9 (0.9) -0.5 (1.1)
Fold differences in gene expression of markers of Th1-associated, Th2-associated and general 
inflammatory responses
mRNA expression was analyzed in aneurysmal wall (AAA; n =17) and atherosclerotic wall (ASD; 
n =11) samples. Gene expression level of the measured genes in ASD was set at 1, and relative 
gene expression levels in AAA tissues are expressed as the median fold increase, together 
with the corresponding 95 % CI of the median fold increase and the P value. The level of mRNA 
expression for each gene of interest was calculated using Ct values. Ct values are defined as 
the number of PCR cycles at which the fluorescent signal generated during the PCR reaches a 
fixed threshold. For each sample, the Ct for the target gene and for the housekeeping gene was 
determined to calculate ΔCt (Ct, target gene ΔCt, housekeeping gene). The relative expression 
of a gene can be calculated from the formula 2−ΔCt. The corresponding ΔCt values for AAA 
and ASD are means ± S.D. (for normally distributed data) or medians (range) (for non-normally 
distributed data). High (low) ΔCt values reflect low (high) mRNA expression levels. A ΔCt value of 
20 represents the detection limit of the assay. TGF-β, transforming growth factor-β.
Characterization on the basis of cellular markers of Th1/Th2 polarization
To characterize aneurysmal (AAA) and atherosclerotic (ASD) aortas further, their cellular 
composition was evaluated with particular emphasis on Th1- and Th2-associated cellular 
responses.
Absolute and relative cytotoxic T-cell infiltration (Th1-associated) was assessed by analyzing 
aortic CD4 and CD8 mRNA expression levels 20. AAA samples had higher CD8 (26 fold; 
P<0.001) and CD4 (12-fold; P=0.24) mRNA expression levels and a higher CD8/CD4 ratio 
C HAP TER 4
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TABLE 3
AAA ASD P value
Th1-associated
IL-2 0.3 [0.04-0.6] Nd <0.001
Interferon-γ 8.2  [2.3-14.9] 0.0 [0-4.4] <0.001
TNF-α 0.2 [0.0-0.8] Nd <0.001
IL-1β 4.3 [1.1-19.1] 0.42 [0.00- <0.001
Th2-associated
IL-4 0.3 [0-1.4] ND 0.12
IL-5 Nd Nd NA
IL-10 ND ND NA
IL-13 1.4 [0.3-5.4] Nd <0.01
General inflammatory
MCP-1 2 13 [85-1781] 116 [48-923] 0.17
MIP-1β   7.5 [5.1-27.4] 7.0 [0.5-14.2] 0.23
G-CSF  6.0 [1.3-31.4] 0.0 [0-0.75] <0.001
GM-CSF 0.3  [0-1.5] Nd <0.01
IL-7    0.2 [0-0.6] Nd <0.01
IL-12 <0.05 [0-0.3] Nd 0.12
IL-17  <0.05 [0-11.7] Nd 0.53
Protein expression (ng/mg of total aortic protein)
Differences in protein expression of markers of Th1-associated, Th2-associated and general inflammatory responses 
 
Aortic wall protein expression levels of markers of Th1-associated, Th2-associated and general inflammatory responses 
were determined in aneurysmal wall (AAA; n =14) and atherosclerotic wall (ASD; n =11) samples using a Bio-Plex assay or 
ELISA for MCP-1. Values are medians (range). ND, not detectable (i.e. below the detection limit of the Bio-Plex assay). NA, 
not applicable.
(P<0.001), suggesting an enhanced influx of cytotoxic T-cells in AAA tissue. Specific IHC 
(immunohistochemical) staining of cytotoxic T-cells in sections prepared from AAA samples 
confirmed an increased abundance of cytotoxic T-cells compared with ASD samples (results 
not shown).
Potential Th2-related cellular effects were evaluated by IHC staining of B-cells (CD20) and an 
assessment of eosinophil infiltration. AAA samples had a dispersed CD20 immunoreactivity, 
which was infrequently observed in ASD samples (limited to infiltrates in the medial-
adventitial transition zone in some ASD controls), clearly demonstrating enhanced B-cell 
infiltration in AAAs (Figures 1A and 1B). Eosinophils were not found in AAA or ASD samples 
(results not shown).
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The results of our cellular characterization are consistent with the cytokine expression 
findings and demonstrate the over-representation of cells important for Th1- and Th2-type 
responses. Subsequently, the downstream consequences were examined by assessing the 
basal expression level and/or the activation status of relevant inflammatory transcription 
factors, i.e. transcription factors mainly involved in the signal transduction of the cytokines 
expressed in AAAs{C/EBPα,C/EBPβ and C/EBPδ,NF-κB and c-Jun [AP-1 (activator protein-1)]}.
Enhanced expression of (activated) pro-inflammatory transcription factors in AAAs
Protein homogenates of AAA and ASD samples were prepared and subjected to Western 
blot analysis. Aortic transcription factor concentrations were quantified relative to β-actin. 
When compared with the ASD samples, the aortic concentrations of the C/EBPα, C/EBPβ, 
C/EBPδ isoforms were 6.3-, 3.1- and 4.2-fold higher (P<0.05) respectively, in the AAA 
samples (Figure 2A). Baseline p65 NF-κB and c-Jun expression levels were comparable in 
the AAA and ASD samples (Figure 2B), but the aortic wall concentrations of their activated 
forms, p65 NF-κBactive and phospho-c-Jun, were 3.7- and 3.3-fold (both P<0.001) higher 
respectively, in the AAA samples as assessed by antibodies specifically detecting activated/
phosphorylated epitopes (Figure 2B). Taken together, these results demonstrate an enhanced 
pro-inflammatory status at the transcription factor level in AAAs, despite enhancement of 
expression of cytokines with anti-inflammatory properties (e.g. IL-10).
Enhanced IL-6 and IL-8 expression in AAAs
Next, we examined whether inflammatory factors that are positively regulated by C/EBPs, 
p65 NF-κB and c-Jun are also elevated in AAAs when compared with ASD. IL-8 transcription 
and IL-6 expression rely on the concomitant activation of signaling pathways activating 
NF- κB and AP-1 (i.e. c-Jun) or NF-κB and C/EBPs21,22. Indeed, IL-6 and IL-8 mRNA expression 
was strongly and significantly elevated in AAA samples compared with ASD samples (Table 
4). Analysis of IL-6 and IL-8 expression levels in AAA and ASD tissue homogenates by ELISA 
confirmed that the AAA samples contained very large amounts of IL-6 and IL-8 (Figure 3A). 
IL-6 and IL-8 levels exceeded the levels of all other cytokines determined in the AAA samples 
and were increased more than 100-fold (P<0.001) compared with the ASD samples. No 
relationship was found between the IL-6 or IL-8 level and the aneurysm diameter.
Hyperexpression of IL-6 and IL-8 clearly demonstrates an inflammatory divergence between 
AAAs and ASD. IHC analysis of IL-6 and IL-8 expression (Figure 3B) confirmed the abundant 
expression of both cytokines in AAA samples. Of note, IL-6 and IL-8 immunoreactivity in 
AAA samples were dispersed throughout all layers of the aortic wall and not essentially 
confined to the intimal layer and intimal border zone of the media as in ASD samples. 
Refined analysis of the cell types expressing IL 6 and IL-8 in AAA samples revealed that 
IL-6 immunoreactivity was predominantly associated with plasma cells and macrophages, 
whereas IL-8 immunoreactivity was mainly associated with lymphocytes and neutrophils. IL-6 
and IL-8 immunoreactivity in ASD samples on the other hand was predominantly limited to 
foam cells/ macrophages, vascular smooth muscle cells and lymphocytes. Taken together, 
these results demonstrate a transmural hyperexpression of IL-6 and IL-8 in AAAs.
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F IGURE 1
F IGURE 2
IHC analysis of the cellular composition of AAA and ASD tissue. Representative 
photomicrographs (similar magnification) of ASD (above) and AAA (under) tissue stained with 
antibodies specifically detecting (A and B) B-lymphocytes (B-cells; anti-CD20), (C and D) 
plasma cells (anti-CD138), and (E and F) neutrophils (MPO). Scale bar, 100 μm.
A
CB
Elevated aortic concentrations of inflammatory transcription factors are characteristic of the AAA 
wall. Basal levels of (A) C/EBPα, C/EBPβ and C/EBPδ, and (B) p65 NF-κB, c-Jun protein and their 
activated forms [NF-κBactive and phospho-c-Jun (p-c-Jun)] were determined by Western blotting in 
homogenates of AAA and ASD samples. Transcription factor expression was determined relative to 
β-actin for each sample. Results are presented in boxplots (median value is indicated by the solid 
horizontal line, the lower and upper quartiles are indicated by the box, and the range is indicated by 
the error bars). *P <0.001 compared with ASD. IOD, integrated optical density.
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Examination of the molecular and cellular effects downstream of IL-6
IL-6-mediated responses depend on the availability of cell-bound IL-6R or sIL-6R. sIL-6R 
can induce IL-6 signaling in cells not constitutively expressing IL-6R (IL-6 trans-signaling) 
but expressing its receptor dimer gp13023. Figure 4(A) shows that sIL-6R was present in 
the aortic wall, and that levels were comparable in AAA and ASD samples. Quantification 
of phospho-STAT-3, a downstream transcriptional effector of IL-6, showed that the AAA wall 
F IGURE 3
Elevated aortic concentrations of IL-6 and IL-8 protein are characteristic of the AAA wall
Aortic wall protein expression levels of IL-6 and IL-8 were determined by specific ELISAs 
for aneurysmal wall (AAA; n =14) and atherosclerotic wall (ASD; n =12) samples. Results 
are presented in box plots as the median, lower and upper quartiles and range. *P <0.0001 
compared with ASD.
Representative photomicrographs (similar magnification) of ASD (left) and AAA (right) 
tissue stained with antibodies specifically detecting IL-6 or IL-8. IL-6 immunoreactivity was 
associated with plasma cells and macrophages; IL-8 immunoreactivity was associated with 
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TABLE 4
Cytokine mRNA Fold increase 
in AAA
 P value  AAA ASD
IL-6 29.9
(10.9–86.8)
0.001 2.8 ±1.7 7.7 ±2.0
IL- 8 21.1
(3.48–65.3) 
0.003 1.4 ±2.1  5.8 ±4.5
ΔCt
contained higher levels of phospho-STAT- 3 (20-fold increase; P<0.01) compared with the 
ASD wall (Figure 4B). The protein levels of the inactive form (nonphosphorylated STAT-3) were 
lower in the AAA wall (Figure 4B). Taken together, these results indicate that hyperexpression 
of IL-6 in AAAs is associated with elevated levels of phospho-STAT3, i.e. enhanced IL-6 
signaling.
Well-established functional downstream effects (readouts) of IL-6 include the differentiation/
maturation of B-cells into plasma cells and the activation of cytotoxic T-cells. Evaluation of 
the plasma cell content in AAA and ASD samples using IHC demonstrated an abundance of 
plasma cells in the AAA wall, whereas plasma-cell specific immunoreactivity (CD138) was 
not, or hardly, present in the ASD wall (Figures 1C and 1D). Expression of perforin, a factor 
which indicates cytotoxic T-cell activation, was significantly elevated in AAA samples, both at 
the transcriptional (13-fold, P=0.006; results not shown) and protein (Figure 4C) expression 
levels.
Examination of the molecular and cellular effects downstream of IL-8
IL-8 strongly promotes neutrophil infiltration and activation, and can exert strong 
pro-angiogenic activities. Quantification of infiltrated neutrophils by IHC staining of MPO 
demonstrated a pronounced recruitment of these cells in AAA samples, but only a scattered 
presence of neutrophils in the adventitial layer of ASD samples (Figures 1E and 1F).
To examine whether increased pro-angiogenic responses were associated with AAAs, the 
number of vasa vasorum in AAA and ASD samples were quantified. The doubling of the 
number of vasa vasorum (9/mm2 in AAA samples compared with 4/mm2 in ASD samples) 
points to an enhanced angiogenic response in AAAs (results not shown).
Increase in IL-6 and IL-8 gene expression in the AAA wall
mRNA expression of IL-6 and IL-8 was analysed in aneurysmal wall (AAA; n =17) and 
atherosclerotic wall (ASD; n =12) samples. The gene expression level of the measured genes 
in ASD was set at 1, and relative gene expression levels in AAA tissues are expressed as 
median fold increase, together with the corresponding 95 % CI of the median fold increase and 
the P value. The mean (±S.D.) ΔCt values are provided in the last two columns. High (low)ΔCt 
values reflect low (high) mRNA expression levels.
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F IGURE 4
Assessment of the functional components of the IL-6 signaling pathway in AAA and ASD walls. 
(A) Aortic wall protein expression levels of sIL-6R was determined by ELISA from aneurysmal  
wall (AAA; n =14) and atherosclerotic wall (ASD; n =12) samples. (B) Basal levels of  
STAT-3 protein and levels of the activated form [phospho-STAT-3 (p-STAT-3)] were determined by 
Western blotting in AAA and ASD homogenates. Expression was determined relative to β-actin. 
*P <0.0001 compared with ASD. (C). Aortic wall protein expression levels of perforin was 
determined by ELISA from aneurysmal wall (AAA; n =14) and atherosclerotic wall (ASD; n =12) 
samples. Elevated perforin protein levels in the aneurysmal wall indicate increased cytotoxic 
T-cell activation in AAAs. Results are presented in box plots as medians, lower and upper 
quartiles and ranges. *P <0.001 compared with ASD. IOD (ODI), integrated optical density.
Discussion
In the present study, we set out to determine the aortic levels of inflammatory cytokines 
in relation to downstream inflammatory transcription factors and cellular responses in 
human AAAs. Comparison of growing AAAs with ASD using biopsies taken from the same 
aortic region allowed us to define inflammatory characteristics of AAAs that distinguish the 
disease from ASD.
The results of the present study demonstrate an enhanced expression of factors associated 
with both Th1- and Th2-type responses in AAAs. Our findings do not, therefore, support a 
clear Th1 or Th2 polarization in AAAs. At the transcription factor level, AAAs clearly differ 
from ASD by having higher concentrations of the pro-inflammatory transcription factors C/
EBPα, C/EBPβ and C/EBPδ, and the activated forms of p65 NF-κB and c-Jun, a component of 
AP-1. Consistent with this, AAAs are characterized by hyperexpression of IL-6 and IL-8, both 
of which are positively regulated by NF-κB and AP-1. We demonstrate that molecular and 
cellular processes that are associated with hyperactivation of IL-6 and IL-8 are exaggerated 
in AAAs: the aortic phospho-STAT-3 and perforin concentrations are elevated in the AAA wall, 
and B-cells, plasma cells and neutrophils are abundantly present in AAA samples, clearly 
distinguishing this pathology from ASD.
The large majority of patients with an AAA also suffer from advanced atherosclerotic 
disease, and AAAs have long been considered to be one of the classical manifestations 
of atherosclerotic disease. However, traditional atherosclerotic risk factors, such as 
cholesterol and diabetes, are not associated with an AAA24, suggesting that an AAA may be 
A B C
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a separate entity. Although AAAs and ASD share an inflammatory component relevant for 
disease evolution, the exact molecular processes causatively involved in the progression of 
AAAs or ASD are not fully understood. In addition, clear-cut mechanistic differences allowing 
the discrimination of AAAs from ASD have not been identified to date.
Recent studies assessing the aortic expression of Th1- and Th2-specific inflammatory 
mediators in human AAAs report controversial observations and claim a predominance of 
either Th1 type or Th2-type responses3,10,11. Our present findings do not support a clear 
Th1/Th2 polarization in AAAs and indicate an upregulation of both immune cell responses 
(as compared with ASD), together with a profound general inflammatory response, which 
is characterized by the high expression of cytokines, chemokines and growth factors 
[e.g. MCP-1, MIF, TGF-β (transforming growth factor-β), MIP-1β and G-CSF]. Our present 
observations are consistent with a recent protein array study by Middleton and co-workers12, 
who characterized the AAA as a classical inflammatory condition which is dominated by a 
generic inflammatory response involving similar pro-inflammatory (e.g. IL-1β and TNF-α) and 
anti-inflammatory cytokines (e.g. IL-10)25.
The net effect at the downstream transcription factor level has not been investigated to 
date. Our present findings demonstrate for the first time that the aortic concentrations of 
major inflammatory transcription factors at baseline (C/EBPα, C/EBPβ and C/EBP δ) or their 
activated forms (p65 NF-κBactive and phospho-c-Jun) are significantly increased in AAAs 
relative to ASD. Elevated aortic levels of phospho-c-Jun are in accordance with an increased 
activation of JNK (c-Jun N-terminal kinase) in an AAA as reported previously26. As IL-8 and 
IL-6 gene expression depend on simultaneous activation of NF-κB and AP-121,22, the aortic 
concentrations of these cytokines in AAAs and ASD were examined at the gene transcription 
level. Indeed, IL-6 and IL-8 mRNA were markedly elevated in AAA samples and this was 
paralleled with a significant increase in IL-6 and IL-8 protein levels. High aortic expression 
levels of IL-6 and IL-8 in human AAAs have also been reported by others13,14,27, but the 
extreme disparity compared with ASD has not been recognized to date. The hyperexpression 
of IL-6 and IL-8 in the AAA samples observed in the present study thus constitutes an 
important difference between the pathologies of AAAs and ASD. Predominance of IL 6 and 
IL-8 in the growing AAA and responses mediated by these cytokines point to a central role of 
these factors in the development of AAAs.
IL-6 is a well-recognized inducer of the hepatic acute phase response and a possible 
cardiovascular risk factor28. Because the IL-6R is expressed predominantly by hepatocytes 
and leucocytes, an extrahepatic role of IL-6 was uncertain. With the discovery of sIL-6R 
allowing ‘IL-6 trans-signaling’ in cells normally not expressing IL-6R23, IL-6 has gained 
importance in vascular disease, and in atherosclerosis IL-6 has been associated with 
lipid homoeostasis, vascular remodeling and plaque remodeling29. Our present results 
demonstrate that sIL-6R is expressed in AAA and ASD walls to a comparable extent. We 
have also demonstrated that a key mediator and downstream effector of IL-6, STAT-3, is 
present in the aorta, together with its activated (phosphorylated) form phospho-STAT3. 
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We have shown that the large differences in IL-6 protein expression in AAA and ASD samples 
are paralleled at the downstream transcription factor level: AAA walls contain higher 
phospho-STAT-3 concentrations than ASD, pointing to a pronounced activation of the IL-6 
(trans) signaling route in AAAs.
Increased IL-6 (trans) signaling may, at least partly, explain the differences in cellular 
composition seen in AAA and ASD wall samples. IL-6 reportedly controls late B-cell 
differentiation and plasma cell formation, and is an established promoter of T-cell 
migration, retention and activation30,31. Enhanced activation of the IL-6 route may very well 
be responsible for the abundant infiltration of B cells observed in the present study and 
by others14,32. Furthermore, the histological results in the present study indicate a high 
abundance of plasma cells (plasmacytosis) in the AAA samples, suggesting a higher B-cell 
differentiation rate33. Analysis of CD4 and CD8 expression indicates mainly increased 
infiltration of cytotoxic T-cells in AAA samples. Moreover, increased perforin expression, 
an established marker of cytotoxic T-cell activation34, demonstrated an increased cytotoxic 
T-cell activation status in AAA compared with ASD samples, which is consistent with the 
observation that apoptosis is enhanced in AAAs35.
Increased IL-8 expression has been reported in several inflammatory conditions, including 
Kawasaki’s disease36 and Behc,et disease37, two conditions that are associated with 
aneurysm formation. Consistent with this, expression of IL-8 in aortic aneurysmal tissue 
has been described12,27. To our knowledge, the hyperexpression of IL-8 associated with 
neutrophil cell infiltration in the AAA samples observed in the present study has not been 
reported to date and suggests that neutrophil infiltration is a hallmark of an AAA, allowing 
the discrimination of AAAs and ASD. Furthermore, G-CSF, the simultaneous expression of 
which facilitates IL-8-dependent Neutrophil cell recruitment38, was highly expressed in the 
AAA, but not in ASD, samples. It is tempting to speculate that the concomitant expression of 
these factors is responsible for neutrophil infiltration which appears critical for the process 
of aneurysm formation39,40.
In summary, our present results demonstrate that inflammation in the AAA wall is clearly 
distinct from inflammation in ASD, and that IL-6 and IL-8 hyperexpression and the dominance 
of IL 6- and IL-8-mediated responses prevail in an AAA. This comprehensive inflammatory 
response in an AAA may well be responsible for the broad, albeit not universal, up-regulation 
of selective members of the MMP (matrix metalloproteinase) class of proteases2,16 {MMP-8 
(neutrophil-derived) and MMP-9 (AP-1-regulated26)}, and the cysteine proteases cathepsin 
K, L and S16 (NF-κB-41, C/EBP-42 and IFN-γ -43 regulated respectively) in the disease. Anti-
inflammatory strategies attenuating IL-6 and IL-8 expression or activity26, and/or IL-6 and 
IL-8 signaling, may prove effective for the pharmaceutical stabilization of AAAs.
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Abstract
Introduction: There is remarkable controversy over the processes driving abdominal aneurysm 
growth. Elucidation of the key inflammatory and proteolytic processes is hampered by the 
inherent limitations of animal and human studies. Human data is largely derived from 
surgical specimens which typically reflect the final stages of the disease process and thus 
do not allow distinction between primary and secondary processes. Clear epidemiological 
and genetic associations between abdominal and popliteal aneurysms suggest that that 
these two pathologies share common grounds. On this basis we reasoned that information 
of corresponding and discordant processes in these aneurysms may provide critical clues 
on the processes that are crucial respectively dispensable for aneurysm progression.
Methods and Results: mRNA (semi quantitative RealTime PCR) and protein analysis (ELISAs, 
Muliplex, Western Blotting), and histology were performed on aneurysm wall samples 
obtained during elective popliteal and abdominal aortic aneurysm repair. Non aneurysmatic 
aorta tissue from organ donors was included as reference. MessengerRNA and protein 
analysis showed that both aneurysms are characterized by a marked activation of NF-ĸB 
and AP-1 proinflammatory transcription factors, and IL-6 and 8 hyperexpression. Clearly 
discordant findings were found for other inflammatory markers such as interferon γ, IP-10, 
TNFα, MCP-1 and MIP1α and β which were all lower in PAA. On cellular level both pathologies 
exhibited profuse infiltration of macrophages, neutrophils and T-helper cells. Results for the 
B-, plasma- and cytotoxic T-cells were clearly discordant with minimal infiltration of these 
cell types in PAA. Evaluation of protease expression and 3 activation showed that both 
conditions are dominated by increased MMP8 and 9, and cathepsin K, L and S expression 
and activation.
Discussion: This explorative study characterizes degenerative aneurysmal disease general 
inflammatory conditions dominated by profound activation of the NF-ĸB and AP-1 pathways, 
IL6 and 8 hyperexpression, and neutrophil involvement. Clearly discordant findings for 
interferon γ, cytotoxic T-cells, B-cells, plasma cells challenge a critical role for these 
factors in the process of aneurysm growth. Pharmaceutical strategies targeting the generic 
components in AAA and PAA may prove effective for the stabilization of AAA.
 
Introduction
An abdominal aortic aneurysm (AAA) is a common, dilating disorder of the aorta and a major 
cause of death due to rupture.1,2,3 Despite consensus on the fact that AAA is best described 
as a chronic inflammatory condition with an accompanying proteolytic imbalance, the exact 
nature of the inflammatory cascades, and the proteases driving aneurysmal growth remain 
unresolved. For example, while AAA was initially designated by Schonbeck and coworkers 
as a Th2-type inflammatory disease,4 later studies suggest that AAA is better characterized 
as a Th1 dominated,5 or alternatively as a general (pro) inflammatory disease.6 With respect 
to the proteases involved, attention has been primarily focused on the gelatinase MMP9. 
Yet, despite ample evidence for a critical role of MMP9 in AAA formation and grow in animal 
models of the disease, the pivotal role of MMP9 in driving human AAA growth is debated,7 
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and additional proteases such as MMP8 and the cysteine proteases cathepsin K, L and S 
have now also been brought forward.8
Interpretation of the available data is further complicated by the fact that most data is 
based on surgical specimens and/or on animal models of the disease. Surgical specimens 
generally represent the final stages of the disease process, making it difficult to discriminate 
between the primary and secondary events in the disease process.9,10 Similarly while animal 
models may provide valuable clues to the disease process, their relevance for AAA in general 
remains to be established.9
Remarkable associations are found between AAA and popliteal artery aneurysms (PAA), the 
by far most common form of peripheral aneurysms.11,12 This is not only reflected by the fact 
that about 40-50% of patients with a PAA are also diagnosed with an AAA,13,14 but also by 
the aggregation of AAA and PAA in relatives of patients with these aneurysms. Altogether, 
these observations suggest that AAA 5 and PAA share common grounds.15 We reasoned 
that identification of putative generic factors in the two conditions may provide clues on 
the nature of the inflammatory and proteolytic pathways involved in aneurysm growth, and 
constitutes a first important step to identify efficient therapeutic targets.
Since a methodical comparison of AAA and PAA is missing, we now performed a systematic 
and comprehensive analysis of inflammatory and proteolytic pathways activated in AAA and 
PAA tissue in order to identify corresponding (i.e. generally relevant) and discordant (i.e. 
aneurysm-subtype specific) processes in these two related pathologies.6
 
Materials and methods
Tissues and ethical concerns
All aneurysm samples were obtained during elective aneurysm repair. Reference samples 
(non aneurysmal abdominal aortic wall samples) were obtained from the Vascular Tissue 
Bank (Department of Vascular Surgery, Leiden, The Netherlands).
Sample collection and handling was performed in accordance with the guidelines of the 
Medical and Ethical Committee in Leiden, Netherlands and the code of conduct of the Dutch 
Federation of Biomedical Scientific Societies. All samples were obtained following consent 
of the patients. None of the patients in the present study had a history of diabetic or chronic 
inflammatory disease. AAA samples (anterior lateral aneurysm wall) were obtained from 
patients with an AAA >5.5 cm undergoing elective open repair (AAA group: n=17; age: 72.4 
± 6.2 years (value is the mean ± S.D.); 14 males/3 females; and AAA diameter, 6.7 ± 1.1 
cm). PAA samples were from patients with PAA>2,0 cm16 undergoing elective repair (PAA 
group: n=12; age: 69.6 ± 12.1 years; 11 males, 1 female).
For comparison of the AAA and PAA wall with the normal aortic wall (non aneurysmal control), 
we used non-aneurysmal aortic wall patches from kidney donations. The patches were 
obtained during clinical organ transplantation with grafts derived from cadaveric donors. 
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The primary cause of the fatal brain injury in of kidney donors was a major head trauma or 
subarachnoidal bleeding. Only patches displaying advanced atherosclerosis with advanced 
atherosclerotic lesions (equaling the characteristics of grade IV–VI lesions according to the 
Stary classification17 were 7 selected (control group; n=11; age, 55.6 ± 10.2 years; seven 
males/four females; aortic diameter, <2.0 cm). Of note, all control samples were obtained 
at the level of the renal artery and during a laparotomy, i.e. from a comparable region and 
during a similar procedure as the AAA samples.
Tissue procurement: any adhering thrombus was carefully removed and the vessel walls 
were halved lengthwise. One half was immediately snap-frozen (liquid nitrogen) and stored 
at -80°C for mRNA (RT-PCR) and protein (Western blot and ELISA) analysis. The other half 
was fixed in formaldehyde (24 h), decalcified (Kristensens solution, 120 h) and embedded 
in paraffin for histological analysis.
Real-Time PCR
Tissue samples were pulverized in liquid nitrogen and RNA was isolated and semiquantitative 
Real-Time LightCycler PCR (RT-PCR) was carried out (Taqman method) as detailed in 
previous publications.18 Total RNA extraction was performed using RNAzol (Campro 
Scientific, Veenendaal, The Netherlands) and glass beads according to the manufacturer’s 
instructions. Copy-DNA was prepared using kit #A3500 (Promega, Leiden, The Netherlands) 
and quantitative real-time polymerase chain reaction (RT-PCR) analysis was performed for 
human IL-1α, IL-1β, IL-2, IL-6, IL-8, TNFα, MCP-1, MIP-1β, MIF, TGFβ, CD4, T-Bet, GATA-3, IL-4, 
IL-10, IL-13, INF γ, CD8, Perforin, Granzyme A, BLIMP-1, MAD4, Immunoglobulin linkerprotein, 
Immunoglobulin heavy chain, MMP- 25, CD 337, Tryptase, MMP2, MMP3, MMP9, MMP13, 
TIMP-1, TIMP-2, TIMP-3, Cathepsin K, Cathepsin L, Cathepsin S, Cystatin C, uPA and PAI-1 
on the ABI-7700 system (Applied Biosytems, Nieuwerkerk a/d IJssel, The Netherlands) using 
8 established primer/probe sets (Assays on Demand, Applied Biosystems) and mastermix 
(Eurogentec, Seraing, Belgium). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
expression was used as a reference and for normalization.
Tissue homogenization
Snap-frozen samples were crushed in liquid nitrogen and mixed with lysis buffer (10 mM Tris 
pH 7.0, 0.1 mM CaCl2, 0.1 M NaCl, 0.25% (v/v) Triton X-100) for protein based assays. After 
centrifugation at 4°C for 15 minutes at 13,000 rpm, the supernatants were collected and protein 
contents were measured with Pierce (Rockford, IL, USA) before storage at -80°C until use. 
IL-6 and IL-8 ELISA
Vessel wall cytokines were measured in the homogenates by the bio plex panel for multiple 
cytokines (Bio-Rad Laboratories B.V, Veenendaal, The Netherlands, IL-1α, IL-1β, IL-13, 
IL-17A, TNFα, IFN-MIP-1α, MIP-1β and G-CSF) or by separate ELISAs (PeliKane compact kit 
(Sanquin, Amsterdam, The Netherlands) for IL-6 and IL 8. We previously concluded that AAA 
IL-2, IL-4, IL-5, IL-7, IL-10, IL-12, IL-17A and GM-CSF wall levels are all at or below the detection 
threshold of the multiplex assay. Hence these cytokines were not included in the analysis.
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Western blotting
Quantifiable Western blots were performed following detailed protocols described by 
Kleemann and colleagues.19 All assays were performed on the tissue homogenates using 
antibodies specific for the human forms of p65-NFκB (active form of p65-NFκ ; Chemicon, 
#MAB3026, Chemicon Europe, Ltd., Chandlers Ford, UK); p65-NFκB 9 (non-active form; 
sc-8008; Santa Cruz, Heerhugowaard, The Netherlands); c-Jun (sc- 45); phosphor (Ser73)-
c-Jun (sc-7981); C/EBPα (sc-9315); C/EBPβ (sc-150); C/EBP δ (sc-636); MMP2 (PC-158, 
the Bindingsite, Birmingham, UK); MMP8 (MAB3316, Chemicon, Chemicon Europe, Ltd., 
Chandlers Ford, UK); MMP9 (TNO-BEA-21); Cathepsin K (IM55L, Calbiochem, Breda, The 
Netherlands); Cathepsin L (AF952, R&D systems, Abingdon, UK); Cathepsin S (sc-6505, 
Santa Cruz) and α-actin (sc- 1615, Santa Cruz) for normalization. All protease antibodies were 
specifically chosen to effectively detect both the pro and activated forms of the proteases.8 
All secondary antibodies were obtained from Santa Cruz Biotechnology. Immunoblots were 
visualized using Super Signal West Dura Extended Duration Substrate (Perbio Science, 
Etten-Leur, The Netherlands), and a luminescent image workstation (UVP, Cambridge, UK). 
Immunoblots were quantified using LabWorks 4.6 software.
Immunohistochemistry
Immunohistochemistry was performed using deparaffinized, ethanol rehydrated tissue 
cross-sections (thickness: 4μm) as reported previously.20 Sections were incubated overnight 
with polyclonal antibodies specifically for human myeloperoxidase (DAKO, Heverlee, Belgium), 
CD4 (clone 1F6, DAKO), CD8 (clone 4B11, Novocastra, Valkenswaard, the Netherlands), 
CD20 (clone L26, DAKO), CD68 (clone KP6, DAKO) and CD138 (clone B-B4, Serotec, 
Oxford, UK). Conjugated biotinylated anti-goat or rabbit anti-IgG were used as secondary 
antibodies. Sections were developed with Nova Red® (Vector Laboratories, Burlingame, CA) 
and counterstained with Mayer Hematoxylin allowing morphological analysis. Specificity of 
the antibody staining was confirmed by omitting the primary antibody. Specimens 10 were 
quantified by counting the number of cells per unit area for at least 20 fields at a 400-fold 
magnification.
Statistical analysis
Messenger RNA and protein expressions, results of the Western blots and 
immunohistochemistry were analyzed by Wilcoxon-Mann-Whitney U test to compare the 
different groups. Statistical significance was accepted if the P-value was < 0.05 Most of the 
data in this study reflects coherent data that fits in the theoretical inflammatory frame works. 
As such non-corrected data is provided,21 yet a Bonferroni correction should be considered 
when interpreting non coherent data. All analyses were performed using SPSS16.0. 11
 
Results
Patient characteristics are shown in Table 1. The observed younger age and smaller size 
of PAA confers with clinical data and reflect the younger peak incident age of PAA22 when 
compared to AAA and smaller size of the popliteal artery and hence the lower intervention 
threshold for PAA (PAA 2.0 cm, AAA 5.5 cm).
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Cellular composition and cellular markers in AAA and PAA walls
We first performed a histological evaluation of infiltrating leucocytes in AAA, PAA and 
non-aneurysmal control aorta. Results of these analyses are shown in Figure 1. Both AAA 
and PAA tissues were characterized by profuse and diffuse infiltration of monocytes (CD68+), 
neutrophils (MPO+) and T-helper cells (CD4+). Findings for B-cells (CD20+), plasma cells 
(CD138+) and cytotoxic T-cells (CD8+) content on the other hand were clearly discordant 
between PAA and AAA, with CD20+, CD138+ and CD8+ abundance in AAA but very limited 
presence in PAA. The findings for the reduced B-cell, plasma cell and cytotoxic T-cell content 
in PAA were in accordance with a reduced mRNA expression of B-cell, plasma cell and 
cytotoxic T-cell markers in PAA (Table 2). In line with the cellular observations no difference 
was found for the expression of monocyte/macrophage, neutrophil and the T-helper cell 
markers in AAA and PAA (Table 2).
Analysis of inflammatory molecular factors in AAA and PAA walls
Comparison of AAA and PAA inflammatory fingerprint on the mRNA level (semi quantitative 
real-time PCR) and protein level shows that PAA and AAA are characterized by particularly 
prominent IL-6 and 8 expression (Table 2, Figure 2)12 although the increase in IL-6 levels 
was less outspoken in PAA than in AAA (P=0.038) (Figure 2). Findings for the other 
proinflammatory factors such as TNFα, interferon γ and IP-10, MCP-1 and MIPα and β were 
clearly discordant between AAA and PAA (P<0.008, Table 3).
The congruent IL-8 hyperexpression in AAA and PAA prompted us to quantify the baseline 
levels of the general proinflammatory transcription factors NF-ĸB, AP-1 and C/EBP. Similar 
baseline but clearly increased NF-ĸB and AP-1 activation (active confirmation (NF-ĸB) and 
phosphor-c-jun (AP-1)) show that both AAA and PAA are associated with a hyperactivation of 
these systems6,23 (Figure 3). Abundance of the C/EBP isoforms α/β/δ was less outspoken 
in PAA (P<0.021) (Figure 3).
TABLE 1
AAA PAA Control aorta
Evaluable patients (n) 15 12 11
Mean Age (years) 74.8 ± 6.2 69.6 ± 12.1 55.6 ± 10.2
Mean diameter (cm) 6.7 ± 1.1 3.35 ± 1.36 <2.0
Female sex (n) 1 1 4
Aneurysm elswhere 1 4 0
Current smoker (n) 6 4 4
Statin use (n) 1 3 0
Anti-hypertensives (n) 8 5 0
Anti platelet therapy (n) 10 9 0
Patient characteristics (mean ± sd)
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F IGURE 1
Immunohistochemical analysis of the cellular composition of AAA, PAA and control aorta 
tissue. The amount of cells/mm2 in AAA and PAA tissues, and control aorta is shown 
after staining with antibodies specifically detecting monocytes and macrophages (CD68), 
neutrophils (MPO), T helper cells (CD4), cytotoxic T cells (CD8), B-lymphocytes (CD20) and 
plasma cells (CD138). There is no significant difference between AAA and PAA with respect 
to CD68, MPO and CD4 . Significant differences were found in the CD8, CD20 and CD138 
content. *P <0.05. White = control aorta, grey = PAA, black = AAA
F IGURE 2
Concentrations of IL-6 and IL-8 protein are characteristic for AAA and PAA wall. Aortic wall 
protein expression levels of IL-6 and IL-8 were determined by specific ELISAs in PAA and AAA 
wall and control aorta samples. There was strong significant difference between the control 
aorta and the aneurysm group with respect to IL-6 and IL-8. Focussing on AAA and PAA, IL-8 
hyperexpression was found in the two conditions but IL-6 hyperexpression was less outspoken 
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Protease profiles in AAA and PAA
MMP2, 8, 9 and cathepsin K, L and S have been implicated as the primary proteolytic culprits 
in AAA.8 Evaluation of these proteases on the messenger and protein level showed a similar 
profile in PAA (Table 2) , although a trend towards lower expression of the cysteine proteases 
was observed in PAA. Activation of these proteases was assessed by quantification of the 
activated forms in Western blot analysis.8 With the sole exception of reduced cathepsin 
K and increased MMP2 activation in PAA (p=0.005), similar activation profiles were found 
in AAA and PAA (Figure 4).13
TABLE 2
Log relative mRNA expression (expression normalized on basis of GAPDH expression) of 
markers of inflammatory responses in AAA, PAA and control aorta. The numbers are the 
median [IQR]. P value is for the comparison of AAA versus PAA.
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F IGURE 3
Concentrations of inflammatory transcription factors are characteristic for AAA and PAA 
wall. Relative (normalized on basis of β-actin levels) basal levels of p65-NF-ĸB, c-jun protein 
and their activated forms (NF-ĸBactive and p-c-jun) and C/EBPα, C/EBPβ, and C/EBPδ in 
homogenates of AAA, PAA and control aorta. NF-κB and AP-1 baseline and activation levels 
were comparable in AAA and PAA. The three isoforms C/EBPα, C/EBPβ, C/EBPδ were 
significantly lower in PAA. *P <0.05.
Aortic wall cytokine protein levels normalized on basis of protein levels (pg/mg protein).  
The numbers are the median [Inter Quartile Range]
TABLE 3
AAA PAA P
IL-1α ND [ND – 0.14] 0.14 [ ND – 0.34] 0.131
IL1β 1.50 [0.87 – 2.46] 2.81 [2.00 – 7.54] 0.04
IL13 ND [ND – 0.06] 0.18 [0.09 –0.28] 0.001
TNFα ND [ND – 0.01] 0.04 [0.01 – 0.11] 0.007
Interferon γ ND [ND – ND] 1.32 [ ND – 3.62] 0.008
IP-10 5.7 [1.3 – 38.8] 141.2 [63.0 – 237.0] 0.0001
MCP-1 67.3 [14.2-127.3] 197.2 [102.1 – 212.7] 0.006
MIP-1α 1.29 [0.38 – 1.83] 4.65 [3.52 – 9.81] 0.0003
MIP-1β 2.77 [0.55 – 5.71] 20.0 [10.1 – 26.6] 0.001
G-CSF ND [ND – 0.13 0.73 [0.40 – 1.77] 0.001
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F IGURE 4
Pro and active forms of MMP and cathepsin proteases are characterized for AAA and PAA. 
Westernblot analysis of pro and activated forms of MMP2, MMP8, MMP9, cathepsin K, L and 
S in AAA, PAA and aorta control tissues. Equal dominance of MMP2, MMP8 and MMP9 were 
found in AAA and PAA both for the pro and active (act) form. Results for the cathepsins were 
more variable and less outspoken in PAA when compared to AAA *P < 0.05.
Discussion
The primary processes driving AAA growth are still unresolved. To obtain clues on the 
factors that are generic for aneurysm growth we performed a systematic comparison of 
inflammatory and proteolytic processes in AAA and PAA. Our findings demonstrate that 
both pathologies share a general pro-inflammatory profile that is dominated by IL-8 and IL-6 
hyperexpression. Abundance of neutrophils, macrophages, and T-helper cell infiltration, as 
well as ample expression of MMP and cysteine proteases are clear features of the diseases. 
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Distinct differences were found for the presence of cytotoxic T-cells, and B- and plasma 
cells and their associated markers, suggesting that abundance of these cells in AAA is not 
generic to the process of aneurysmal growth.
The pathology of AAA is complex and poorly understood.1 Remarkable controversy exists 
on the inflammatory cascades driving aneurysm growth.24 In a first evaluation, Schonbeck 
and colleagues reported dominance of the Th2 associated cytokines IL-4, IL-5 and IL-10, 
along with minimal expression of the Th1 associated cytokine interferon-γ in AAA.4 On 
this basis the authors concluded that AAA is best described as a Th2 driven disease. As 
opposed to these findings, Xiong et al (mouse model) and Galle et al (human AAA) reported 
a Th1 polarization in AAA.5,25 As of these apparent contrasting findings we performed a 
comprehensive evaluation of the inflammatory fingerprint of AAA and concluded that in AAA 
is best described as a general pro-inflammatory condition with IL-6 and IL-8 hyperexpression, 
and dominance of IL-6 and IL-8-related responses.6 The persistent inflammatory state 
in AAA is held responsible for a proteolytic imbalance that underlies the excess matrix 
degradation in the disease. With respect 14 to the proteases involved attention has been 
primarily focused on the gelatinases MMP2 and 9.26,27 Yet, it has been pointed out that 
these proteases cannot degrade the load bearing fibrillar collagens in the aortic wall,7,8 and 
that it is thus unlikely that these proteases are directly responsible for the weakening of 
the aortic wall. As such it is very likely that other proteases contribute to the weakening of 
the aortic wall as well. As of the large number of open questions and the complexity of the 
inflammatory and proteolytic cascades in AAA we reasoned that a systematic evaluation 
of common and discordant inflammatory and proteolytic processes in AAA and PAA may 
provide critical clues on key processes driving aneurysm growth.
Evaluation of the inflammatory and proteolytic fingerprints in AAA and PAA shows remarkable 
similarities and dissimilarities. Both conditions are characterized by a strong activation 
of the general inflammatory transcription factors NFκB and AP- 1 (c-jun), profuse IL-8 and 
IL-6 expression, a high neutrophil and macrophage content, and abundant expression and 
activation of the MMP proteases neutrophil collagenase (MMP8) and gelatinase (MMP9) 
and the cysteine proteases cathepsin K, L and S. As opposed to the congruent findings 
for IL-6 and 8 much lower levels were found for soluble factors such as interferon γ, the 
interferon γ-induced protein (IP-10, CXCL-10), TNF α, MCP-1, MIP-1α and β in PAA. These 
latter observations may indicate that these factors are less critical to aneurysm growth 
and particularly challenge a role for interferon γ in the progression of AAA.28 Dominance of 
neutrophil-derived proteases and neutrophil abundance in AAA and PAA biopsies implies 
that these cells are generic for these forms of aneurysmal disease. Neutrophils have long 
been considered part of an acute inflammatory response and their role in chronic conditions 
has long been ignored.29 Recent studies15 ,however show that neutrophils do participate in 
chronic inflammatory processes such as COPD and rosacea.29,30 We previously identified 
the neutrophil derived collagenase MMP8 as the most prominent MMP protease in AAA and 
as an important target for doxycycline therapy in AAA,8,31 suggesting that neutrophils may 
also be actively involved in AAA growth. This notion is support by animal studies by Eliason32 
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and Pagano33 that both show that abrogated neutrophil influx in an animal models of AAA 
inhibits AAA development. Neutrophil abundance in AAA and PAA can well be explained by 
the local IL-8 hyperexpression that is found in the two pathologies. This notion is supported 
by observations from a clinical trial showing a strong association (r=0.84) between aortic 
wall neutrophil content and IL-8 levels.31
Remarkable differences were found with respect to the cytotoxic T-cell, B-cell and plasma cell 
content between AAA (abundant) and PAA (minimal). These differences on the histological 
levels were confirmed by a clear reduction of cell-type specific markers on the messenger 
RNA level. A clear cut explanation for this finding is missing but possible explanations are 
the reduced expression of C/EBP family of transcription factors in PAA34,35 or alternatively 
that the cytotoxic T-cell, plasma cell and B-cell abundance in AAA reflects presence of the 
vascular associated lymphoid tissue36 (VALT) in this section of infra renal aorta.
One possibility is that the reduced cytotoxic T-cell content reflects skewing of the Th1/Th2 
balance towards a more Th1 dominated response as indicated by similar T-bet but lower 
GATA-3 levels in PAA. Yet, such a scenario is not supported by the reduced interferon γ 
and IP-10 levels in the disease. Another possibility is that the differences in the T-helper 
cell and cytotoxic T-cell content relates to diverging roles of specific signaling pathways in 
CD8+ T cell and CD4+ T cell biology.37,38 Minimal B16 cell and plasma cell infiltration in 
PAA challenges a critical role for these cells (and the concept of AAA as an auto-immune 
phenomenon) in aneurysm growth. Yet, little is known about the pathophysiological role 
of these cells in the context of AAA and further mechanistic studies are necessary to 
investigate the contribution of these cells and the relevance of a possible auto immune 
phenomenon39,40 to AAA formation and progression. The proteolytic imbalance in AAA with 
prominent expression of MMP2, 8, 9 and the cysteine proteases cathepsin K, L and S is a key 
factor of AAA. With the notable exception of reduced cathepsin K activation and increased 
MMP2 in PAA, the inflammatory differences between AAA and PAA were not followed by a 
change in MMP or cysteine protease levels or activation. We have no clear explanation for 
the reduced cathepsin K and increase MMP2 activation in PAA. One possible explanation 
for the reduced Cathepsin K activation in PAA is that it reflects reduced expression and/or 
activity of the osteoclastic proton pump V-H-ATPase8 that is required for maintenance of an 
acidic pericellular micro environment that is required for cathepsin K activation and stability.
In conclusion, our explorative study demonstrates that growing AAA and PAA are both best 
described as a localized general inflammatory condition that is dominated by activation 
of NF-ĸB and AP-1 pro-inflammatory transcription factors and IL-6 and 8 hyperexpression. 
Dominance of neutrophil and macrophage derived proteases point to a generic role of 
these cell types in AAA and PAA progression, whereas the discordant findings for B cells, 
plasma cells and cytotoxic T cells challenge a critical role for these cell types in aneurysm 
progression. Therapies17 targeting neutrophil influx or macrophage activation appear the 
preferred strategy for stabilizing growing AAA.
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Our findings demonstrate remarkable overlap between AAA and PAA, and characterize the 
two pathologies as general inflammatory conditions dominated by activation of the NF-ĸB 
and AP-1 pathways; IL8 hyperexpression and neutrophil involvement, and ample activation of 
selected MMP and cysteine proteases. Remarkable and consistent differences were found 
with respect to B-cells, plasma cells and cytotoxic T-cells and their markers, suggesting that 
these cell types are specific for AAA and not critical to the process of aneurysmal growth. 
Pharmaceutical strategies targeting the generic components in AAA and PAA may prove 
effective for the stabilization of AAA.10 18
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Abstract
Background: Doxycycline has been shown to effectively inhibit aneurysm formation in 
animal models of abdominal aortic aneurysm. Although this effect is ascribed to matrix 
metalloproteinase-9 inhibition, such an effect is unclear in human studies. We reevaluated 
the effect of doxycycline on aortic wall protease content in a clinical trial and found that 
doxycycline selectively reduces neutrophil-derived proteases. We thus hypothesized that 
doxycycline acts through an effect on vascular inflammation.
Methods and Results: Sixty patients scheduled for elective open aneurysmal repair were 
randomly assigned to 2 weeks of low-, medium-, or high-dose doxycycline (50, 100, or 300 
mg/d, respectively) or no medication (control group). Aortic wall samples were collected 
at the time of operation, and the effect of doxycycline treatment on vascular inflammation 
was evaluated. Independently of its dose, doxycycline treatment resulted in a profound but 
selective suppression of aortic wall inflammation as reflected by a selective 72% reduction 
of the aortic wall neutrophils and a 95% reduction of the aortic wall cytotoxic T-cell content 
(median values; P<0.00003). Evaluation of major inflammatory pathways suggested that 
doxycycline treatment specifically quenched AP-1 and C/EBP proinflammatory transcription 
pathways (P<0.0158, NS) and reduced vascular interleukin-6 (P<0.00115), interleukin-8 
(P<0.00246, NS), interleukin-13 (P<0.0184, NS), and granulocyte colony-stimulating factor 
(P<0.031, NS) protein levels. Doxycycline was well tolerated; there were no adverse effects.
Conclusions: A brief period of doxycycline treatment has a profound but selective effect on 
vascular inflammation and reduces aortic wall neutrophil and cytotoxic T-cell content. Results 
of this study are relevant for pharmaceutical stabilization of the abdominal aneurysm and 
possibly for other inflammatory conditions that involve neutrophils and/or cytotoxic T cells.
Clinical perspective: Pharmaceutical stabilization of abdominal aneurysms, thereby reducing 
the need for aneurysm repair, holds many promises. Matrix metalloproteinase-9 is 
considered pivotal to the process of aneurysm formation. Because of its ability to reduce 
matrix metalloproteinase-9 expression and activity, the tetracycline analogue doxycycline 
has been brought forward as a promising lead candidate. Although animal studies have 
convincingly shown that doxycycline inhibits both aneurysm formation and growth, the 
effects of doxycycline on matrix metalloproteinase-9 are controversial in human studies. In 
this study, we confirm that doxycycline lowers aneurysmal wall matrix metalloproteinase-9 
protein levels but also show that this reduction may be secondary and related to an effect 
on neutrophils, a cell type loaded with preformed matrix metalloproteinase-9 protein. We 
demonstrate that doxycycline has a profound but selective suppressive effect on inflammation 
in abdominal aortic aneurysms; doxycycline specifically lowers aortic wall neutrophil (-76%) 
and cytotoxic T-cell (-96%) content, 2 types considered crucial for aneurysm formation. 
Moreover, it is shown that treatment reduces interleukin-6 and -8 hyperexpression, a key 
feature of abdominal aortic aneurysm. Results of this study are relevant for pharmaceutical 
stabilization of the abdominal aneurysm and possibly for other (vascular) inflammatory 
conditions involving neutrophils and/or cytotoxic T cells such as Kawasaki disease and 
Behçet syndrome. 
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Introduction
Pharmaceutical strategies inhibiting aneurysm growth, thereby reducing the need for surgical 
repair, could have major advantages for patients and socioeconomically.1,2 An abundance 
of matrix metalloproteinase-9 (MMP9) in growing abdominal aortic aneurysms (AAAs),3 
along with the observation that disruption of MMP9 gene prevents AAA formation,4 led to 
the notion that MMP9 is critically involved in AAA formation.5 It was thus proposed that 
pharmaceutical inhibition of MMP9 could restore the balance between matrix degradation 
and deposition,5 thereby reducing aneurysmal growth.6
Independently of its antibiotic properties, the tetracycline analogue doxycycline has been 
shown to reduce both MMP9 expression and activity,7 suggesting that doxycycline treatment 
may reduce aneurysmal growth. Indeed, doxycycline has been convincingly shown to prevent 
AAA formation in a variety of animal models,6,8–10 and the results from 2 small clinical 
studies suggest that doxycycline also reduces AAA expansion in humans.11,12 Remarkably, 
although the rationale behind doxycycline therapy is based on its putative effects on MMP9 
expression and activity,6 the effects of doxycycline on MMPs in the human aneurysm are 
unclear, with published studies13,14 suggesting that doxycycline acts through a different 
mechanism.1
In vitro studies characterize doxycycline as a pleiotropic anti-inflammatory and 
immunomodulatory agent.7 However, the relevance of this well-tolerated compound15 for 
modulating inflammation in human disease in general and AAA in particular is unclear. In 
this prospective clinical trial, we systematically examined the effect of 3 pharmacologically 
relevant doses (low [50/d], regular [100 mg/d], or high [300 mg/d]) of doxycycline on MMP9 
expression and inflammatory processes in the aneurysmal wall of patients scheduled for 
elective open aneurysm repair. Evaluation of the effect of doxycycline treatment showed that 
MMP9 was reduced on the protein but not on the mRNA level. Because aortic neutrophils 
carry large amounts of preformed MMP9 protein and lack de novo protein synthesis,16,17 we 
hypothesized that the observed reduction of MMP9 protein may relate to a change in the 
aortic content of neutrophils. The present study shows that a brief period of 2 weeks of 
doxycycline treatment significantly reduces the aortic content of neutrophils and of cytotoxic 
T cells, another cell type considered crucial for the process of AAA formation.18–21 Based on 
these findings on the cellular level, a molecular analysis on the level of relevant cytokines 
and transcription factors22 was performed next.
 
Materials and methods
The present randomized, dose-ranging study was performed in patients awaiting open 
aneurysm repair. The trial included 3 treatment groups and 1 nontreated (control) group. 
Randomization was performed by block randomization (blocks of 20 patients). Randomization 
lists were generated by the Leiden University Medical Center Department of Medical Statistics, 
and randomization was performed by the Leiden University Medical Center pharmacy. The 
study was performed in an investigator-blinded fashion. Planned open aneurysmal repair 
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of an infrarenal aortic aneurysm was the primary inclusion criterion. Decision for open 
repair was based on anatomic (eg, neck, elongation) and patient (age) characteristics and 
patient preferences. Patients with kidney dysfunction (estimated clearance <30 mL/min), 
chronic inflammatory disease, or (suspected) so called inflammatory aortic aneurysms were 
excluded from participation in the study. Before randomization, 2 patients were excluded 
because of a suspected inflammatory aneurysm. Between November 2001 and April 
2005, a total of 60 patients from 4 centers in the Netherlands were randomized to receive 
doxycycline (at a dose of 50, 100 or 300 mg once daily) or no medication (control group) 
in the 2 weeks preceding open elective aneurysm repair (AAA diameter >5.5 cm). In 2 
patients in the low-dose (50 mg/d) doxycycline group, the operation had to be postponed 
for logistical reasons; hence, 13 patients were therefore evaluated in this group. Medication 
was started 14 days before the planned operation, and the last dose was taken in the 
evening before surgery. Patient compliance was assessed by counting the medication (pills) 
at the end of the treatment period. This multicenter study was first approved by the Leiden 
University Medical Center Institutional Review Board; subsequent approval was obtained 
from the medical ethics committees of the other participating centers as required by Dutch 
law. Informed consent was obtained from each patient.
Immediately after opening of the aneurysm sac and removal of the adhering thrombus, 
an aortic wall tissue sample was obtained from the anterior-lateral aneurysm wall at the 
maximum diameter of the aneurysm. Wall samples were immediately halved; one half 
was snap-frozen in CO2-cooled isopentane or liquid nitrogen and stored at -80°C for later 
analysis. The other half was fixed in formaldehyde (24 hours), decalcified (Kristensen’s 
solution, 120 hours), and paraffin embedded for histological analysis. All analyses were 
performed in an investigator-blinded fashion.
RNA Extraction and mRNA Analysis
Total RNA extraction was performed with RNAzol (Campro Scientific, Veenendaal, the 
Netherlands) and glass beads according to the manufacturer’s instructions. Copy DNA was 
prepared with the A3500 kit (Promega, Leiden, the Netherlands), and quantitative real-time 
polymerase chain reaction analysis was performed for MMP9, MMP12, cathepsin K, 
BLIMP-1, MAD-4, Ig linker protein, and IgG heavy chain on the ABI-7700 system (Applied 
Biosytems, Nieuwerkerk a/d IJssel, the Netherlands) with established primer/ probe sets 
(Assays on Demand, Applied Biosystems) and Mastermix (Eurogentec, Seraing, Belgium). 
Analyses were performed according to the manufacturer’s instructions and as previously 
reported.23 GAPDH expression was used as a reference and for normalization.
Tissue Homogenization for Protein Analysis
Aortic wall tissues were pulverized in liquid nitrogen and homogenized in 2 volumes of lysis 
buffer (10 mmol/L Tris, pH 7.0; 0.1 mmol/L CaCl2; 0.1 mol/L NaCl; 0.25% [vol/vol] Triton 
X-100). This protocol releases both soluble and membrane-bound proteins. Samples were 
subsequently centrifuged at 10 000g for 15 minutes at 4°C, snap-frozen in liquid nitrogen, 
and stored at -80°C until use. Protein content in homogenates was determined with a 
bicinchoninic acid protein assay kit (Pierce, Rockford, Ill).
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Immunohistochemistry
Immunohistochemistry was performed with deparaffinized, ethanolrehydrated tissue cross 
sections (thickness, 4 µm) as reported previously.23 Cross sections were incubated overnight 
with polyclonal antibodies specifically staining human myeloperoxidase (rabbit polyclonal; 
1:4000 dilution; DAKO, Heverlee, Belgium), CD4 (clone 1F6; 1:15 dilution; DAKO), CD8 
(clone 4B11; 1:200 dilution; Novocastra, Newcastle, UK), CD20 (clone L26; 1:1000 dilution; 
DAKO), CD68 (clone KP6; 1:400; DAKO), and CD138 (clone B-B4; 1:1000 dilution; Serotec, 
Oxford, UK). Conjugated biotinylated anti-goat or rabbit anti-IgG was used as a secondary 
antibody. Sections were developed with Nova Red (Vector Laboratories, Burlingame, Calif) 
and counterstained with Mayer hematoxylin, allowing morphological analysis. Specificity 
of the antibody staining was confirmed by omitting the primary antibody and by isotype 
controls.
 
Specific Immunocapture MMP Activity Assays
Because of the rapid inactivation of active enzymes by endogenous inhibitors released 
after cell destruction by homogenation, direct measurement of active MMPs in aortic 
tissue homogenates is not feasible.23 Therefore, MMP activities were measured only after 
in vitro activation (p-aminophenylmercuric acetate) of captured latent proenzymes. Activity 
was determined in established MMP8 and MMP9 immunocapture protease activity assays 
(Amersham Biosciences, Buckinghamshire, UK).
Western Blot Analysis
Western blot analyses was performed essentially as described previously22 with antibodies 
specific for the human forms of perforin (sc-7417; Santa Cruz Biotechnology, Heerhugowaard, 
the Netherlands), granzyme A (M1791; Sanquin, Amsterdam, the Netherlands), p65-nuclear 
factor (NF)κB (nonactive conformation; sc-8008), p65- NFκB (active conformation of 
p65-NFκB; Chemicon, Billerica, Mass; MAB3026), c-Jun (sc-45), phospho(Ser73)-c-Jun 
(sc-7981), C/EBPα (sc-9315), C/EBPβ (sc-150), C/EBPδ (sc-636), and STAT3 (sc-7179) (all 
Santa Cruz Biotechnology); phospho-STAT3 (Epitomics PS727, Huissen, the Netherlands); 
and β-actin (sc-1615; Santa Cruz Biotechnology).
Corresponding secondary antibodies were obtained from Santa Cruz Biotechnology (donkey 
anti-goat) and Pierce (Etten-Leur, the Netherlands; goat anti-rabbit and goat anti-mouse). 
Immunoblots were visualized and quantified with the Super Signal West Dura Extended 
Duration Substrate (Perbio Science, Etten-Leur, the Netherlands), LabWorks 4.6 software, 
and a luminescent image workstation (UVP, Cambridge, UK). Protein expression levels were 
standardized for β-actin, and separate anti–β-actin immunoblots were performed for each 
sample.
Multiplex Assay and ELISAs
Aneurysm wall interleukin (IL)-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17A, 
granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage–CSF, interferon-γ, 
monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1β, and 
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tumor necrosis factor-α protein levels were determined by the 17-Plex panel for multiple 
cytokines (Bio-Rad Laboratories BV, Veenendaal, the Netherlands). All analyses were 
performed in a single run. Detection thresholds for the above cytokines were <0.5 pg/mL 
(IL-1, IL-2, IL-5, IL-6, IL-7, IL- IL-8, IL-10, tumor necrosis factor-_), <1 pg/mL (IL-12, IL-17A), and 
<5 pg/mL (IL-4, IL-13, G-CSF, granulocyte macrophage–CSF, interferon-γ, MCP-1).
Most of the IL-6, IL-8, and MCP-1 levels exceeded the upper detection limit of the 17-Plex 
panel and were reevaluated in separate ELISAs (IL-6 and IL-8: PeliKane Compact Kit, Sanquin, 
Amsterdam, the Netherlands; MCP-1: Quantikine Kit, R&D Systems, Abingdon, UK).
Statistical Analysis
Power calculation for this study was based on data published in Reference 13. In that 
publication, doxycycline therapy reduced relative MMP9 mRNA expression from 7.2 (SE, 3.1) 
to 1.3 (SE, 0.5) units. The present study was designed to have a 90% power to detect a 50% 
reduction of MMP9 mRNA levels at a significance level of 0.05.
All values are expressed as means (SD) for normally distributed data or medians [interquartile 
range] for nonnormally distributed data (skewed). The level of statistical significance was 
dictated by Bonferroni-Holm’s correction (33 variables). One-way ANOVA for normally 
distributed data or the Kruskal–Wallis test for nonnormally distributed data did not indicate 
a difference between the 3 doxycycline doses for all variables studied (all P>0.16; detailed 
data available from the corresponding author on request). To increase the power of the 
study, all doxycyclinetreated individuals were therefore evaluated as a single group.
The sequence of our analyses was as follows. We first analyzed the effect of doxycycline 
on MMP9 mRNA and protein levels. Because of the selective reduction of MMP9 protein 
only, we analyzed putative changes in the aortic wall neutrophil content. On observing an 
effect on neutrophil content, we performed a further evaluation. This analysis showed that 
doxycycline treatment selectively reduces aortic wall neutrophil and cytotoxic T-cell content. 
On the basis of this cellular evaluation, a subsequent analysis of relevant upstream- and 
downstream-acting cytokines and transcription factors was performed.20
Differences between the control group and the doxycycline-treated groups were evaluated 
in 1-way ANOVA with contrasts (for the normally distributed data) or by the Wilcoxon–Mann–
Whitney test in the case of nonnormally distributed continuous data. Possible associations 
between aortic wall IL-6 and IL-8 levels and cellular content were evaluated by Pearson’s 




Three relevant doses of doxycycline (low [50 mg/d], regular [100 mg/d], or high [300 mg/d] 
were evaluated.24 A total of 60 patients were enrolled in the study. For logistical reasons, 
aneurysm repair had to be postponed in 2 patients; hence, a total of 58 patients could be 
analyzed. Doxycycline was well tolerated, and there were no withdrawals. 
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Patient characteristics are shown in Table 1. All 4 groups are comparable with regard to age, 
sex, statin use, and AAA diameter.
Statistical analysis did not indicate a difference between the 3 doxycycline doses for all 
variables studied; hence, all 3 doxycycline doses were combined. Probability values are for 




Control AAA 50 100 300 P
Evaluable patients, n 15 13 15 15 NS
Mean age (range), y 74.8 (69-84) 72.7 (62-85) 74.1 (50-88) 72.1 (58-87) NS
Mean AAA diameter, cm 6.7 6.5 6.3 6.7 NS
Mean time between 
diagnosis and 
surgery, mo
6 7 5 5
Female sex, n 1 2 2 3 NS
Current smoker, n 6 6 7 5 NS
Statin use, n 1 1 1 2 NS
Antihypertensives, n 8 7 8 7 NS
Antiplatelet therapy, n 10 8 8 8 NS
Nontreated Control Doxycycline-Treated
Subjects Subjects P*
MMP9 –1.21 (0.44) –1.40 (0.61) 0.206 (NS)
MMP12 –2.57 (3.30–1.97) –2.18 (3.28–1.55) 0.326 (NS)
Cathepsin K –1.74 (0.69) –1.85 (0.49) 0.486 (NS)
BLIMP-1 –1.64 (0.59) –1.81 (0.48) 0.265 (NS)
MAD-4 –1.11 (0.36) –1.11 (0.25) 0.890 (NS)
lg linker protein 0.34 (0.39) 0.28 (0.48) 0.714 (NS)
lgG heavy chain 1.73 (0.60) 1.36 (0.48) 0.020 (NS)
Patient characteristics
mRNA expression
NS indicates level of significance not reached after Bonferroni-Holm’s correction. Log-
transcript level relative to GAPDH (GAPDH=0) of markers of monocyte/macrophage activation 
(MMP9 and MMP12, cathepsin K) and B-cell/plasma cell activation (BLIMP-1, MAD-4, Ig 
linkerprotein, IgG heavy chain). Values are mean (SD) or median (interquartile range) as 
appropriate. *Probability value is for the comparison of the combined doxycycline groups 
versus the nontreated control group.
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Doxycycline and MMP9 Expression
Evaluation of the effect of 2 weeks of doxycycline therapy indicated a trend toward reduced 
MMP9 proenzyme levels (P<0.00263, NS; Figure 1A) but did not influence MMP9 mRNA 
expression (P<0.206; Table 2).
F IGURE 1
The effect of doxycycline on aneurysm wall leukocyte content, the neutrophil markers MMP8 and MMP9, and the cytotoxic 
T-cell markers perforin and granzyme A. A trend toward reduced MMP9 protein levels (proenzyme) was observed (A) after 
doxycycline therapy (P<0.00263, level of significance not reached after Bonferroni-Holm’s correction). Evaluation of a putative 
effect on cellular content showed that treatment reduced aortic wall neutrophil (B, C; myeloperoxidase staining) and cytotoxic 
T-cell (C, D; CD8 staining) content (P<0.000025, P<0.000001, respectively) but not that of other cell types (E). The reduction 
of neutrophils and cytotoxic T cells is paralleled by a trend to reduced levels of the neutrophil marker MMP8 (A; neutrophil 
collagenase; P<0.0053, NS) and the cytotoxic T-cell activation markers perforin (P<0.0158, NS) and granzyme A (P<0.00001; 
F). #Significant difference between doxycycline-treated patients (gray) and nontreated control subjects (white).
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Doxycycline and the Inflammatory Responses in AAA
Because of the selective effect of doxycycline treatment on MMP9 protein levels but not on 
mRNA expression, we next analyzed the aortic wall neutrophil content. Figure 1B and 1C show 
that doxycycline markedly reduced the aortic wall neutrophil content (76% reduction of the 
median value; P<0.000025). Further evaluation of other cell types in the aorta also revealed 
a profound reduction of the aortic wall cytotoxic (CD8+) T-cell content (96% reduction of 
the median value; P<0.000001; Figure 1C and 1D) but not on other cell types (monocytes/
macrophages [CD68+]; T-helper cells [CD4+], B cells [CD20+], and plasma cells [CD138+]; 
Figure 1E). Figure 1B and 1D illustrate that the effects of the individual doxycycline doses 
are equivalent.
Tissue distribution of these cells as assessed by immunohistochemistry was not influenced 
by doxycycline.
The decrease in neutrophil and cytotoxic T-cell count was paralleled by a reduction of 
granzyme A (P<0.000010; Figure1F), a specific marker of cytotoxic T-cell activation. The 
effect on the neutrophil-specific marker neutrophil collagenase (MMP8; P<0.0053; Figure 
1A) and the cytotoxic T-cell marker perforin (P<0.0158) did not reach statistical significance.
 
mRNA levels of markers of monocyte/macrophage activation (ie, macrophage elastase 
[MMP12] and cathepsin K) were not affected by doxycycline therapy. Similarly, except for a 
small reduction of IgG heavy-chain expression, doxycycline therapydid not influence markers 
of B-cell/plasma cell activity (MAD-4, BLIMP-1, and IgG linker protein; Table 2).
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Effects of Doxycycline on Cytokine and Chemokine Expression
Doxycycline treatment resulted in a selective suppression of aneurysmal wall cytokine 
and chemokine protein levels (Table 3). IL-6 hyperexpression, a characteristic feature of 
AAA,22 was reduced from median values of 462 to 148 pg/g protein (IL-6; P<0.00115). The 
reduction of IL-8 levels (median values in thecontrol group and the treated group, 165 and 
70 pg/g protein, respectively) did not reach statistical significance (P<0.00246). The strong 
positive relationship between neutrotactic chemokine IL-8 and aortic wall neutrophil content 
in the control group (r=0.84, P<0.00016) was not found in the doxycycline-treated group 
(r=-0.037, P<0.819).
Consistent with the absence of an effect on monocyte/macrophage activation markers, 
doxycycline therapy did not influence the levels of inflammatory cytokines and chemokines 
that are associated predominantly with monocytes/macrophages, ie, IL-1β (P<0.352), tumor 
necrosis factor-α (0.579), MCP-1 (CCL-2; P<0.329), and macrophage inflammatory protein-1β 
(CCL4; P<0.166; Table 3).
TABLE 3
Effect of Doxycycline Treatment on Aneurysm Wall Cytokine and Chemokine Protein Expression
NS indicates level of significance not reached after Bonferroni-Holm’s correction; GM-CSF, granulocyte 
macrophage CSF; MIP, macrophage inflammatory protein; and TNF, tumor necrosis factor. Values were 
assessed by the BioRad 17-Plex panel for multiple cytokines. IL-4, IL-5, IL-10, IL-12, and IL-17A levels 
were all below the detection threshold of the assay and are therefore not shown. Levels of IL-6, IL-8, 
and MCP-1 exceeded the upper detection threshold and were accurately quantified in separate ELISAs. 
Values are median (interquartile range). *Probability value is for the combined doxycycline groups versus 
the nontreated control group.
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F IGURE 2
Effects of Doxycycline on Mechanistically Relevant Inflammatory Transcription Factors
Doxycycline reduced the aortic wall protein concentrations of cytokines/chemokines that 
are regulated by AP-1 (IL-6 and IL-8) and/or C/EBP (IL-8, G-CSF) but did not affect the 
level of cytokines/chemokines that are controlled predominantly by NFκB (eg, IL-1β and 
MCP-1). These observations suggest that doxycycline therapy specifically quenches the 
inflammatory transcription factors AP-1 and/or C/EBP. Evaluation of AP-1, C/EBP, and NFκB 
protein expression levels and their activation status (active phosphorylated c-jun for AP-1, 
active p65-NFκB protein confirmation for NFκB; Figure 2A and 2B) provided indications for 
an effect on the protein levels of all 3 C/EBP isoforms (α/β/δ; all P<0.00117; Figure 2C) and 
possibly on the activation of the AP-1 system (phosphorylated c-jun, the major effector of 
AP-1; P<0.0158, NS). Levels of inactive and active p65-NFκB, the major effector of NFκB, 
were not influenced by doxycycline (P<1.000 and P<0.7301, respectively; Figure 2A).
The effect of doxycycline on the NFκB, AP-1, and C/EBP inflammatory pathways. Doxycycline 
may reduce AP-1 activation (phospho-c-Jun; P<0.0158, NS) and reduces C/EBPα, β, and 
δ expression (all P<0.00117) but does not influence basal AP-1 (c-Jun) (P<0.905) and 
NFκB (P<1.000) levels and NFκB activation (P<0.730). #Significant difference between 
doxycyclinetreated patients (gray) and nontreated control subjects (white).
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To test whether the doxycycline-mediated suppression of IL-6 levels is sufficient to impair 
the IL-6 signaling pathway, we evaluated the levels of STAT-3, the primary downstream 
transcriptional effector of the IL-6 signaling pathway. Basal STAT-3 expression levels were 
comparable in doxycycline-treated and nontreated individuals (P<0.3428, NS), but a trend 
(P<0.0268, NS) toward reduced STAT-3 phosphorylation (ie, the activated form of this 
transcription factor) suggests diminished IL-6 signaling on doxycycline therapy (Figure 3).
 
Discussion
In this clinical trial, we demonstrate that doxycycline treatment has strong, highly selective 
effects on vascular inflammation in the AAA. The lowest doxycycline dose tested (50 mg/d) 
led to a profound reduction of aneurysmal wall neutrophil and cytotoxic T-cell content, 2 cell 
types considered crucial for the process of aneurysm formation.18–21
AAA is a common pathology and a major cause of death resulting from rupture. The hallmark 
pathology of AAA is a localized, chronic inflammatory response accompanied by a proteolytic 
imbalance.5,22,23 Increased proteolytic activity in the disease is responsible for the increased 
matrix turnover and progressive weakening of the aortic wall. Prominent MMP9 expression 
in AAA,3,5,6 along with resistance of MMP9 knockout mice to aneurysm formation,4 led to 
the concept of MMP9 inhibition as a means of reducing AAA formation and expansion.2 
Independently of their antimicrobial properties, members of the tetracycline family have 
been shown to inhibit MMP9 expression7 and activity25 and to effectively prevent tissue injury 
F IGURE 3
The effect of doxycycline treatment on basal STAT-3 levels and STAT-3 phosphorylation, the 
primary downstream effector pathway of IL-6 signaling. Doxycycline does not influence basal 
STAT-3 levels (P<0.3428), but a trend toward reduced STAT-3 phosphorylation (p-STAT-3; 
P<0.0268) suggests reduced IL-6 signaling. White indicates nontreated control subjects; 
Gray, doxycycline-treated subjects.
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in animal models of gingivitis, arthritis, and other inflammatory disorders.7 On the basis of 
these and similar studies, it was proposed that the tetracycline analogue doxycycline may 
inhibit AAA progression.2 Indeed, doxycycline has shown to forestall AAA formation and 
growth in various animal models of the disease.6,8–10 Results from two preliminary human 
studies suggest that these experimental findings may also apply to human disease.11,12
Remarkably, although the rationale behind doxycycline therapy is based on its putative 
effects on MMP9 expression and activity,2,6 the effects are discussed controversially in 
published human studies.13,14 In the first published study, Curci et al13 evaluated the effects 
of preoperative doxycycline treatment (100 mg orally twice a day for 7 days) in 8 patients with 
an AAA and compared the results with 7 nontreated controls. They showed that doxycycline 
treatment resulted in a 2.5-fold reduction of MMP9 protein levels (immunoblot) and an 
82% reduction of MMP9 mRNA expression (determined by a semiquantitative method, 
competitive real-time polymerase chain reaction). In a later placebo-controlled study, Ding et 
al14 tested the effect of 1 month of doxycycline treatment (100 mg once a day) or placebo on 
MMP mRNA expression (real-time polymerase chain reaction) and protein levels (both ELISA 
and immunocapture assays) in 51 patients scheduled for open repair. Unlike the initial study 
by Curci et al,13 no effect was found on MMP mRNA or protein expression.
Our findings suggest an effect of doxycycline therapy on MMP9 protein levels (P<0.00263), 
as reported by Curci et al.13 Yet, in line with Ding et al,14 we did not find an effect of doxycycline 
on MMP9 mRNA expression levels (P<0.206). The reducing effect of doxycycline on MMP9 
protein but not on mRNA may be explained by reduced aneurysmal wall neutrophil content. 
Neutrophil MMP9 is produced (transcribed and translated) during neutrophil maturation in 
bone marrow, and the protein is subsequently stored in the secondary granules. MMP9 
mRNA expression in circulating or infiltrated neutrophils is neglectable.15,16 The absence 
of an effect of doxycycline on aortic wall MMP9 mRNA expression suggests that treatment 
does not affect MMP9 expression in other cell types (eg, macrophages). Together, these 
observations may suggest that the reduction of MMP9 protein can be ascribed mainly to the 
disappearance of aortic wall neutrophils and that the effects of doxycycline therapy relate 
to an anti-inflammatory effect.
This study shows that the immune modulatory effects of doxycycline in AAA are profound 
and potentially therapeutically relevant and that these effects are highly selective; a brief 
period of 2 weeks of doxycycline treatment suffices to strongly reduce aortic wall neutrophil 
and cytotoxic T-cell content. These cellular effects were paralleled by reduced levels of 
cytotoxic T-cell–specific marker granzyme A. The effects on perforin (P<0.0158), another 
cytotoxic T-cell activation marker, and the neutrophil markers neutrophil collagenase 
(MMP8) and neutrophil gelatinase (MMP9) (P<0.0053 and P<0.00263, respectively) did not 
reach significance after Bonferroni-Holm’s correction. Doxycycline did not affect the number 
and activation status of other prominent cell types in AAAs (ie, T-helper cells, monocytes/
macrophages, B cells, or plasma cells),22 showing that the immune modulatory effects of 
doxycycline are selective rather than universal.
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In the present relatively small study, we did not observe a dose-response relationship for 
the parameters studied. All doxycycline-treated groups were well matched with respect to 
age, sex, and medication. We minimized well-known confounding factors that may affect 
bioavailability. For example, we specifically instructed patients to avoid simultaneous 
ingestion of doxycycline and cation-containing preparations and excluded patients with 
kidney dysfunction.
The absence of a dose-response relationship in our study presumably indicates that the 
anti-inflammatory effects in AAA are already maximal at the lowest dose of doxycycline used 
in this study (50 mg). Consistent with this, subantimicrobial doses of doxycycline (20 mg 
BID) are approved by the Food and Drug Administration for inhibition of excess MMP8 and 
MMP9 activity in periodontitis,26 showing that low-dose systemic doxycycline treatment has 
clinical effects. For logistical reasons, the treatment period in this study was relatively short 
(2 weeks), yet observations from other chronic inflammatory conditions involving neutrophils 
such as periodontal disease, acne, and rosacae7 suggest that the effects of doxycycline 
persist during prolonged treatment.
A molecular explanation for the reduction of the aortic wall neutrophil content after 
doxycycline treatment may be the reduction of neutrophil chemoattractants such as IL-827 
in the aneurysm wall. This notion is supported by the robust correlation between aortic 
wall IL-8 levels and aortic wall neutrophil content that is present in the nontreated controls 
and that is lost after doxycycline treatment. The possible reduction of G-CSF levels 
(P<0.00308, NS) may contribute to this effect because G-CSF reportedly stimulates 
survival, differentiation, and function of neutrophil precursors and mature neutrophils.28,29 
Available preclinical studies suggest that doxycycline may also dose dependently interfere 
with neutrophil migration.30 Yet, the relevance of this effect has been questioned because 
of the results of an earlier clinical study.31
The selective reduction of CD8+ T cells, along with their activation markers perforin 
and granzyme A, after doxycycline treatment has not been reported previously. Our data 
demonstrate that the observed reduction of CD8+ T cells is selective because there was no 
effect on CD4+ T cells. To the best of our knowledge, T-cell trafficking and homing signals 
concur. In the absence of an effect of doxycycline treatment on CD4+ T cells, we hypothesize 
that the reduction presumably reflects a direct effect on CD8+ T cells. There is evidence 
for diverging roles of specific signaling pathways in CD8+ T-cell and CD4+ T-cell biology. 
For example, specific roles for the AP-132 and IL-6/STAT333 signaling pathways have been 
reported in the context of cytotoxic T-cell proliferation (AP-1) and survival (IL-6/STAT3). In the 
absence of known direct toxic effect of doxycycline on cytotoxic T cells,17 we speculate that 
the selective reduction of cytotoxic T cells on doxycycline treatment may be mechanistically 
linked to the reduced AP-1 and/or STAT-3 activation after doxycycline therapy.
Direct inhibition of the AP-1 pathway has been shown to prevent and even reverse aneurysm 
formation in animal models of aneurysmal disease.34 This published report showed not only 
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that AP-1 is critically involved in the inflammatory cascade and the proteolytic imbalance in 
AAA but also that reduced AP-1 signaling resulted in increased matrix deposition.
We found that doxycycline therapy reduced aortic wall G-CSF levels. G-CSF expression is 
under primary control of C/EBP transcription factors. All 3 isoforms (α, β, δ) are elevated 
in AAA,22 and increased aortic C/EBP expression is positively associated with aortic wall 
inflammation in atherosclerotic occlusive disease.35 Anti-inflammatory strategies that 
reduce C/EBP expression have been described to also reduce atherosclerotic disease.36 Yet, 
little is known about the pathophysiological role of C/EBP in the context of AAA, and further 
mechanistic studies are necessary to investigate the contribution of C/EBP to AAA growth.
 
Conclusions
We report that a period of 2 weeks of doxycycline treatment in patients with advanced 
abdominal aneurysms results in a profound and selective reduction of aortic wall neutrophil 
and cytotoxic T-cell content. This cellular effect is paralleled by a selective suppression 
of inflammation on the molecular level, ie, cytokines (IL-6, IL-8) and transcription factors 
(AP-1, C/EBP, STAT3), which are relevant for neutrophil and cytotoxic T-cell inflammation, 
as well as by a specific reduction of neutrophilderived proteases. Our findings show that 
doxycycline therapy may be a useful strategy to selectively quench specific cellular and 
molecular aspects of vascular inflammation in AAA. The ability of doxycycline to reduce 
aneurysmal growth awaits confirmation in a sufficiently powered clinical trial. These data 
provide a promising avenue for further research evaluating the efficacy of doxycycline in 
other chronic vascular and nonvascular inflammatory conditions involving neutrophils and/or 
cytotoxic T cells such as Kawasaki disease37 and chronic obstructive pulmonary disease.38
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Abstract
An aneurysm of the aorta is a common pathology characterized by segmental weakening 
of the artery. Although it is generally accepted that the vessel-wall weakening is caused 
by an impaired collagen metabolism, a clear association has been demonstrated only for 
rare syndromes such as the vascular type Ehlers–Danlos syndrome. Here we show that 
vessel-wall failure in growing aneurysms of patients who have aortic abdominal aneurysm 
(AAA) or Marfan syndrome is not related to a collagen defect at the molecular level. On the 
contrary our findings indicate similar (Marfan) or even higher collagen concentrations (AAA) 
and increased collagen cross-linking in the aneurysms. Using 3D confocal imaging we show 
that the two conditions are associated with profound defects in collagen microarchitecture. 
Reconstructions of normal vessel wall show that adventitial collagen fibers are organized in 
a loose braiding of collagen ribbons. These ribbons encage the vessel, allowing the vessel 
to dilate easily but preventing overstretching. AAA and aneurysms in Marfan syndrome show 
dramatically altered collagen architectures with loss of the collagen knitting. Evaluations 
of the functional characteristics by atomic force microscopy showed that the wall has lost 
its ability to stretch easily and revealed a second defect: although vascular collagen in 
normal aortic wall behaves as a coherent network, in AAA and Marfan tissues it does not. 
As result, mechanical forces loaded on individual fibers are not distributed over the tissue. 
These studies demonstrate that the mechanical properties of tissue are strongly influenced 




Aortic aneurysms are localized dilatations of the aortic wall that are caused by segmental 
weakening of the vessel wall. Although aneurysms generally are without clinical symptoms, 
larger aneurysms may rupture, and bleeding from a ruptured aneurysm is responsible for 
more than 15,000 annual deaths in the United States alone.1 Aneurysm formation relates 
to a primary or secondary (acquired) defect in the matrix structures supporting the vessel 
wall resulting in attenuation and ultimate failure of the vessel wall.2 Although extensive 
loss of medial elastin traditionally is considered the hallmark of aneurysm formation, it now 
is acknowledged that aneurysmal growth and ultimate rupture relate to impaired collagen 
homeostasis.2 Remarkably, although numerous studies have looked for putative quantitative 
changes in aortic collagen, results reported to date are controversial.3–5 With the exception of 
rare mutations in the collagen III gene such as the vascular type of Ehlers–Danlos syndrome, 
no clear association between impaired collagen homeostasis and aneurysm growth and/
or rupture has been identified. In search of the collagen defect(s) underlying aneurysm 
formation, we applied an integrated approach of biochemical analyses, multiple imaging 
modalities, and functional analysis by atomic force microscopy (AFM) to identify the putative 
collagen defect in aortic abdominal aneurysm (AAA) and in Marfan syndrome, by far the two 
most common forms of aortic aneurysms. Results of this evaluation show that advanced 
stages of aneurysmal disease are characterized by distinct defects in the adventitial collagen 
skeleton armoring the vessel wall rather than by purely biochemical defects.
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Materials and methods
All human arterial wall samples were provided by the Vascular Tissue Bank, Department of 
Vascular Surgery, Leiden, The Netherlands. Sample collection and handling was performed 
in accordance with the guidelines of Medical Ethical Committee of the Leiden University 
Medical Center, Leiden, The Netherlands, and the code of conduct of the Dutch federation 
of Biomedical Scientific Societies.
Anterior lateral aneurysm wall samples were obtained from patients with an AAA >55 mm 
undergoing elective open repair (AAA group: n = 17,mean age 72.4 ± 6.2 years). Thoracic 
aortic aneurysms (ascending aorta, diameter >50 mm) of Marfan patients were obtained 
during elective repair (Bentall procedures) (Marfan group: n = 11, age 26.9 ± 8.2 years). All 
Marfan patients met the international criteria for Marfan syndrome.6
Control (normal) abdominal aortic wall was obtained during kidney explantation for organ 
donation. All these control samples were obtained from the level of the renal artery, i.e., 
from a location comparable to that of the samples from AAA patients (n = 11, age 55.6 ± 
10.2 years). The primary cause of the fatal brain injury in this control group was a major head 
trauma or subarachnoidal bleeding.
Control thoracic aorta (post mortems) from patients dying from noncardiac causes was used 
as a histological reference for the Marfan tissue. Following excision, half of the sample was 
fixed in formalin for 24 h, decalcified in Kristensen’s solution, and subsequently embedded 
in paraffin for immunohistochemical analysis. The remaining half was immediately flash-
frozen in liquid nitrogen for mRNA analysis and for the preparation of cryosections.
Collagen and Cross-Link Analysis
Ten 10-μm slices of paraffin-embedded tissue were deparafinized in xylene, and the samples 
were hydrolyzed (110 °C, 20–24 h) in 1 mL 6 M HCl in 5-mL Teflonsealed glass tubes. The 
samples were dried and redissolved in 1 mL of water containing 10 μmol/L of pyridoxine 
[internal standard for the cross-links hydroxylysylpyridinoline (HP) and lysyl-pyridinoline] and 
2.4 mmol/L of homoarginine (internal standard for amino acids) (Sigma). Samples were 
diluted 5-fold with 0.5% (vol/vol) heptafluorobutyric acid (Fluka) in 10% (vol/vol) acetonitrile 
for cross-link analysis; aliquots of the 5-fold diluted sample were diluted 50-fold with 0.1 M 
sodium borate buffer (pH 8.0) for amino acid analysis. Derivatization of the amino acids with 
9-fluorenylmethyl chloroformate and reversed-phase HPLC of amino acids and crosslinks 
was performed on aMicropakODS-80TMcolumn (150mm×4.6 mm) (Varian) as described 
previously.7,8 The quantities of the cross-link HP were expressed as the number of residues 
per collagenmolecule, assuming 300 hydroxyproline (Hyp) residues per triple helix. This 
procedure is well established, because Hyp is a collagen-specific amino acid and because 
the prolyl hydroxylation level in collagen is stable.
RNA Extraction and mRNA Analysis
Total RNA extraction was performed using RNAzol (Campro Scientifics) and glass beads 
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according to the manufacturer’s instructions. Copy-DNA was prepared using kit #A3500 
(Promega), and quantitative realtime PCR analysis was performed for collagen type I and III 
and lysyl oxidase on the ABI-7700 system (Applied Biosystems) using established primer/
probe sets (Assays on Demand; Applied Biosystems) and MasterMix (Eurogentec). Analyses 
were performed according to the manufacturers’ instructions and as previously reported.9 
GAPDH expression was used as a reference and for normalization.
Histology
Histochemistry and immunohistochemistry was performed on 4-μm deparaffinized, ethanol-
dehydrated tissue sections. Collagen staining was performed by the Sirius Red-picrine 
method.10 Immunohistochemical staining for collagen type I and III and fibrillin was performed 
using specific antibodies for collagen type I (C7510-17K; US Biological), collagen type III 
(C7510-39G; US Biological), or fibrillin (MAB1919, Chemicon). Pepsin-trypsin retrieval was 
required for optimal collagen I and III staining, and a 10-mM (pH 6.0) citrate retrieval was 
required for the fibrillin staining.
AB-conjugated biotinylatedanti-goat or rabbit anti-IgG was used as secondary antibody. 
Sections were stained with NovaRed(Vector Laboratories) and counterstained with Mayer’s 
hematoxylin. Controls were performed by omitting the primary antibody.
We used confocal microscopy (LSM615; Zeiss) for the visualization of the collagen network 
structures. Tissue slices (20 μm) were stained with Sirius Red, and Sirius Red fluorescence 
was used for the reconstruction. Fibrillin deposition was evaluated by immunohistochemical 
staining (see above) using the Alexa 647 mouse anti-goat antibody for visualization. Serial 
confocal sections of x-y images (stack size 206 × 206 μm) of representative sections of 
the medial and adventitial layer were made along the z axis with a distance of 0.5 μm. The 
excitation and emission wavelengths were 543 and 633 nm, respectively, for the Sirius 
Red staining and were 633 and 647 nm, respectively, for immunohistochemical (Alexa 647) 
staining. The pinhole was set at 108 μm. Three-dimensional reconstructions of confocal 
stacks (20 serial images at 0,5-μm intervals) were performed using the stacks- Z-function 
on the Zeiss LSM Image Examiner version 3.2.0.115.
Atomic Force Microscopy
Atomic force microscopy (AFM) measurements were performed on 8-μm-thick tissue slices. 
To that end, tissue was cryosliced to 8-μm thickness, perpendicular to the flow of the blood, 
and stored at -80 °C. Measurements were done using a Molecular Imaging PicoScan atomic 
force microscope controlled with a custom scripting program written in Labview (National 
Instruments) and Visual Basic 6 (Microsoft). Data were recorded with a National Instruments 
card at 100 kS/s and then processed into higher-resolution force–volume images than can 
be taken with the control software of the AFM. All force–distance curves were performed at 
a rate of 1 Hz.
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Tissue was probed at two different resolutions: A sharp tip (20-nm tip radius) was used 
to probe the tissue on the fibril level, anda 10-μm ball tip was used to probe at the tissue 
level.11,12 The sharp tips were Nanoprobe tips model NP (Veeco). Cantilevers were calibrated 
using the thermal method.13
Balls tips were specially modified tips from Novascan. These tips are Park cantilevers 
(Veeco) to which a 10-μm glass ball is attached. Because the effective stiffness of the 
tissue is greater when probed at a larger scale, we choose cantilevers with a force constant 
of 0.32 N/m. Tips were coated by a layer of polyethylene glycol (molecular weight 3,400 kDa) 
to prevent fouling.
All AFM measurements were performed in a liquid cell (Molecular Imaging) in PBS. Preliminary 
evaluation showed that the AFM measurements on the aorta sections were independent of 
the spring constant of the cantilevers. Consistency of the data was checked by measuring 
the variations in stiffness in a number of healthy individuals. As shown in Figure 1, the 
variation among the individuals tested is consistent with the conclusion that the differences 
found among different tissues are disease specific rather than representing variation among 
individuals.
F IGURE 1
Force distribution of three distinct healthy aortas (black, gray, and white bars) measured by the sharp tip.
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AFM Function and Nano indentation
Force–extension curves were performed by laying a section of tissue on a glass slide 
and immersing it in the PBS buffer in the liquid cell. Tissue then was loaded in the AFM 
microscope, and a force–volume dataset was produced by pushing the cantilever into the 
tissue at each point on a grid. This technique allowed the collection of a 2D grid of indentation 
data that then was transformed as explained below into effective Young’s modulus as well 
as a constant-force topography.
The Young’s modulus was determined using the methods of A. Hassan et al.14 This technique 
is more robust to the errors that are inherently present in fitting the Hertz model15 of an 
indenter to data collected from AFM force–distance curves. A detailed discussion of the 
methods that can be used to find the Young’s modulus from AFM force–extension curves 
can be found in Stolz et al.16 or in A-Hassan et al.14 This technique involves determining 
the work performed by the cantilever on the tissue sample and then comparing this work 
with a known standard. By integrating the total area under the force–distance curve, local 
variations are minimized, and the curve fitting becomes less difficult. Most importantly, the 
exact point of contact between surface and AFM cantilever is no longer needed, because 
the area under the curve at the estimated contact point is small compared with the total 
area under the curve. Its ease of application and, more importantly, its reproducibility, make 
this technique the more desirable method of determining the effective Young’s modulus of 
the tissue.
In this case, Sneddon’s equations17 were used to estimate the curve that would be expected 
with a conical (sharp tip) or spherical (ball tip) Hertz model indentor. Although this estimation 
negates some of the advantages of this method, namely the ability to divide the shape, 
force constant, and sensitivity of the tip from the equation, it still produces a standard curve 
to which all of the curves analyzed by this method have been compared. Thus, although 
the absolute value for the Young’s modulus has a large error, the error is systematic, and 
comparisons between the various datasets are still completely valid.
Validity and Reproducibility of the AFM Measurements
Two different force constants were used between the ball tips and the sharp tips. To determine 
what effects the differing force constants would have, we performed an experiment with the 
sharp tip on aortic abdominal aneurysm (AAA) tissue. Various cantilevers were available on 
the nanoprobe chip; we used cantilevers with the 0.06-N/m and the 0.32-N/m tips, force 
constants that were chosen specifically to match the stiffness of the tissue and therefore 
to maximize the force resolution.
The effect from the force constant of the cantilever over this range is negligible. The observed 
differences pale in comparison with the differences between the Marfan and AAA tissue. 
Therefore we can safely assume that the differences seen in the aneurysmal tissue between 
the ball tip and the sharp tip result solely from the differences in tip shape.
C HAP TER 7
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Action of Ball Tip vs. Sharp Tip
The different-sized tips allow very different information about the collagen networks to be 
collected, and the data provide a sense of the coherence of the matrix network. The two tips 
allow an understanding of the collagen networks as well as interacting directly with individual 
proteins. The sharper tip is smaller than the radius of a collagenfibril. It is able to interact 
directly with these structures in the extracellular matrix as well as slip between the fibers. 
The ball tip was chosen to interact with the tissue on a micrometer scale. This tip is able to 
push tens of fibers and directly measures the network indentation properties of the tissue. 
The size is a compromise between seeing the large network behavior and yet remaining 
small enough to handle with an AFM tip.
 
Nano indentation Stiffness Maps
The force-vs.-distance curves were processed into a combination topography and stiffness 
image by combining all the force–extension curves from the AFM measurements into a grid 
and then taking the extension at which the force reached a certain level as the intensity 
at that point. This method is sensitive to both the initial height of the tissue and to the 
stiffness of the tissue under the cantilever. Regions where the tissue is stiffer will indent 
less before the required force is reached and will therefore appear higher than regions that 
were equally high before indentation but that are softer. We find that these images provide 
information complementary to the collagen confocal images.
Statistics
Differences between the groups were evaluated by an unpaired t test (for the normally 
distributed data) or by the Wilcoxon–Mann–Whitney test (for non–normally distributed 
continuous data). The level of significance was set at P < 0.05. All analyses were performed 
using SPSS16.0 (SPSS Inc.)
 
Results
Vascular load-bearing collagen is composed of highly stable type I and III fibrillar collagens 
that are stabilized further by intramolecular cross-linking.18 Biochemical as well as 
morphometric evaluation showed similar collagen concentrations in aneurysm wall from 
patients with Marfan syndrome and normal, non-aneurysmal control aorta, whereas elevated 
collagen concentrations were found in AAA (Figure 2A). The ration of type I/III collagen mRNA 
expression was similar in control aorta, Marfan syndrome, and AAA (Figure 3). Expression 
of lysyl oxidase was higher in the aneurysm wall from patients with Marfan syndrome 
(P < 0.05; Figure 3). Evaluation of intermolecular collagen cross-linking through quantification 
of nonreducible lysyl oxidase-initiated collagen cross-links (hydroxylysyl pyridinoline/lysyl 
pyridinoline cross-links)19 showed increased intramolecular collagen cross-linking in the 
aneurysmal wall in both AAA and Marfan tissue (Figure 2). These biochemical findings for 
AAA are in line with reports in the available literature, and none of the findings indicates 
a quantitative or qualitative defect in vascular collagen at the molecular level in AAA or in 
aneurysms of patients with Marfan syndrome.
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In the absence of a clear defect at the biochemical level, we sought for possible structural 
defects in collagen organization. Histological evaluation (Picrosirius Red collagen staining) 
(Figure 2B) and immunohistological staining for collagen type I and III (Figure 4) show distinct 
differences in collagen organization in the medial and adventitial layers of the (grossly) 
normal aortic wall. A similar pattern but with minor fibrotic changes is seen in the aneurysm 
wall of patients with Marfan syndrome (Figure 2B and Figure 4). Collagen deposition in AAA, 
on the other hand, is hallmarked by complete loss of vessel-wall architecture and deposition 
of disorganized and condensed collagen (Figure 2B and Figure 4), a finding that is consistent.
 
Because the regular 2D images may mask structural defects in the third dimension,20 we 
also created 3D reconstructions of the medial and adventitial collagen microarchitecture 
using the Z-stack function on the confocal microscope. These reconstructions show a 
clearly distinct collagen organization in the medial and adventitial layers of the normal 
aortic wall (Figure 5). Collagen deposition in the medial layer is best characterized by small, 
interdispersed collagen fibrils that run mainly perpendicular to the circumferential elastic 
sheets (Figure 5A). Adventitial collagen, on the other hand, is arranged in a loose knitting 
of highly organized ribbon-like collagen bands that brace the medial and intimal layers 
of the vessel wall (Figure 5B). These different architectures appear optimal for achieving 
the different functionalities for the aortic medial and adventitial layers (elastic recoil and 
resilience, respectively).21,22
Evaluation of collagen architecture in aneurysms of patients with Marfan syndrome showed 
minor changes in the medial layers of the aortic wall (Figure 5C) but a dramatically disturbed 
collagen architecture in the adventitial layer, with complete absence of the normal collagen 
fibril organization and deposition of thin parallel collagen fibrils (Figure 5D).
Reconstructions for the AAA (Figure 5E) show complete loss of the normal architecture, loss 
of the distinction between medial and adventitial collagen organization, and deposition of 
aggregated, parallel collagen sheets that appear rigid.
The disordered properties of the collagen microarchitecture in AAA and in the adventitial 
layer of aneurysms from patients with Marfan syndrome suggest that defects in adventitial 
collagen organization underlie the weakening of the aortic wall. To test this hypothesis, we 
performed functional analysis by AFM on normal and aneurysmal adventitial aortic sections. 
AFM is an established means to test the mechanical properties of individual proteins, cells, 
and tissue.23,24 AFM experiments are performed by indenting the tissue at multiple points 
with a needle and testing the mechanical response.25 The tissue response to the indentation 
then is used to calculate the elasticity (Young’s modulus) for the given point. Multiple 
individual elasticity measurements then are integrated to create a visual representation 
(stiffness map) of the probed area. The high force resolution of the AFM (in pico-newtons) 
and its high lateral resolution (i.e., several elasticity measurements per square micrometer) 
makeAFM ideal for precisely mapping the mechanical properties of tissue at the microscale 
level, thereby allowing comparison of the elasticity map with the confocal images (Figure 5). 
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F IGURE 2
(A) Aortic wall collagen levels were 
assessed by the hydroxyproline/ proline 
ratio, and the extent of intramolecular 
collagen cross-links was assessed by the 
number of hydroxylysyl pyridinoline and 
lysyl pyridinoline cross-links per triple helix. 
Open box, control; light gray box,  
Marfan syndrome; dark gray box, AAA; 
 ●, P < 0.00001.
(B) Collagen deposition (Sirius Red 
staining) in normal aortic wall and 
aneurysmal wall in Marfan syndrome 
and AAA. The images are oriented with 
the media layer in the upper half and the 
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Collagen type I and III distribution in medial-adventitial border zone of control (abdominal) 
aorta, ascending aortic aneurysm in Marfan syndrome, and AAA. (Scale bar, 100 μM.)
F IGURE 3
F IGURE 4
mRNA expression relative to GAPDH (GAPDH = 1) of type I and III collagen, and lysyl oxidase 
(a key enzyme required for collagen cross-linking). Open box, Control; light gray box, Marfan 
syndrome; dark gray box, AAA; ●, P < 0.00001.
Moreover, the individual elasticity measurements can be compiled into a histogram that 
can be used to express the distribution of the elasticity of the arterial wall at a larger scale.
Tissue (adventitial layer) was probed at two different levels by using different AFM cantilevers: 
a sharp tip (20-nm end radius) and a blunter ball tip (10-μm radius). These two tips allow 
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a comparison of the different scales in the tissue. The size of the sharp tip is chosen to 
interact only with individual molecules in the tissue (individual fiber level), whereas the 
larger ball tip is designed to probe at the tissue level (fibril behavior). The elasticity modulus 
(Young’s modulus) was calculated for each indentation, because then the size and shape 
of the indenter can be removed, allowing direct comparison of the two measurements. The 
combined measurements provide a complete picture of the mechanical properties of the 
tissue and allow the AFM measurements to be compared with previous conventional studies 
of the mechanical properties of AAA and normal aorta segments.26,27 Note, however, that all 
measurements are performed on a microscale level, not fully loading the fibers.
F IGURE 5
(A and B) Three-dimensional reconstructions of collagen networks in the normal media 
and adventitial layer. (C and D) Aneurysms in patients with Marfan syndrome. (E) Aortic 
abdominal aneurysm.
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Stiffness histograms combining the individual data points show that the tissue response 
of the control adventitia is independent of the size of the tip that is used. This finding 
indicates that the normal adventitial tissue behaves as a highly coherent network. The 
stresses encountered by the tissue are dispersed equally over the whole network, and 
the scale of the challenger does not matter. The fact that the sharp indenter is not able to 
penetrate the network to a greater extent than the ball tip shows that the individual collagen 
fibers are densely interconnected, because the fibers do not slide out of the way and are all 
pulled when a single fiber is moved.
F IGURE 6
Histograms showing the distribution of the effective Young’s modulus for the different 
conditions. Black bars show curves taken with the sharp tip; white bars show curves taken 
with the ball tip. Values are plotted on a log scale to improve the comparison of the modulus.
The major difference between the aneurysmal tissues and normal tissue is immediately 
apparent from the histogram in Figure 6 and the AFM force–volume spectroscopy (Figure 7). 
Unlike normal tissue, the stiffness of AAA tissue is clearly dependent on the size of the AFM 
tip: The ball tip, which interacts with the larger structures, senses a very stiff tissue. This 
observation is in line with our confocal images and conventional biomechanical studies that 
show that AAA tissue has become stiffer.28 The sharp tip, on the other hand, meets hardly 
any resistance, suggesting that the sharp tip pushes the fibers of the extracellular matrix 
aside. This observation indicates that the interconnections that normally allow the tissue to 
behave as a coherent network are missing in AAA.
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F IGURE 7
Probing of Marfan aneurysmal tissue shows a tissue behavior that is clearly distinct from 
both control aorta and AAA tissue. The larger ball tip senses stiffness similar to that of 
normal tissue, suggesting that under the conditions of the AFM experiment (a resting, 
nonstretched state) the tissue elasticity at a larger scale equals that of normal aortic wall. 
The sharp tip, on the other hand, finds little resistance and plunges through the tissue just 
as it did with AAA tissue. This observation indicates that the individual fibers are pushed 
aside when probed with the 25-nm tip and thus that the loaded fibrils are unable to transfer 
the stress and strain to the neighboring fibrils (i.e., absence of network behavior).
Another remarkable finding distinct to the Marfan tissue is that sections of the tissue 
collapse as the force is applied (Figure 8). These sections appear to be small voids in the 
collagen network that also are observed in the confocal images (Figure 5D). Such voids 
could provide sites susceptible to dissection or rupture.29
Topography maps for the various tissues as determined from AFM force–volume spectroscopy 
at 11 nN of constant force. Marfan tissue probed with the pyramidal tip (A) and sharp tip 
(B). The inset in A shows the Marfan tissue at 40 nN; it is apparent that the force collapses 
something in the tissue at various points resulting in a much smoother-looking surface. 
Healthy tissue probed with pyramidal tip (C) and ball tip (D). AAA tissue probed with pyramidal 
tip (E) and ball tip (F).
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F IGURE 8
Individual force extension curves. “Extension” refers to the length of the piezoelectric tube. 
Motion toward zero results in indentation of the tissue by the cantilever tip. (Top) Curves 
sampled from control tissue. (Middle) Curves sampled from AAA tissue showing the nonlinear 
interactions common on the AAA tissue with the ball tip. It is proposed that the nonlinearity is 
a result of one collagen fiber being pushed into a second fiber, resulting in markedly stronger 
forces with nonlinear transitions at the connection. This behavior is consistent with the 
notion that there are fewer interconnections between the various collagen fibers resulting 
in no warning for the second fiber and its sudden recruitment. (Bottom) Curves sampled 
from Marfan tissue showing the collapses that are common with the Marfan tissue. These 
collapses could be the result of the weakened collagen fibers slipping to the side of the tip 
or could indicate structural weaknesses in the tissue. The confocal images in Fig. 5 A and B 
show the presence of small voids.
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Discussion
This study shows that advanced aneurysms in AAA and Marfan syndrome are associated 
more with distinct defects in the collagen microarchitecture than with a collagen defect at 
the biochemical level. These architectural defects result in loss of the normal stress–strain 
curve and in impaired collagen network behavior, both of which can contribute to the aortic 
wall failure.
Visualization of adventitial collagen structures in the control aorta shows a collagen 
architecture that is best described as a loosely knitted network of interwoven collagen 
ribbons encasing the medial layer. A similar architecture has been described previously 
for the adventitial layer of the urine bladder, and it was shown that the collagen ribbons 
align during bladder filling, thereby allowing the bladder to distend easily but preventing 
overstretching.30 The aortic adventitial layer may serve a similar purpose: Its flexibility 
allows the arterial wall to dilate easily but resists overstretching once fully loaded. Such a 
construction is similar to the textile and metal plies in a steel-belted radial tire that allow 
flexibility but prevent failure in extreme conditions.
The different architectures of the medial and adventitial layers may well explain the J-shaped 
stress–strain curve (i.e., the nonlinearity of the curve) of the normal vessel wall and suggest 
that the two layers have different functionalities, the elastic medial layer being responsible 
for the flat, horizontal part of the curve and the adventitial knitting resulting in the steep arm 
of stress–strain curve.31
Visualization of the collagen braiding in Marfan aneurysms and AAA in vessel-wall samples 
that were obtained at the time of operation (i.e., from advanced stages of the disease) 
shows that the collagen fibrils run almost in parallel, thereby limiting their ability to stretch, 
and therefore stiffen the vessel. This observation is well in line with biomechanical studies 
that show that both AAA and Marfan aneurysms are stiffer than the normal vessel wall.18,32
The increased stiffness of AAA tissue also is immediately apparent from the AFM experiments 
performed with a ball tip that show a sharp increase in the effective Young’s modulus for 
AAA tissue, indicating that the tissue resisted even the minimal indentations (2–3 μm) by the 
AFM tip. The similar Young’s moduli for ball-tip experiments in normal aorta and aortas from 
patients with Marfan syndrome seemingly conflict with biomechanical studies that indicate 
that Marfan tissue is stiffer than normal tissue.32 This apparent contradiction presumably 
reflects a limitation when AFM measurements are performed under resting, nonstretched 
conditions. The confocal images clearly show that under such conditions collagen fibrils in 
Marfan tissue adopt a wave-like pattern that allows them to stretch when probed with the 
AFM tip.
Findings from this study also point to defects in collagen network behavior in the aneurysmal 
tissues studied. Network behavior has long been recognized as a key to mechanical stability 
in the field of structural design, but, remarkably, in the biomedical context network behavior 
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has only been reported for bone tissue.24 Our results indicate that aneurysms in both 
AAA and Marfan tissue are associated with defects at all three scale lengths (i.e., at the 
intrafibril, intrafiber, and suprafiber levels). Impaired network behavior may interfere with the 
dissipation of the mechanical forces over the arterial wall, thereby contributing further to the 
mechanical failure of the aortic wall.
In conclusion, the findings in this study provide a structural explanation of how biological 
tissue (i.e., normal arterial wall) can acquire its typical nonlinear stress–strain curve and 
also can settle the longstanding controversy regarding the existence of a collagen deficiency 
in AAA. We show that defects in collagen architecture and network behavior, rather than a 
defect at the molecular level, explain the debilitation of the aortic wall in AAA and aneurysms 
in Marfan syndrome. The observed changes in AAA do not necessarily reflect the primary 
cause of AAA formation. More likely, the changes in AAA reflect inappropriate collagen 
deposition (fibrosis) in an environment that is characterized by sustained inflammation and 
activation of multiple proteolytic pathways. The findings in Marfan syndrome, on the other 
hand, may reflect a primary defect: Unlike AAA, aneurysms in patients with Marfan syndrome 
do show signs of increased inflammation and proteolytic activities.33 As such, the observed 
defects in the collagen microarchitecture may reflect a primary defect that could relate to 
impaired TGF-β signaling. However, the strong link between a defect in the fibrillin gene and 
development of Marfan syndrome also may reflect a role of fibrillin in the organization of 
the collagen bands in the adventitial layer. This notion is supported by the fact that fibrillin 
is localized predominantly in the adventitia of the normal aortic wall (Figure 9A) and by the 
pattern of fibrillin deposition that is similar to that of the adventitial collagen network (Figure 
9B). Our findings confirm the longstanding assumption that Marfan syndrome is a collagen 
disorder34 and show that Marfan syndrome is associated with a defect in collagen network 
organization. Such a defect may well explain most of the other phenotypical features of 
Marfan syndrome which appear related to collagen dysfunction (e.g., skeletal deformities, 
hernias, dural ectasia, and ectopia lentis).
We speculate that defects similar to those in AAA explain the longstanding apparent 
contradiction between increased collagen content but reduced mechanical strength during 
wound healing and scar formation.35 Microarchitectural defects in collagen network formation 
may well contribute to scar formation in post fetal wound healing that currently is attributed 
to a reduced elastin transcription after birth.36
C HAP TER 7
1 28
C OLL AgEN mIC ROARC HITEC T uRE IN ANEuRySm AL d ISE A SE 
Fibrillin localization in the normal aortic wall. (A) Fibrillin (reddish-brown) is present primarily 
in the adventitial layer of the aortic wall. (B) 3D reconstruction by confocal microscopy 
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The development (initiation) of abdominal aortic aneurysms (AAAs) is caused by as yet 
a cascade of only partially defined pathological changes in the aortic wall. The process 
of AAA progression is driven by chronic inflammation of the aortic wall and proteinase-
mediated degradation of the extracellular matrix.1,2 It has been well documented that the 
strength of the aortic wall depends on the collagen network in the vessel wall.3 Therefore we 
hypothesized that strategies preserving the integrity of the collagen structures will stabilize 
the aneurysm wall, and so reduce aneurysm progression.
Structural collagen within the arterial wall is predominantly type I and III fibrillar collagen that 
is highly resistant to proteolytic degradation.3 Proteolysis of these types of collagen requires 
the action of specific collagenases that are able to cleave the native triple helical region 
of fibrillar collagens. In Chapter 2, we demonstrated excess turnover of fibrillar collagen in 
AAA. We identified members of the cysteine protease family, cathepsin K, L, and S, along 
with neutrophil collagenase (MMP-8), as the culprit collagenases in AAA disease. Moreover, 
we found a secondary deficiency of cystatin C (the primary extracellular inhibitor of cysteine 
proteases). We present evidence for a mechanism in which the inhibitor of one class of 
proteases is degraded by proteases from a different class; i.e cystatin C can be degraded by 
the MMPs 8 and 9 as well as by the serine protease neutrophil elastase, indicating crosstalk 
between different classes of proteases.
The tetracycline antibiotic doxycycline has been shown to inhibit both MMP production 
and activity. Doxycycline has an excellent safety record and has been proposed as a 
pharmaceutical approach to inhibit aneurysm growth. However, it is unknown how the effect 
of doxycycline translates to the collagen homeostasis in human AAA disease. Therefore in 
Chapter 3 we evaluated the effect of two weeks of doxycycline treatment on the activity 
of MMP and cysteine collagenases in patients scheduled for open repair. Results of this 
randomized clinical trial indicate that doxycycline improves the proteolytic balance through 
a dual effect on proteases and their inhibitors. Doxycycline treatment reduced MMP 8 and 
9 expression and activation, and increased the levels of the protease inhibitors TIMP1 and 
cystatin C. Since the effects on MMP 8 and 9 expression were only observed at the protein 
level, we reasoned that this reduction reflects an effect on neutrophils. Indeed, evaluation of 
the neutrophil content in the aneurysmal wall revealed that the administration of doxycycline 
in patients with a large aneurysm over 14 days significantly reduced the number of infiltrating 
neutrophils in the tunica media and adventitia as compared with controls.
Neutrophils have long been considered part of an acute inflammatory response and their 
abundance in aneurysmal wall often been ignored. Recent studies, however, show that 
neutrophils may also participate in chronic inflammatory processes, and studies in mice show 
that neutrophils are critically involved in experimental AAA.4,5 The presence of neutrophils 
in the aneurysmal wall, and therefore the effect of doxycycline, is not explained by the 
current concepts of inflammation in AAA. In Chapter 4 we set out to explain the presence 
of neutrophils in human AAA, and contribute to the characterization of the inflammatory 
footprint of the disease. Results of this evaluation showed increased activation of general 
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pro-inflammatory transcription factors, accompanied by IL-6 and IL-8 hyperexpression, and 
exaggerated downstream cellular responses, particularly related to neutrophils.
As all these analyses were performed on surgical specimens collected during open repair, 
the data will therefore typically reflect the final stages of the disease process, and so 
do not allow distinction between primary and secondary (bystanding) processes. AAAs are 
epidemiologically associated with popliteal artery aneurysms (PAAs), suggesting that these 
two pathologies share common ground. In Chapter 5 we carried out a systematic analysis of 
inflammatory and proteolytic pathways in AAA and PAA tissues to identify corresponding and 
discordant processes in these aneurysms. This, in turn, may provide clues on the processes 
that are crucial for aneurysmal growth. Findings show a remarkable overlap between the 
two diseases (AAA and PAA). Both are characterized by activation of the NF-κB and AP-1 
pathways, IL-8 hyperexpression and neutrophil involvement.
In Chapter 6 we showed that the profound suppression in neutrophil content after a short 
intervention with doxycycline is related to a selective suppression of inflammation of the 
vascular wall. This is reflected by inhibition of the AP-1 and C/EBP inflammatory pathways, 
and a strong reduction of the aortic wall neutrophil and cytotoxic T-cell content and activity. 
This study provides the rationale for the clinical evaluation of doxycycline as an anti-
inflammatory drug in AAA disease.
Although impaired collagen metabolism is generally considered the hallmark of AAA 
progression, no clear collagen deficiency or defect has yet been identified in this disease. 
In Chapter 7 we studied the collagen characteristics in AAA disease and showed that AAA 
is not characterized by a collagen deficiency but that the mechanical weakening relates to 
defects in the collagen micro-architecture, indicating a qualitative rather than a quantitative 
defect.
Future perspectives
Information on current treatments and the focus of future management
Traditionally, abdominal aneurysms were considered as a purely local mechanical dilatation 
of the aorta caused by atherosclerotic disease that ultimately led to rupture and death. In 
the last 50 years, much progress has been made in the surgical techniques of aortic repair. 
Surgical techniques have been developed based on the concept of mechanically excluding 
the aneurysm from the circulation, rather than targeting the processes driving aneurysm 
progression.
Aortic open repair and endovascular repair are now the mainstay of treatment. Unfortunately, 
both techniques remain associated with a significant mortality and morbidity. Therefore 
aneurysm repair (either open or endovascular) is only applied when risk of aneurysm rupture 
outweighs the risk of operation. Risk of rupture is largely dependent on the diameter of the 
aneurysm. Several large, randomized, prospective trials have evaluated the optimal size to 
treat abdominal aortic aneurysms.6,7,8,9 The guidelines and conclusions from these studies 
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recommend intervention when the aneurysm reaches a transverse diameter of 5.5 cm. 
Currently, small aneurysms (i.e. diameter of 5.5 cm or less) are best approached with a wait-
and-see policy. However, due to the aging population, the incidence of AAA is increasing, 
and screening of individuals which is proposed in a number of countries will detect many 
small asymptomatic AAAs. It would be beneficial to develop a medical management plan 
that would prevent the transformation of small aneurysms into large aneurysms, thereby 
decreasing the risk of rupture, and decreasing the number of therapeutic operations.
Furthermore, the presence of an abdominal aneurysm is associated with elevated rates of 
total mortality, cardiovascular disease mortality, and incident cardiovascular disease. These 
associations are independent of age, sex, other clinical cardiovascular disease, and extent 
of atherosclerosis.10 This means that AAA disease is not only a local disease but also a 
symptom and a prognostic factor of significant cardiovascular systemic disease associated 
with morbidity and mortality. Therefore research must focus on the role of cardiovascular 
risk management in patients with AAA. It is expected that with this strategy, a decrease in 
the risk of mortality in patients with AAA could be achieved.
Current treatments (open and endovascular repair) are developed before understanding the 
pathology of abdominal aneurysms, and do not target the pathophysiology of aneurysm 
growth. Therefore we need a better understanding of the pathology to create opportunities 
for better treatments in patients with AAA. 
Future perspectives on the pathophysiology of AAA
In this thesis we showed that human aneurysms are characterized by the destruction of the 
well-organized lamellar structure of the aorta. The proteins that are damaged include elastin 
and collagen, both highly stable proteins. Collagen is responsible for the mechanical stability 
of the healthy vessel wall.11 We, among others, have implicated MMPs and cathepsins 
because of their ability to degrade collagen. We found abundant presence of multiple 
members of the MMP and cathepsin family in human AAA tissue. To find out if the identified 
MMPs and cathepsins are causatively involved in the pathophysiology of aneurysm disease 
or whether they are simply bystander proteins that accompany an inflammatory response, 
we need to further evaluate the role of the MMP’s and cathepsin family members in animal 
models of AAA.
One of the true collagenases that is most abundantly present in our human aneurysm 
tissues is the neutrophil-derived MMP-8. Neutrophil depletion or intervention with neutrophil 
activation has been shown to prevent AAA formation in established animal models of the 
disease.12,13 Although these observations support a role for neutrophils in AAA, they do 
not directly help to determine a effective and safe therapeutic strategy. Our findings show 
abundant expression of the chemokine IL-8, a strong neutrophil attractant. Therefore we 
hypothesize that blocking IL-8 signaling will reduce granulocyte recruitment to the vessel 
wall. IL-8 signalling is largely mediated by the CXCR2 receptor. Oral CXCR2 antagonists are 
currently under preclinical investigation. A next step would be to test these compounds 
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in established mouse AAA models.14,15 Although MMP inhibitors failed during clinical 
evaluation,16 a number cathepsin K and S inhibitors are in early clinical evaluation.17,18 In 
light of this, we suggest to perform cathepsin inhibition in the mouse AAA model to evaluate 
the role of this class of proteases in aneurysm formation and progression.
Since inflammation is the primary driving force in the pathogenesis of AAA and major regulator 
in the production and activation of proteases, it would be of great interest to do additional 
studies to evaluate the role of inflammatory pathways in AAA disease. For example, the 
migration of leukocytes to sites of stress is regulated by chemokines and their receptors. In 
atherosclerosis, it has been shown that the monocyte chemoattractant protein-1 (MCP-1)/
chemokine receptor CCR2 pathway has a key role in leukocyte recruitment.19,20,21 In addition, 
in our human aneurysm tissue specimens, we detected very high levels of MCP-1, suggesting 
an involvement for this chemokine in AAA. Indeed, in the mouse AAA model, transplantation 
of apolipoprotein E (ApoE)-deficient (hyperlipidemic) mice with bone marrow derived from 
CCR2/ApoE double-deficient mice largely prevented aneurysm formation.22 This suggests 
that CCR2-mediated leukocyte recruitment has a major role in aneurysm formation. As an 
effective way to study the role of CCR2-mediated response in an animal aneurysm model, we 
could inhibit CCR2-mediated recruitment by applying gene transfer of a dominant-negative 
form of MCP-1 via in vivo electroporation in the skeletal muscle of the mice.23
Research is focusing on the role of the inflammatory and proteolytic factors in AAA animal 
models, providing better understanding of the pathology of AAA and defining therapeutic 
targets. However, there is an uncertainty as to how therapeutic targets that are set by 
animal models will translate to humans. AAA animal models, that are available, are based 
on artificial development of aneurysms, and their results should be interpreted with caution. 
The widely used angiotensin II/hypercholesterolemia models bear limited resemblance to 
human AAA, and appear to merely reflect dissection of the vessel wall.24 As such, it holds 
limited information on the development of an aneurysm. Although the elastase and calcium 
chloride animal models are characterized by transmural inflammation and proteolytic 
imbalance, aneurysms in these models seldom rupture, questioning their relevance.24 To 
identify effective therapeutic targets, we require to design an experimental model that 
represents the progression of an existing aneurysm, including rupture. Another important 
point of consideration is that most animal studies so far focus on the prevention of AAA 
development. However, the main focus of pharmaceutical strategies in man is on the 
prevention of AAA progression and, even more importantly, on prevention of rupture.
A number of observational studies have suggested that some antihypertensive drugs 
(ACE-inhibitors), non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics (doxycycline), 
and statins may reduce aneurysm growth rates. Unfortunately, the data has not yet be 
confirmed in larger studies. The observed sharp increase of cardiac disease, and the high 
incidence of cardiovascular death in AAA patients stresses the importance of cardiovascular 
risk management in this group. As such, the use of statins, antihypertensives and NSAIDs, 
together with lifestyle modification such as stopping smoking, should become standard 
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advice to patients with a small aortic aneurysm.25 Further studies of these agents on AAA 
progression, and incident cardiac disease and death in AAA patients is warranted.
Perspectives on doxycycline use in patients with AAA
Doxycycline is a safe drug with immunomodulatory activities. It has been shown to inhibit 
the inflammation and proteases in the vessel wall and as such may reduce the growth of 
an AAA. Preclinical data clearly show that that doxycycline suppresses the formation of 
aneurysm in a number of animal models.26 In this thesis, we showed that two weeks of 
doxycycline is safe and inhibits specific inflammatory and proteolytic pathways in large AAAs 
that required open surgical repair. A critical question is whether these observations will 
translate to small AAAs and whether long-term doxycycline treatment will result in inhibition 
of aneurysm growth. The efficacy of doxycycline remains to be established in a prospective, 
sufficiently powered clinical trial. Therefore we recently started a multicenter randomized 
trial, the Pharmaceutical Aneurysm Stabilisation Trial (PHAST), which evaluates the effects 
of doxycycline versus placebo on AAA growth in patients under surveillance for a small 
(3.5–5.0 cm) or patients with larger (over 5.5 cm) AAA who are unfit for, or refuse intervention. 
Outcome parameters of PHAST are aneurysm growth determined by ultrasound, possible 
side effects of doxycycline, need for elective aneurysm repair, rupture rate and mortality.
In this thesis we showed that the effect of doxycycline is specific on the C/EBP and 
AP-1 pathway and not on NF-kB pathway. This observation suggests that an intervention 
targeting NF-kB-regulated pathways may be complementary to doxycycline. Such a strategy 
could be considered when the effect of doxycycline on aneurysm growth is limited. In 
vitro studies show that statins, vitamin D receptor agonists and ACE inhibitors all reduce 
NF-kB activity.27,28,29,30,31,32 Yet, it is unknown how these preclinical findings translate to the 
human situation. Future studies should focus on the effects of these compounds, and on 
the additive value of combination therapy of doxycycline, with the aforementioned drugs.
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Een abdominale aneurysma (verwijding) van de grote lichaamsslagader komt veel voor bij 
ouderen. Terwijl kleine aneurysma’s weinig klachten geven en een zeer geringe kans hebben 
om spontaan te scheuren (ruptureren) neemt de kans op scheuren bij grotere aneuysma’s snel 
toe. Ondanks verbeteringen van de medische zorg overlijdt nog steeds 80% van de mensen bij 
wie een aneurysma ruptureerd. Het huidige beleid is er dan ook op gericht op het voorkomen 
van een ruptuur van het aneurysma. Hiervoor staan twee behandelingen ter beschikking: 
het operatief vervangen van de grote lichaamsslagader door een kunststof prothese of, 
indien mogelijk, het via de bloedbaan plaatsen van een prothese (stentprothese) binnen in 
het verwijde deel van de lichaamsslagader. Beide ingrepen zijn echter niet probleemloos: 
in ongeveer 3 % van de gevallen komt de patiënt te overlijden tijdens de ingreep terwijl 
het operatief vervangen van de lichaamsslagader een zware ingreep is waarvoor patiënten 
lang-during in het ziekenhuis moeten verblijven. Uit prospectief gerandomiseerd onderzoek 
is gebleken dat bij het plaatsen van een prothese via de bloedbaan (EVAR) er op de korte 
termijn de sterfte lager is dan die bij de conventionele techniek. Echter, op de langere termijn 
verdwijnt dit voordeel. EVAR kan dan vooral problemen geven door technische problemen 
van de stent. Momenteel gaan de operatieve behandeling gepaard met een relatief hoge 
mortaliteit en morbiditeit, er is een behoeft aan een medicamenteuze behandeling dat de 
goei van aneurysmata remt.
Het ontstaan van de abnormale verwijding van de grote lichaamsslagader en het vervolgens 
scheuren van het aneurysma wordt veelal geassocieerd met het verdwijnen van elastine, 
een belangrijk struktureel eiwit van de vaatwand, en een chronische ontsteking. Onlangs is 
gesuggereerd dat het medicamenteus remmen van elastine afbraak operaties zou kunnen 
voorkomen. Echter, hoewel het verdwijnen van elastine uit de wand zeer karakteristiek is 
voor aneurysmavorming, blijkt uit microscopisch onderzoek dat het verdwijnen van elastine 
zeer vroeg optreedt in het proces van aneurysmavorming en dat ook in kleine aneurysma’s 
vrijwel al het elastine reeds verdwenen is. De stevigheid van de wand van lichaamsslagader 
blijkt met name bepaald te worden door een ander structureel eiwit, collageen. De collageen 
afbraak in aneurysma’s is verhoogd. Remmen van de verhoogde collageenafbraak is dan 
ook een aantrekkelijke optie om verdere groei van aneurysma’s te voorkomen.
Afbraak van de structurele eiwitten in de wand van aneurysmata wordt met name 
toegeschreven aan eiwitten van de matrix metalloproteinase (MMP) familie, een grote 
familie met proteinases met een verschillende specificiteit. Voor de afbraak van collageen 
zijn primair de zgn collagenases (MMP 1, -8 en –13) verantwoordelijk, als deze eenmaal 
het collageen hebben aangetast dan zijn de gelastinases (MMP 2 en -9) in staat om het 
collageen verder af te breken. In dit proefschrift tonen we een sterk verhoogde expressie 
en activiteit van zowel collagenases als gelatinases in de aneurysmawand. Tevens wordt de 
ontstekings process in de aneurysma wand in kaart gebracht.
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Van doxycycline, een veel gebruikt antibioticum, is bekend dat het de activiteit van MMP’s 
en ontsteking remt. In diermodellen van aneurysmavorming is van doxycycline is aangetoond 
dat het de vorming van aneurysma’s tegen gaat. Verder blijkt uit een een beperkt onderzoek 
bij de mens dat doxycycline de activiteit van MMP gelatinases in de aneurysmawand 
remt. Tot op heden is er geen goede verklaring voor het effect van de doxycycline op de 
aneurysma. Dit proefschrift laat het effect van verschillende doxycycline doseringen op de 
proteinases en ontsteking zien. De resultaten laten een remming zien van de proteinases en 
ontsteking en kan mogelijk de groei van een aneurysma belemmeren. De resultaten vormen 
de basis voor een groter prospectief multi-centre onderzoek naar het effect van langdurige 
behandeling met doxycycline op de groei van kleine aneurysma’s. 
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